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Abstract 
Over the last two decades, research into the imaging of inflammation has been thoroughly in-
vestigated as it presents a promising therapeutic target for many diseases, including 
neurodegenerative and cardiovascular diseases. There are only a few radiopharmaceuticals 
which are currently in general use for imaging inflammation, e.g. 18F-FDG, nuclear labelled 
autologous white blood cells, 67Ga-citrate etc. However, none is specific for inflammation thus 
there is a need to investigate novel imaging agents for distinguishing sterile inflammation 
from infection. 
Formyl peptide receptors (FPRs) were originally identified as chemoattractant receptors, 
which have been shown to be implicated with potential therapeutic benefits for inflammatory 
diseases. Highly specific hexapeptides, cFLFLFK (cinnamoyl-Phe-D-Leu-Phe-D-Leu-Phe-
Lys-NH2) and WKYMVm (Trp-Lys-Tyr-Met-Val-D-Met-NH2), which are selective antagonist 
and agonist for FPR1 and FPR2 respectively, have been modified by conjugating to a cyclen 
based chelate for metal ions, allowing for specific imaging of inflammation using non-
invasive imaging techniques such as MRI, PET and SPECT. 
This thesis depicts the synthesis of a bifunctional chelate, DOTAGA containing five acetate 
arms. Ln.DOTAGA-conjugates were prepared by coupling the Ln(III) complexes of DOT-
AGA onto the desired peptides without a protection step as the four pendant acetate arms were 
involved in coordination. Their binding affinities and biological functions were assessed by 
various in vitro assays such as radioligand binding assays, chemotaxis and TNF-α induced 
cytokine release. In vivo imaging of inflammation using the synthesised compounds and a mu-
rine model of inflammation was performed. Further to this, the DOTAGA was further 
modified to an anhydride analogue, which allows for post radiolabelling after conjugation to 
the peptides. Subsequent complexation with Cu(II) and Ga(III) ions indicated their potential 
use in nuclear imaging. 
Two organic chromophores based on Cy5 bearing two orthogonal functional groups have been 
synthesised. Successive conjugation with cFLFLFK and confocal microscopy indicated their 
potential use in optical imaging. Multimodal imaging agents featuring a Cy5 chromophore and 
a DOTAGA for inflammation have been designed and synthesised. Subsequent complexation 
with Gd(III) and Tb(III) resulted in MRI/optical and dual luminescent imaging agents, respec-
tively. 
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1 Introduction 
1.1 Thesis Outline 
This thesis is devoted to the development of cyclen-based contrast agents for imaging inflam-
mation by targeting neutrophils via FPRs using non-invasive imaging modalities. 
Chapter 2 describes the synthesis of cyclen-based bifunctional chelates for lanthanide (Ln) 
complexes. 
Chapter 3 and 4 focus on the development of peptide-based contrast agents by linking the sta-
ble Ln(III) complexes to the desired peptides, cFLFLFK and WKYMVm targeting FPR1 and 
FPR2 respectively. These chapters also describe the photophysical and paramagnetic proper-
ties of the synthesised compounds. Biological functions were assessed using various biological 
in vitro assays. Magnetic resonance imaging (MRI) of murine model of inflammation was per-
formed using a cFLFLFK-based contrast agent.  
Chapter 5 describes an alternative synthetic route to prepare the activated analogue of the che-
late for direct labelling to peptides and proteins. Thus the resultant compounds can undergo 
complexation with various radiometals such as 64Cu(II) and 68Ga(III), and can be used for nu-
clear imaging of inflammation. 
Chapter 6 focuses on the design and synthesis of dual-modal contrast agents featuring an or-
ganic fluorophore and cyclen-based chelate for Ln(III) ions or various radionuclides. This 
chapter also includes a synthesis of a cyanine-based fluorophore, which is conjugated to the 
selected peptide, cFLFLFK for in vitro confocal imaging. 
Chapter 7 describes the use of the multi-component Ugi condensation reaction to synthesise a 
series of diamides in the development towards non-peptide based contrast agent. It outlines the 
issues encountered during the development of the chelates and a way to overcome these prob-
lems. The difficulties of using Ugi condensation to synthesise a series of diamides are also 
described. 
Chapter 8 features the conclusions to the thesis and suggests future work. 
1.2 Molecular Imaging 
In vivo imaging is a major research topic in modern medicine and biology. Techniques such as 
X-ray provide information on a macroscopic scale, whilst molecular imaging promises to be a 
revolutionary technique that provides in-depth understanding of biological processes, allowing 
early detection and characterisation of diseases in a non-invasive manner. Commonly used 
imaging modalities include positron emission tomography (PET), single photon emission 
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computed tomography (SPECT), MRI, optical imaging, ultrasound and X-ray computed to-
mography (CT). Each imaging modality has its strengths and weaknesses, varying in 
sensitivity, spatial and temporal resolution, cost, and depth of tissue penetration (Table 1-1).1-2 
Modalities Cost Sensitivity 
Resolution 
Spatial Temporal 
MRI 
 
high 
 
low 
 
10-100 µm 
 
ms 
 
Nuclear medicine 
PET 
SPECT 
 
 
high 
moderate 
 
high 
high 
 
mm 
mm 
 
s to min 
min 
Optical 
Bioluminescence 
Fluorescence 
 
 
moderate 
low 
 
high 
high 
 
1-2 mm 
µm 
 
min 
ms 
Ultrasound low high 50 µm ms 
X-ray CT low low 50-100 µm s 
Table 1-1 Resolution and sensitivities for various molecular imaging modalities.1-2 
MRI, optical imaging and nuclear imaging are emerging as key modalities for in vivo imaging 
because of their abilities to detect molecular events when combined with their corresponding 
contrast agents. In this project, these imaging modalities are investigated for imaging inflam-
mation. 
1.3 Inflammation 
Inflammation is a complex biological response and mechanism of vascular tissues to combat 
conditions caused by noxious stimuli, such as pathogens, noxious mechanical and chemical 
agents, and autoimmune responses.3 It is a highly complex process involving precise orches-
tration of a number of different cell types, such as leukocytes and endothelial cells etc. In 
physiological conditions, inflammation first eliminates pathogens or noxious agents, then it 
controls the restoration of tissue integrity and function.4 However, inadequate or poor regula-
tion of the response can result in tissue destruction and lead to organ dysfunction in 
pathogenic situations. Inflammation remains as one of the main therapeutic targets in diverse 
disorders including autoimmune diseases and neurological disorders (Table 1-2).5-6 
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Disorders in which inflammation plays an important pathogenetic role. 
Alzheimer’s disease 
Asthma 
Atherosclerosis 
Atopic dermatitis 
Chronic obstructive pulmonary disease 
Gout 
Ischaemia-reperfusion injury (occlusive and em-
bolic stroke and myocardial infarction) 
Multiple sclerosis 
Osteoarthritis 
Psoriasis 
Rheumatoid arthritis 
Type 1 diabetes mellitus 
Ulcerative colitis 
Xenograft rejection 
Diseases of infectious origin in which inflammation may cause more damage than the microbe. 
Bacterial dysentery 
Cystic fibrosis pneumonitis 
Filariasis 
Hepatitis C 
Influenza virus pneumonitis 
Sepsis syndrome 
Tuberculosis 
Table 1-2 Examples of inflammatory disorders, table adapted from ref [7]. 
At a basic level, the acute inflammatory response triggered by infection or tissue injury in-
volves the coordinated delivery of blood components (plasma, leukocytes and platelets) to the 
site of infection or injury. This response has been characterised and reviewed.8 Initial recogni-
tion of infection or injury is mediated by tissue resident macrophages and mast cells, leading 
to the production of a variety of inflammatory mediators, including cytokines e.g. interleukin 
(IL)-1β, IL-6, IL-8 and tumour necrosis factor-α (TNF-α), eicosanoids etc. The immediate 
effect of these mediators is to elicit an inflammatory response, to which leukocytes are recruit-
ed through the post-capillary venules to the extravascular tissues at the site of infection or 
injury. Much attention in inflammation research has focused on the recruitment of inflamma-
tion and leukocyte extravasation has been proposed as a target for anti-inflammatory therapy.8-
10 
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Figure 1-1 Leukocyte adhesion cascade. Recruitment of leukocytes is regulated by inflammatory 
cytokines such as interferon γ (IF-γ), TNF-α, and IL-1. In response to these cytokines, endothelial 
cells overexpress cell surface adhesion molecules, including selectins such as E-selectin that are 
involved in rolling of leukocytes along the vascular wall and immunoglobulin-like adhesion mole-
cules such as intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1) that support firm adhesion and extravasation of leukocytes into the tissue.11 
Recruitment of leukocytes through the endothelium and into the target site requires adhesion 
and transmigration through blood vessels. The leukocyte adhesion cascade has been updated 
recently to include capture, rolling, slow rolling, arrest, adhesion strengthening, intravascular 
crawling and transmigration (Figure 1-1).11 Since recruitment of leukocytes is an early event 
within the inflammatory cascade, a specific tracking of these cells would be an ideal target for 
a molecular imaging approach to visualising acute inflammation. 
1.3.1 Imaging of Inflammation 
Understanding the cellular events involved in inflammation is crucial, as rational and specific 
interventions for resolving inflammation in disease might be developed and applied. In addi-
tion, it helps identification of targets for imaging and thereby increases the sensitivity and 
specificity of the desired imaging agent. Biomarkers can be developed for molecular imaging 
to achieve the visualisation of inflammatory processes ranging from the molecular to physio-
logical level. An overview of characteristics of imaging agents used for inflammation is 
tabulated in Table 1-3.  
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Physiological 
Characteristics 
Targeting mechanism 
Imaging 
Agent Class 
Labelled Compound Ref 
Vascular permeability Non-specific uptake  Albumin 12 
Endothelial activation Antigen binding Antibodies Anti-E-selectin 13-14 
Influx of leukocytes Leukocyte influx  Leukocytes 12, 15 
 Antigen binding Antibodies Anti-SSEA-1 IgM 16 
 Receptor binding Cytokines IL-8 17 
  Leukotrienes LTB4 antagonist 18-19 
  FPR ligands fMLF 
cFLFLFK 
20 
21-23 
Metabolic increase Enhanced glucose uptake  18F-FDG 24 
Table 1-3 Overview of characteristics of imaging agents used for in vivo imaging of inflammation. 
Inflammatory processes such as increased blood supply, increased vascular permeability and 
enhanced transudation are processes that are utilised for non-specific accumulation of imaging 
agents, for example 67Ga-citrate, radiolabelled leukocytes and 111In or 99mTc-labelled antibodies 
have been used for SPECT imaging, and fluorescently labelled albumin for fluorescence imag-
ing.12, 25 Unlike non-specific imaging, targeted imaging of inflammation involves cellular 
targets specific for inflammatory processes. There are several strategies to design and develop 
targeted imaging agents for live cell imaging of inflammation: 1) targeting leukocytes to the 
site of inflammation; 2) targeting mediators that are involved in inflammation; and 3) targeting 
increased glucose uptake of infiltrated granulocytes and macrophages. 
Leukocytes migrate to the site of inflammation in direct response to locally produced media-
tors and chemotactic factors. The ability to detect inflammation can be accomplished by 
labelling of leukocytes directly or indirectly. Ex vivo labelling of leukocyte with radioisotope 
99mTc is the ‘gold’ standard for infection and inflammation imaging using SPECT imaging 
technique.25 However, the labelling process is lengthy, laborious and possesses potential risks 
to clinical staff due to the handling of human blood samples. Therefore, there is an increasing 
demand for the development of sensitive and novel imaging agents to minimise and eventually 
replace the use of labelled leukocytes. 
This thesis aims to target neutrophils, which are one of the first cells migrating into the site of 
inflammation, for imaging inflammation. The primary principle of targeting neutrophils is 
based on the ligand-receptor interaction on the cell surface. This allows for high specific tar-
geting and thus increasing the sensitivity of the imaging technique. Several reports 
demonstrated that FPRs could be targeted to visualise inflammation when a FPR ligand such 
as fMLF and cFLFLFK are conjugated to an imaging motif.20-22, 26-28 FPRs are therefore select-
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ed as the targets for labelling neutrophils and their history and biological roles are discussed in 
the following section. 
1.4 Formyl Peptide Receptors as Targets 
1.4.1 History 
FPRs are a family of seven transmembrane G-protein coupled receptors (GPCRs) which were 
identified in 1975 as bacterial chemoattractant receptors on the basis of their abilities to bind 
N-formyl peptides such as CHO-Met (N-formyl-methioninyl-leucyl-phenylalanine) produced 
by the degradation of either bacterial or host cells.29 The N-formyl peptide receptor was shown 
to exhibit potent chemotactic activities for phagocytic leukocytes. Extensive research was per-
formed to investigate the structure-activity relationships using synthetic peptides as 
chemotactic factors with rabbit neutrophils. The studies resulted in the identification of fMLF 
(N-formyl-methionyl-leucyl-phenylalanine) as the most potent agonist based on its ability to 
stimulate chemotaxis in a Boyden chamber (equipment used to test for chemotaxis that are 
separated by a filter).30 The high activity of the peptide was attributed to the position of the 
phenylalanine in the C-terminal, as the activity was low when it was located as the second 
amino acid from the N-terminal. The studies also revealed the structural specificity of fMLF 
which was associated with a stereospecific receptor on the neutrophil surface.31 As a result, 
fMLF has become a prototype for studying neutrophil activation by chemoattractants. 
1.4.2 FPR Family 
Human FPR1 was first cloned in 1990 by Boulay et al. from a differentiated HL-60 myeloid 
leukemia cell cDNA library.32 This revealed that this receptor shares the seven transmembrane 
domain structure characteristic of the GPCR family. Functionally, FPR1 is activated by low 
concentrations of fMLF (pM to μM) and is thus also identified as a high-affinity fMLF recep-
tor. 
Following the isolation of human FPR1, two additional variants of the human FPR1 were iso-
lated by a low stringency hybridisation with a human FPR cDNA probe.32 To date, the human 
FPR family includes three members i.e. FPR1, FPR2 and FPR3. All three genes are clustered 
on chromosome 19q13.3.33 Further molecular cloning indicated that FPR1 may be the only 
gene that is expressed by neutrophils that encodes a receptor capable of binding prototypic N-
formyl peptides, indicating a functional divergence of these receptors.34 FPR2 is defined as a 
low-affinity fMLF receptor, based on its activation only by high concentrations of fMLF (μM 
range) in vitro.35 FPR3 does not bind or respond to N-formyl peptides36 but instead shares 
some non-formylated chemotactic peptides identified as ligands for FPR2.37 
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FPR1 and FPR2 were initially identified in phagocytic leukocytes but it has been shown that 
other cell types also express these receptors, however with undefined biological significance. 
Unlike FPR1 and FPR2, FPR3 transcripts were not found in neutrophils but in monocytes,34 
and its functional agonists remain unclear. Functional FPR3 is also expressed in mature den-
dritic cells.38 Recently, a novel chemoattractant peptide, F2L acting specifically through FPR3, 
has been identified.39 F2L is an acetylated amino-terminal peptide derived from the cleavage 
of human heme-binding protein. The peptide activates FPR3 at low concentrations (nM range) 
and triggers intracellular calcium release and inhibition of cAMP accumulation.40 It has been 
shown to induce chemotaxis when tested with monocytes and monocyte-derived dendritic 
cells. However, F2L has also been reported to inhibit FPR1- and FPR2-mediated signaling in 
neutrophils.41 
The FPR family has a complex evolutionary history. The number of genes in the family varies 
in different mammalian species. In the mouse, the Fpr gene cluster (on chromosome 17) has 
undergone differential expansion, and eight different members of the FPR family have been 
identified to date, designated Fpr1 through Fpr3, and Fpr-related sequences (Fpr-rs) 3 through 
Fpr-rs 7 (Figure 1-2).42-43 Fpr1 is considered the murine orthologue of human FPR1, whereas 
both Fpr2 and Fpr3 are structurally and functionally most similar to human FPR2.44 It has been 
reported that Fpr2 has 76% and 63% identity with human FPR2 and FPR3, respectively.42, 44 
Fpr-rs 3-5 appear to lack human counterparts and are considered orphan receptors. In addition, 
very little is known for the biological functions of Fpr-rs 3-5 as the genes do not encode full-
length receptors.45 However, Fpr-rs 6 and Fpr-rs 7 appear to represent classical GPCRs but the 
physiological ligands remain unclear. To date, a pseudo-gene ΨFpr-rs 2 has been cloned and 
ΨFpr-rs 2(-/-) mice have been successfully bred. The results have shown that ΨFpr-rs 2 is 
expressed in phagocytes and regulated by bacterial products. Therefore, the pseudo-receptor 
has been proposed to be a new atypical member, Fpr-rs 8 of the FPR family.46 The FPR gene 
family has undergone a differential expansion in mammals, implying functional divergence 
and complexity in human and mouse. 
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Figure 1-2 Sequence homology among the members of the FPR gene cluster, diagram taken from 
ref [42]. 
Human 
Receptor Tissues Cell Types 
FPR1 Adrenal glands 
Autonomic nervous system 
Bone marrow 
Colon 
CNS 
Eye 
Heart 
Kidney 
Liver 
Lung 
Ovary 
Placenta 
Spleen 
Stomach 
Testis 
Thyroid 
Uterus 
Adrenal cortical cells 
Astrocytes 
Carcicoma cells 
Endothelial cells 
Epithelial cells 
Fibroblasts 
Hepatocytes 
Immature dendritic cells 
 
Neuroblastoma cells 
Kupfer cells 
Microglial cells 
Monocytes/macrophages 
Platelets 
PMNs 
Smooth muscle cells 
U937 cells 
 
FPR2 Bone marrow 
Brain 
Lung 
Placenta 
 
Spleen 
Stomach 
Testis 
 
Adrenal cortical cells 
Astrocytes 
Endothelial cells 
Epithelial cells 
Fibroblasts 
Hepatocytes 
Neuroblastoma cells 
Microglial cells 
Monocytes/macrophages 
Platelets 
PMNs 
FPR3 Adrenal gland 
Liver 
Lung 
Lymph nodes 
Trachea 
Placenta 
Small intestines 
Spleen 
Stomach 
 
Dendritic cells 
HL-60 cells 
Monocytes/macrophages 
 
Table 1-4 Tissue and cellular distribution for FPR1-3 in human, adapted from ref [43, 47-48]. Abbre-
viation: PMN = polymorphonuclear leukocyte, CNS = central nervous system. 
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differentiation of these receptors.  Therefore, for the rest of this thesis, murine FPRs 
will be referred to as Fpr1, Fpr2 and Fpr3 for Fpr1, Fpr-rs2 and Fpr-rs1, respectively. 
 
 
 
 
 
 
 
 
 
 
 
F igure 1.7: Structural relationships among members of FPR gene cluste r. 
Dendogram representing structural similarities between human and mouse FPR-
related amino acid sequences (Ye et al., 2009). 
 
To assist with the understanding of the potential relevance of each receptor, a 
summary of our current knowledge of the expression profile and ligands of the FPRs 
is provided in Tables 1.1-6.   
FPR1 (man) 
Fpr2 (mouse)
Fpr3 (mouse)
FPR3 (man)
FPR2 (man)
Fpr-rs 3 (mouse)
Fpr-rs 4 (mouse)
Fpr-rs 5 (mouse)
Fpr-rs 6 (mouse)
Fpr-rs 7 (mouse)
Fpr1 (mouse) 
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Mouse 
Receptor Tissues Cell Types 
Fpr1 Anterior pituitary 
Adrenal gland 
Hippocampus 
Hypothalamus 
Liver 
Lung 
Spleen 
Dendritic cells 
Microglial cells 
 
Mononuclear cells 
PMNs 
Fpr2 Anterior pituitary 
Adrenal gland 
Hippocampus 
Hypothalamus 
Lung 
Spleen 
Microglial cells 
PMNs 
 
Fpr3 Anterior pituitary 
Adrenal gland 
Heart 
Hippocampus 
Hypothalamus 
Liver 
Lung 
Spleen 
Microglial cells 
Leukocytes 
 
Table 1-5 Tissue and cellular distribution for Fpr1-3 in mouse, adapted from ref [43, 47-48]. Note: 
Murine Fpr-rs 3-7 not included. 
1.4.3 FPR Ligands 
FPR ligands have a prominent diversity and unusual features. With the exception of lipoxin A4 
(LXA4), all known FPR family ligands are peptides. A number of agonists and antagonists of 
FPR have been identified and isolated from exogenous sources or by artificial synthesis. Ta-
bles 1-6 to 1-8 show the agonists and antagonists for human FPRs, which will aid the 
identification of suitable candidates for the development of inflammation targeted imaging 
agents. 
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FPR1 
Agonist/Antagonist Ligand Potency 
Agonists Bacterial peptides 
fMLF 
formylated peptides 
 
Kd = 0.04 nM 
EC50 = 0.01-1 nM 
 Host-derived 
Annexin A1 
Ac2-26 
Ac9-25 
Cathepsin G 
 
Kd = 4 µM 
EC50 = 1.4 µM 
EC50 = 20 µM 
Kd = 85 nM 
 HIV-1 envelope peptides 
T20 (DP178) 
T21 (DP107) 
 
EC50 = 5 nM 
EC50 = 50 µM 
 Peptide library 
MMWLL 
WKYMVm 
 
EC50 = 2 nM 
EC50 = 25 nM 
 Non-peptide 
AG-09/1 
AG-14 
1753-103 
 
EC50 = 3.4 µM 
EC50 = 41 nM 
EC50 = 131 nM 
Antagonists Peptide 
Boc1 
Boc2 
CHIPS 
Cyclosporin A 
Cyclosporin H 
CDCA 
DCA 
 
IC50 = 0.64 µM 
IC50 = 0.26 µM 
Kd = 0.35 nM 
IC50 = 0.60 µM 
IC50 = 0.5 µM 
IC50 = 140 µM 
IC50 = 100 µM 
 Non-peptide 
3570-0208 
BVT173187 
BB-V-115 
Pyrazole 20 
 
Ki = 95 nM 
IC50 = 0.1 µM 
Ki = 270 nM 
IC50 = 3.98 nM 
Table 1-6 Agonists and antagonists for human FPR1. 
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FPR2 
Agonist/Antagonist Ligand Potency 
Agonists Bacterial peptides 
fMLF 
Hp(2-20) 
 
Kd = 400 nM 
EC50 = 0.3 µM 
 Host-derived 
Annexin A1 
Ac2-26 
Aβ(1-42) 
D2D3 
F2L 
Humanin 
LL-37 
LXA4 
PACAP27 
Prp (106-126) 
SAA 
sCKβ8-1 
SHAAGtide 
 
EC50 = 0.15 µM 
EC50 = 1.8 µM 
EC50 = 200 nM 
EC50 = 83 nM 
EC50 = 567 nm 
EC50 = 3.5 nM 
EC50 = 25 µM 
EC50 = 1.7 nM 
EC50 = 0.33 µM 
EC50 = 10 µM 
EC50 = 0.25 µM 
EC50 = 1.4 nM 
EC50 = 19 nM 
 HIV-1 envelope peptide 
T21(DP107) 
 
EC50 = 50 µM 
 Peptide library 
MMK-1 
N36 
V3 
WKYMVm 
WKYMVM 
 
EC50 = 1 nM 
EC50 = 1 µM 
EC50 = 1.5 µM 
EC50 = 75 pM 
EC50 = 2 nM 
 Non-peptide 
Quin-C1 
Pyrazolone 43 
BB-V-115 
 
EC50 = 1.88 µM 
EC50 = 44 nM 
Ki = 270 nM 
Antagonists Peptide 
Boc1 
Boc2 
FLIPr 
CDCA 
WRW4 
PBP10 
 
 
IC50 = 1- 50 µM 
IC50 = 2.5 nM 
IC50 = 80 µM 
IC50 = 0.23 µM 
IC50 = 33 n 
 Non-peptide 
Quin-C7 
1754-31 
 
Ki = 6.45 µM 
IC50 = 81 nM 
Table 1-7 Agonists and antagonists for human FPR2. 
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FPR3 
Agonist/Antagonist Ligand Potency 
Agonists Bacterial peptides 
Hp(2-20) 
 
EC50 = 30 µM 
 Host-derived 
Annexin A1 
F2L 
Humanin 
 
EC50 = 1-10 µM 
Kd = 11.7 nM 
EC50 = 2.6 nM 
 Peptide library 
WKYMVm 
WKYMVM 
 
EC50 = 3 nM 
EC50 = 80 nM 
Antagonists Peptide 
Boc1 
Boc2 
WRW4 
 
 
 
IC50 = 1 µM 
Table 1-8 Agonists and antagonists for human FPR3. 
1.4.4 Role of FPRs in Inflammation 
The pathophysiological role of FPRs is investigated based on their abilities to recognise en-
dogenous ligands e.g. bacterial chemotactic peptides, annexin A1 (AnxA1) and LXA4. 
Functional studies indicate that FPR1 is a key contributor to host defence against pathogens. 
In neutrophils and monocytes, fMLF binding to FPR1 triggers and modulates various cellular 
responses associated with inflammation, including degranulation, adhesion, chemotaxis, tran-
sendothelial migration and cytokine production.49 This receptor also responds to certain virus 
peptide fragments, in particular T20/DP178 from HIV-1 envelope protein gp41, which medi-
ates viral fusion with human host cells. When it binds to FPRs, T20 appears to elicit 
chemotaxis.50 In addition, T20 has been tested in clinical trials and shown to significantly re-
duce viral load in AIDS patients due to its potent anti-HIV-1 activity in vitro.51-52 Although 
T20 has been shown to be a chemotactic agonist to FPR1, whether interactions of FPR1 with 
viral proteins in leukocytes contribute to its anti-HIV-1 activity in vivo are unknown. 
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Figure 1-3 A selection of FPR ligands. 
AnxA1, also referred to as lipocortin 1, is a glucocorticoid-regulated protein which has been 
shown to activate FPR1 on human neutrophils. Peptides derived from the N-terminal domain 
of AnxA1 act as FPR ligands and trigger different signalling pathways in a dose-dependent 
manner. These findings indicate AnxA1 peptides can act as novel endogenous FPR ligands 
and the mechanistic effect of AnxA1-mediated anti-inflammatory effects has been estab-
lished.53 AnxA1 peptides have been shown to initiate chemotactic responses in human 
monocytes which express all three FPR family members and de-sensitise the cells towards 
subsequent stimulation with bacterial peptide agonists.54 In a model of murine peritonitis, FPR 
antagonists Boc1 (Boc-MLF) and Boc2 (Boc-FLFLF) inhibited the anti-migratory effects of 
AnxA1 N-terminal peptides Ac2-26 and Ac2-12.55 In addition, binding of AnxA1 to circulat-
ing leukocytes was lower in FPR knock-out mice indicating that FPRs play functional roles in 
the anti-migratory effects of AnxA1 and its N-terminal peptides.55 
LXA4 is a lipid mediator and its aspirin-triggered isomer 15-epi-LXA4 are both potent agonists 
to FPR2 (Figure 1-3).56 In human neutrophils, LXA4 was identified as the first endogenous 
ligand for FPR2. Functional studies have indicated that LXA4 possesses anti-inflammatory 
properties by inhibiting neutrophil infiltration,57 which has perceived to be through induction 
of nitric oxide production and thus suppressed leukocyte-endothelial cell interaction.42 Recent 
studies using FPR2 knock-out mice indicated that LXA4 is unable to inhibit PMN trafficking 
in response to cytokine administration, providing evidence that the anti-inflammatory effects 
of LXA4 act through FPR2 in vivo.58 In addition, LXA4 also suppresses production of pro-
inflammatory cytokines, inhibition of NF-κB and stimulation of IL-10.59-61 It has been reported 
that LXA4 and its stable analogue is able to induce intracellular Ca(II) release in monocytes 
but not in neutrophils,62 suggesting that the intracellular signalling cascades of FPR2 elicited 
by LXA4 are specific and tissue dependent. This also supports the hypothesis that LXA4 could 
contribute to the conversion of inflammatory response from acute to chronic phase by inhibit-
ing neutrophils, but promoting recruitment of monocytes. Recent research using a 
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carrageenan-induced paw oedema model has shown a greater activation of macrophages, 
which was derived from monocytes in FPR2 knock-out mice, giving evidence that LXA4 has 
dual roles in inflammation.63 
The presence of FPR1 and FPR2 in microglial cells, which make up the innate immune system 
of the central nervous system (CNS), suggests potential roles of FPRs in the diseases of 
CNS.49 Microglial cells are considered to play a key role in the pathogenesis of neuroinflam-
matory and neurodegenerative diseases, for example Alzheimer’s disease and multiple 
sclerosis.64-65 The findings are that FPR2 is a functional receptor for at least three forms of am-
yloidogenic protein and peptide agonists, serum amyloid A (SAA), amyloid β 42 (Aβ 42) and 
PrP106-126. All these peptides are able to activate phagocytes and elicit chemotaxis.66-68 
SAA, an acute phase protein secreted mainly by hepatocytes, is normally present in serum at 
0.1 µM levels. Chronic inflammation causes a marked increase (1000-fold) in serum SAA 
concentration and this can result in amyloidosis.69 SAA is enzymatically cleaved into frag-
ments to form amorphous amyloid fibril deposits.70 Since phagocytic leukocytes are the source 
of SAA cleaving enzymes, these cells are present at the sites of amyloid deposits, and elevated 
SAA levels can attract and activate leukocytes through FPR2 for degradation of amyloid de-
posits. However, leukocyte activation may also exacerbate inflammatory response and cause 
tissue injury in association with amyloidosis. 
Aβ42 is an enzymatic cleavage fragment of the amyloid precursor protein (APP) and it plays an 
important role in the neurodegenerative process of Alzheimer’s disease. Alzheimer’s disease is 
a progressive, neurodegenerative disease characterised by the presence of multiple senile 
plaques in the brain, and the major component is aggregated forms of Aβ42. Recent studies 
have revealed that FPR2 is a chemotactic receptor of Aβ42, which induces monocyte migration 
and activation.71 FPR2 promotes uptake of Aβ42 by rapid internalisation into the cytoplasmic 
compartment in the form of Aβ42-FPR2 complexes. Persistent exposure to Aβ42 results in in-
tracellular retention of Aβ42-FPR2 complexes and formation of Congo red-positive fibrils in 
mononuclear phagocytes.71 Thus, FPR2 has been proposed as a potential therapeutic target for 
Alzheimer’s disease since it not only accounts for Aβ42-induced recruitment and activation of 
mononuclear phagocytes in senile plagues, but also participates in Aβ42 uptake and formation 
of fibrils in Alzheimer’s disease. 
FPRs have been shown to be associated with many inflammatory diseases and they represent 
potential diagnostic and therapeutic targets for inflammation. At present, routine use of imag-
ing inflammation has yet to be achieved. Understanding the physiological roles of FPRs in 
inflammation is crucial in identifying targets for imaging and thereby increases the sensitivity 
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and specificity of the desired imaging agents. Molecular imaging targeting FPRs could lead to 
the visualisation of inflammation processes ranging from molecular to physiological level. 
1.5 MRI and Gadolinium(III)-based Contrast Agents 
In the last few decades, MRI has been developed as a powerful technique for application in 
diagnostic clinical and biomedical research. MRI is a non-invasive imaging technique that ex-
ploits the magnetic properties of hydrogen and its interaction with a large external magnetic 
field and radiowaves to produce high-resolution three-dimensional images of the body for di-
agnosis. Since the body is composed principally of water (72%) its hydrogen protons are the 
most abundant and readily observed in vivo.  
MRI contrast agents are pharmaceuticals that are used to improve the image contrast indirectly 
by alternating the relaxation time of water protons in the surrounding tissue. This alternation is 
a result of the dipolar magnetic interaction between the magnetic moments of the protons in 
close proximity to the electronic magnetic moment of the paramagnetic metal centre such as 
Gd(III), Fe(III) and Mn(II) complexes. Gd(III), a lanthanide ion, is particularly favourable be-
cause of its seven unpaired electrons which exhibit the strongest paramagnetism (7.9 Bohr 
Magneton µB/Am2) of all elements on longitudinal relaxation time (T1). In addition, its sym-
metric electronic S-state leads to a long electronic relaxation time (~10-9 s), which gives rise to 
highly efficient relaxation enhancement of water protons. 
Free Gd(III) ion is extremely toxic at the concentrations needed for MRI studies. It inhibits 
calcium channels and is considerably toxic to cardiovascular and neurologic systems. In mice, 
the LD50 (the median lethal dose, the amount required to kill 50% of the population) of GdCl3 
is 100-200 mg/kg.72 As a result, it must be administered in the form of stable complexes, in 
which the ligands are designed to encapsulate the metal ion forming both thermodynamically 
and kinetically stable complexes to avoid releasing the toxic Gd(III) ion before excretion. A 
selection of clinically approved Gd(III) based contrast agents is illustrated in Figure 1-4, fea-
turing a linear or cyclic octadentate chelate. Furthermore, the ligands can be utilised with 
different functionalities to suit a variety of clinical purposes and to satisfy the basic require-
ments for pharmaceuticals such as good water solubility, biocompatibility and low toxicity. 
 
Figure 1-4 A selection of clinically proven Gd contrast agents. 
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1.5.1 Contrast Agents Enhancement  
In order to enhance the sensitivity of Gd-based MRI contrast agents, T1 relaxation times need 
to be altered and the main approaches are 1) increasing the number of water molecules directly 
bound to the Gd(III) ion; 2) shortening the proton residence lifetime, τM; and 3) increasing ro-
tational correlation time, τR by increasing the ligand molecular weights (Figure 1-5). 
 
Figure 1-5 Schematic representation of a Gd(III) complex with one inner-sphere water molecule, 
surrounded by bulk water. τR is the rotational correlation time of the complex, τM is the proton 
residence lifetime and kex is the proton exchange rate.  
1.5.1.1 Hydration Number, q 
Inner sphere relaxivity is linearly proportional to the number of directly bound water mole-
cules to the paramagnetic metal centre. However, an increase in q is often accompanied by a 
decrease in thermodynamic stability and kinetic inertness, especially where the paramagnetic 
metal centre is Gd(III), as free Gd(III) ions are highly toxic. Therefore, the metal ion has to be 
incorporated into a multidentate ligand to protect it and approved Gd(III)-based contrast 
agents often feature poly(aminocarboxylate) complexes where the chelating ligand occupies 
eight coordination sites leaving one vacant site for water binding interaction. 
1.5.1.2 Water Exchange 
The residence lifetime of proton (τM) is the time designated for an inner sphere water molecule 
to exchange with the bulk. It plays a dual role in determining the proton relaxivity. It modu-
lates the efficiency of chemical exchange of protons from the inner sphere of the metal centre 
to the bulk, and it also contributes to the overall correlation time (τC) which governs the di-
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pole-dipole interaction between the nuclear spin and the electron. The water exchange rates 
(kex) reported for different Gd(III) contrast agents can vary over four orders of magnitude. 
It has been shown by NMR that macrocyclic Ln.DOTA complexes exist in solution as a mix-
ture of four slowly interchangeable stereoisomeric complexes, related as two enantiomeric 
pairs: the mono-capped square antiprismatic geometry (SAP or M) and the mono-capped 
twisted square antiprismatic geometry (TSAP or m). The enantiomeric pairs differ in the octa-
dentate ligand conformation by either cooperative ring inversion (δδδδ ↔ λλλλ) or concerted 
acetate arm rotation (Λ ↔ Δ), as illustrated in Figure 1-6. 
 
Figure 1-6 Schematic representation of the structures and dynamics of Ln.DOTA complexes, 
looking down along the Ln-water O bond. The water molecule is not shown for clarity, adapted 
from ref [73]. 
The relative concentrations of the two species depend on the size of the Ln(III) ion, tempera-
ture, pressure and the concentration of added inorganic salts.74-75 It is well known that the 
TSAP geometry results in faster water exchange kinetics than those of the SAP geometry.76-77 
This has important implications to the design of DOTA-based contrast agents for MRI, since it 
revealed the necessity of synthesising complexes that exist mainly in the fast exchanging iso-
mers in solution. 
1.5.1.3 Rotational Correlation Time, τR 
For small Gd(III) complexes, rotational correlation time (τR) is the limiting factor for proton 
relaxivity at magnetic field strength up to 3 T, which is typically employed for MRI.78-79 High 
relaxivity can be achieved by lengthening τR, which reflects the molecular tumbling rate. In-
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creasing the hydrodynamic volume of the contrast agents results in longer τR, which slows 
down the molecular tumbling.80 Several approaches to increase τR have been considered, e.g. 
physical attachment of Gd(III) complexes to a slowly tumbling polymer or dendrimers,81 or 
exploiting non-covalent interactions between Gd(III) complex and proteins in vivo.82-83  
1.5.2 The Lanthanides 
Gadolinium is a member of the f-block lanthanide group of the periodic table. The paramag-
netic Gd(III) ion has some spectroscopic limitations e.g. 1H NMR cannot be recorded 
accurately as its long electronic relaxation time broadens NMR lines. Moreover, fluorescence 
studies of Gd(III) complexes are not useful as Gd(III) ion has excited states above the ligand 
triplet states, while its neighbouring ions Eu(III) and Tb(III) ions have a large number of ex-
cited states promoting energy loss by non-radiative decay routes. Therefore, there are limited 
analytical techniques that can be employed to characterise Gd(III) complexes directly. It is 
therefore a usual practice to prepare analogous Eu(III) and Tb(III) complexes and their photo-
physical and NMR properties are studied in detail to elucidate the solution behaviour of the 
Gd(III) species. 
1.5.2.1 Lanthanide Coordination Chemistry 
The common trivalent lanthanide ions are hard Lewis acids and bind preferentially to hard ba-
ses such as O and N donors. Across the periodic table, there is a decrease in both the atomic 
radii and in the radii of the Ln(III) ions. Shielding of the 4ƒ orbitals within the Ln(III) ions by 
the xenon core (54 electrons), particularly the large radial expansion of the 5s and 5p subshells 
makes the valence 4ƒ orbitals “inner” orbitals. This is called lanthanide contraction. The 4ƒ 
orbitals are not available for covalent interaction with the ligands, crystal-field effect is small 
and thus spectroscopic and magnetic properties of Ln(III) ions are largely independent of the 
environment. 
As 4ƒ orbitals are not available for covalent interaction, metal-ligand interaction is largely 
electrostatic and coordination geometry of Ln(III) complexes is dictated by steric considera-
tions due to lanthanide contraction. The ligands generally encapsulate the metal ions in such a 
way that interligand repulsions are minimised and the coordination number and geometry are 
largely determined by the steric factors adopting a lanthanide ion.84-85 Owing to the large size 
of Ln(III) ions (0.8-1.0 Å) comparing to the largest transition metal, Ti(III) (0.67 Å), coordina-
tion number for Ln(III) complexes is generally high with 8 or 9; coordination numbers 
between 2 and 12 are known in lanthanide complexes and geometries correspond to the simple 
polyhedra that are predicted from electron-pair repulsion models. 
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In aqueous solution, Ln(III) ions are solvated with H2O molecules with a coordination number 
of 9 for larger ions (La-Nd) or 8 for smaller ions (Dy-Lu). Ln(III) ions undergo hydrolysis at 
pH > 6 resulting in precipitation of insoluble Ln(OH)3, thus it is important to control the pH 
during the Ln(III) complexation in aqueous solution.86 
1.5.2.2 Lanthanide Luminescence 
With the exception of La(III) and Lu(III) ions, Ln(III) ions and their complexes exhibit excel-
lent luminescence properties due to the characteristics of their ƒ–ƒ transitions, including long-
lived lifetimes (µs-ms) and narrow bandwidth emissions in the 900-1600 nm region.87-88 The ƒ-
ƒ emission bands are electric-dipole forbidden by the Laporte selection rule but weak interac-
tions with the ligand field or vibrational states in electronic states give rise to low intensity 
sharp absorption with narrow bands. 
Since the dipole strengths of ƒ-ƒ transitions are very small, direct excitation into the 4ƒ excited 
states rarely yields highly luminescent complexes. In order to overcome this disadvantage, an 
alternative pathway has been established which is called the ‘antenna effect’ or luminescence 
sensitisation. Ln(III) ions are imbedded into an organic chromophore that has a much higher 
absorption coefficient. Upon excitation of the antenna, energy is transferred from the excited 
surroundings to the Ln(III) ions, affecting the population of the lanthanide luminescent state. 
 
Figure 1-7 Schematic representation of energy transfer in a lanthanide complex. S = singlet state, 
T1 = triplet state. 
The sensitisation pathway involves excitation of the chromophore into its singlet excited state 
(S1), subsequent intersystem crossing (ISC) of the chromophore to its triplet state (T1) and en-
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ergy transfer from the triplet state to the metal ion. These processes, with competing processes, 
are illustrated in a simplified Jablonski diagram as seen in Figure 1-7. 
There are certain Ln(III) ions with excited states that are slightly lower in energy than the tri-
plet states of typical ligands and they exhibit strong fluorescence. Gd(III) ion has all its excited 
states above the ligand triplet states, while Eu(III) and Tb(III) have a large number of excited 
states promoting energy loss by non-radiative routes. Thus, Eu(III) and Tb(III) are the most 
useful ions for luminescence studies with green and red luminescence respectively (Table 1-9). 
The luminescence spectra of Eu(III) complexes, which exhibit 4f 6 electronic configuration, 
arise from 5D0 → 7FJ (ΔJ = 0 to 4) transitions. The most intense bands observed are 5D0 → 7F1 
and 5D0 → 7F2 transitions, in particular the latter one centred around 612 nm. This hypersensi-
tive band gives strong and sharp emission line due to its electric dipole character. Similarly, in 
Tb(III) spectra (4f 8 electronic configuration) the main emission bands for luminescence are 
5D4 → 7FJ (ΔJ = 2 to -2) with 5D4 → 7F5 centred at 543 nm being the most intense.  
Transition Emission/nm Relative intensity Characteristics and sensitivity to ligand envi-ronment. 
Eu(III)    
5D0 → 7F0 
      → 7F1 
      → 7F2 
 
      → 7F3 
      → 7F4 
578-580 
585-600 
610-630 
 
645-660 
680-705 
Weak 
Strong 
Strong-very strong 
 
Weak 
Medium-weak 
Absent in high symmetry 
Magnetic dipole, insensitive to environment 
Hypersensitivity, increase intensity as sym-
metry is lost 
Weak intensity and sensitivity 
Intensity and structuring moderate sensitive 
Tb(III)    
5D4 → 7F6 
      → 7F5 
      → 7F4 
      → 7F3 
      → 7F2 
485-500 
540-555 
580-595 
615-625 
645-655 
Medium-strong 
Strong-very strong 
Medium 
Medium-weak 
Weak 
Moderate sensitivity 
Hypersensitivity 
Moderate sensitivity 
Fine structure at high resolution 
Moderate sensitivity 
Table 1-9 Characteristics of emission spectra of Eu(III) and Tb(III) adapted from ref [88]. 
1.5.2.3 Determination of Hydration Number 
As mentioned previously, the luminescent properties of Eu(III) and Tb(III) analogues of 
Gd(III) chelates enable the hydration number (q) to be determined via time-dependent lumi-
nescence lifetime decay. It has been shown that luminescence of Eu(III) and Tb(III) 
complexes was more intense in D2O than in H2O and the lifetimes were longer in D2O. This is 
because of less effective coupling in O-D oscillators than to the O-H oscillators (Figure 1-8).89 
The excitation occurs from the ground states followed by emission showing the ΔJ = 2 transi-
tion for Eu(II) and ΔJ = 1 for Tb(III). There is a greater overlap of the ν = 3 vibrational state 
of H2O with the 5D0 excited state of Eu(III) (5D0 → 7F2 around 612 nm) than with the 5D4 ex-
cited state of Tb(III) (5D4 → 7F5 around 545 nm) resulting in greater quenching and shorter 
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lifetime of Eu(II). In contrast, overlapping of the less populated ν = 4 and 5 vibrational levels 
of D2O with the excited states of Eu(III) and Tb(III) respectively, results in reduced quenching 
and longer lifetimes in D2O. 
 
Figure 1-8 Vibrational quenching of Eu(III) and Tb(III) with O-H and O-D oscillators, adapted 
from ref [90]. 
This phenomenon has been used by Horrocks to derive an equation for determining the q of 
luminescent lanthanides.91 The difference in luminescence lifetimes k measured in H2O and 
D2O solutions is related to the q of the complex:  𝑞!" = 𝐴!" 𝑘!!! −   𝑘!!!  
where ALn is a proportionality constant specific to a given lanthanide ion, reflecting its sensi-
tivity to H2O quenching. For Tb complexes, A = 4.2 ms-1 and for Eu, A = 1.05 ms-1. 
Other energy matched exchangeable X-H oscillators may also quench the excited states of Ln 
ions, including amine N-H, amide N-H and C-H. Moreover, the presence of outer sphere water 
molecules is contributed to the quenching. As a consequence of these effects, a correction fac-
tor is introduced to account for the quenching effect of closely diffusing unbound water 
molecules and the effect of other exchangeable X-H oscillators, notably N-H groups.92 𝑞!" = 1.2 𝑘!!! −   𝑘!!! − 0.25  𝑞!" = 5 𝑘!!! −   𝑘!!! − 0.06  
Measuring emission intensity vs. time in both D2O and H2O allows the first order decay con-
stants, 𝑘!!!  and 𝑘!!!  to be determined. When applied to the above equations, q can be 
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calculated and the solution to these equations is to give non-integer values representing an av-
erage of the hydration numbers of Ln(III) complexes with an error of ± 0.2 water molecules.90 
1.6 Fluorescence Imaging 
In vivo fluorescence encompasses a wide range of resolution and imaging depths, including 
subcellular analysis with intravital microscopy (IVM) and whole animal imaging with fluores-
cence molecular tomography (1-3 mm spatial resolution, < 10 cm depths).93 Fluorescence 
imaging at greater depths (> 1 mm) requires near infrared (NIR) fluorophores with excitation 
and emission wavelengths in the range of 700-1000 nm. Water, haemoglobins and lipids, 
which are major absorbers in the range of 200-650 nm, have low absorption coefficients in the 
NIR region (Figure 1-9).  
 
Figure 1-9 Absorbance of various tissue and blood components from 200 to 1000 nm, from ref [94]. 
The tissue transparency window ranging from 650 to 1450 nm is the greatest for tissue penetra-
tion. 
NIR fluorophores as contrast agents are the preferred choice for in vivo fluorescence imaging 
as the autofluorescence from non-targeted tissues is minimal. Fluorophores can be either or-
ganic or inorganic, and each has its own advantages and limitations. The intrinsic properties 
such as excitation and emission wavelengths, photostability, quantum yield and absorption 
coefficient of a fluorophore are important factors for determining the effectiveness of an imag-
ing agent. Recent research has focused on the development of NIR fluorophores with 
excitation and emission maxima in the range of 650-1000 nm.94-96 
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1.7 Nuclear Imaging 
Nuclear imaging is characterised by the use of radiopharmaceuticals or radiolabelled imaging 
agents administered in pM-nM concentrations allowing for visualisation, assessment and 
quantitation of molecular and physiological processes in vivo. Nuclear imaging can be divided 
into SPECT and PET depending on the radionuclides used (Table 1-10). 
SPECT requires the use of a contrast agent labelled with an γ-emitting radionuclide, which 
should have an ideal γ-energy of 100-250 keV. These γ-rays are recorded by γ-camera to ac-
quire multiple two dimensional (2D) images. After signal processing, the data can be 
converted into an image identifying the localisation of the radiotracer. 
Similar to SPECT, PET imaging based on the decay of a singe radionuclide which emits a 
positron; it then travels a short distance before being annihilated with an electron to release 
two 511 keV γ-rays 180° apart, which are detected by a PET scanner. The image is then ac-
quired by successively summing of all the detected positron emission events in either two or 
three dimensions. PET has greater advantages over SPECT with respect to sensitivity and res-
olution. However, PET suffers from low spatial resolution, making it difficult to localise 
original signals from biological samples. 
Both SPECT and PET provide minimal anatomical information, therefore it is a usual practice 
to obtain images using CT prior to nuclear imaging. Both PET-CT and SPECT-CT have 
evolved to be hybrid nuclear imaging techniques that have been widely used in oncology ow-
ing to their remarkable sensitivity as functional processes detected by PET or SPECT can be 
more precisely localised when aligned to anatomic imaging obtained from CT. 
Isotope t1/2 (h) Decay mode Eγ (keV) Eβ+ (keV) 
SPECT     
67Ga 78.26 EC (100%) 91, 93, 185, 296, 388  
99mTc 6.0 IT (100%) 141  
111In 67.9 EC (100%) 245, 172  
PET     
62Cu 0.16 β+ (98%) EC (2%)  2910 
64Cu 12.7 β+ (19%) EC (41%)  656 
68Ga 1.1 β+ (90%) EC (10%)  1880, 770 
86Y 14.7 β+ (33%) EC (66%)  2335, 2019, 1603, 
1248, 1043 
Table 1-10 Important γ  and positron emitting radionuclides for SPECT and PET imaging, 
adapted from ref [97]. Abbreviations: EC = electron capture, IT = isomeric transition. 
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1.8 Project Concepts 
As discussed previously in this chapter, inflammation is an enormous subject, encompassing 
diverse topics including cell biology and pathology. It has emerged as a pathophysiological 
basic for many diseases that were not initially known to be associated with inflammatory re-
sponse, such as cardiovascular disease, arthritis, cancer and asthma.7, 98-99 To better 
understanding and managing diagnosis and treatment of these diseases, it is important to de-
velop a non-invasive imaging approach to detect inflammation in vivo. The core project of the 
thesis is to develop novel imaging agents targeting inflammation and to investigate imaging 
approaches for detecting acute inflammation in vivo using a suitable murine model. 
FPR family has been selected as one of the targets to image inflammation by tracking the im-
mune cells that express FPRs involved in the inflammatory processes, e.g. neutrophils which 
are the first cells to reach the site of inflammation and have been shown to express FPR1 and 
FPR2. Molecular imaging targeting FPRs could offer insights into the underlying biological 
processes of the inflammatory processes involving FPRs expressed cells. 
1.9 Aims and Objectives 
The overall objective of development and evaluation of the novel exogenous imaging agents 
targeting inflammation encompasses the following steps: 
• Synthesise bifunctional cyclen-based ligands to form highly stable metal complexes 
for in vivo imaging. 
• Synthesise novel imaging agents by conjugating the cyclen-based ligands to the pep-
tides of interests, cFLFLFK and WKYMVm for FPR1 and FPR2, respectively. 
• Synthesise the metal complexes of the synthesised peptide-cyclen conjugates using 
Gd(III), 67Ga(III) and 67Cu(II) ions for MRI, SPECT and PET imaging respectively. 
• Synthesise NIR fluorophores which enables conjugation to cFLFLFK or WKYMVm 
for fluorescence imaging. 
• Synthesise and develop non-peptide FPR1 targeted imaging agents using the multi-
component Ugi condensation reaction. 
• Investigate the biological properties such as receptor binding affinity and neutrophil 
functions of synthesised imaging agents using various in vitro techniques: 
o competitive radioligand binding assay using [125I]-fnLLFnLYK and HEK cells 
stably expressing FPR1 or FPR2. 
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o chemotaxis of neutrophils upon stimulation of cFLFLFK, WKYMVm and the 
synthesised complexes. 
o cytokine production of neutrophils upon stimulation of cFLFLFK, 
WKYMVm and the synthesised complexes. 
• Investigate the in vivo imaging properties of synthesised imaging agents using a mu-
rine model of inflammation, such as localised inflammation induced by an endotoxin 
in the brain or in the thigh for MRI and nuclear imaging respectively. 
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2 Synthesis Towards Orthogonally Protected Bifunctional 
Chelating Agents 
2.1 General Background of Bifunctional DOTA Chelates 
Over the past few decades, a large number of metal-based pharmaceuticals has been developed 
by labelling biomolecules with a metal or radioactive metal ion.1-3 A detailed discussion on 
various targeting biomarkers is beyond the scope of this thesis, though a few review articles 
has been published dedicated to the synthesis and development of targeted molecular imag-
ing.4-6 Gd(III) ions remain one of the common metal ions for MRI where as radioactive metal 
ions are of particular interest for radiopharmaceutical development owing to their wide range 
of nuclear properties, coordination chemistry and readily availability. The success of various 
nuclear imaging agents such as 111In-DTPA-octreotide (OctreoScan®) and 99mTc-P829 (Neo-
Tect®) for tumour imaging, has led to exploration of the potential uses of other radiometals. 
The most reliable and most commonly used method of linking the metal ion to a biomolecule 
is by the use of bifunctional chelating agents (BFCAs).7-8 These are small molecules contain-
ing two different moieties: a strong metal chelating unit and a reactive functional group. The 
latter is directed to react with various functional groups to form a stable covalent bond with 
the carrier while the chelating unit is able to coordinate strongly to a metal ion. Depending on 
the selected metal ion, these complexes have found applications in medicine as diagnostic or 
therapeutic agents. 
It is well known that free metal ions are toxic as they form stable and soluble complexes with 
ligands such as amino acids, proteins and phospholipids that are present in plasma. The chal-
lenge in synthesising metal-based pharmaceuticals is to render the metal ions safe without 
impairing their physical properties. DOTA (1,4,7,10-tetrakis(carboxylmethyl)-1,4,7,10-
tetraazacyclododecane) and its derivatives represent a major class of chelating agents for bio-
medical applications owing to their excellent complexation properties towards a variety of 
divalent and trivalent metal ions with high thermodynamic and kinetic stability. Besides form-
ing very stable complexes with lanthanides Gd(III) as MRI contrast enhancing agents, DOTA 
also forms stable complexes with various divalent (64Cu) and trivalent radionuclides (68Ga, 90Y, 
111In), making it useful for both diagnostic and therapeutic applications in nuclear medicine.9-12 
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Scheme 2-1 Generic structures of monofunctionalised DOTA analogues.2 
Modification of the ligand structure to introduce an easily functionalisable group can occur at 
one of the carbons of the macrocyclic ring (Scheme 2-1, Z) or on one of the chelating arms 
(Scheme 2-1, X and Y). Initial approach to incorporate a DOTA unit involves direct modifica-
tion of one of the carboxylic groups with lysine side chains which are usually located on the 
surface of proteins leading to a DOTA-monoamide unit (Scheme 2-1, X). Even though the 
carboxyamide oxygen generally coordinates to metal ions, it has been shown that both the 
thermodynamic and kinetic stability constants of the majority of metal complexes decrease by 
two or three orders of magnitudes (Table 2-1). High kinetic stability is important as it means 
that the undesired in vivo release of the metal ion and transmetallation reaction with endoge-
nous metal ions such as Zn(II) and Ca(II) are avoided.13 Thus, the imaging agents can circulate 
in the body for a long period of time in order to localise at the targeted site. Previous studies 
have also revealed that the substitution of an acetate group of the DOTA by the less strongly 
coordinating amide group results in an undesirable decrease of the water exchange rate (kex) on 
the Gd(III) chelate.14-16 
Ligand r1 (20 MHz; 298 K)/mM-1s-1 q kex x 10
6/s-1 𝜏!!"#/µs log  k!"/ms-1 References 
Aqua - 8 804 1.24 - 17 
DTPA 4.02 1 3.3 303 22.2 18 
DOTA 4.74 1 4.1 244 25.6 18 
DOTASA 5.93 1 6.3 159 27.2 19-20 
DOTAM 2.50 1 0.053 18900 13.1 21-23 
Table 2-1 Kinetic parameters and stability constants on selected Gd(III) chelates. 
The initial synopsis of this work was to design and synthesise DOTA-based chelates to form 
stable Gd-based MRI contrast enhancing agents featuring a functional group for conjugating to 
the N-terminus or other amino functions of biomolecules in bioimaging applications. This 
chapter will describe the synthetic routes towards orthogonally protected BFCAs via function-
alisation at the α-C of one of the acetate groups (Scheme 2-1, Y). The desired chelate would 
provide four intact carboxylic groups besides the macrocyclic tetraazacyclododecane ring for 
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an efficient and stable binding of metal ions and a functional group for conjugation to a bio-
molecule of interest. 
2.2 Synthesis Towards Orthogonally Protected BFCAs 
A retrosynthesis analysis of the target ligand 1 is shown in Scheme 2-2. The strategy to syn-
thesise the orthogonally protected BFCAs is based on the following concepts, i.e. designing 
and synthesising DOTA-based chelates with a carboxylic functional group for conjugation to 
amino functional groups of biomolecules, while maintaining the thermodynamic and kinetic 
stability, as well as the relatively fast water exchange of the Gd.DOTA unit. The metal com-
plex M.1 is made from the metal-free ligand 1 by the addition of an appropriate metal source 
e.g. GdCl3 for Gd(III), YCl3 for Y(III). Ligand 1 is formed by the removal of the ester units of 
the acetate groups of 2. Most applications that involve DOTA derivatives are generally syn-
thesised from the alkylation of the protected DO3A 3 with an appropriate pendant arm 4. The 
desired pendant arms 4 are dicarboxylic acid diesters containing an appropriate leaving group 
i.e. bromine at the α-position to the carbonyl group. 
 
Scheme 2-2 Retrosynthesis analysis of chelate 1. 
The metal complex M.1 can couple with biomolecules with an amino functional group without 
any protection step as four acetate arms of DOTA are involved in the coordination of metal 
ions. This is a so-called ‘metal protection’ approach. In contrast to the metal protection ap-
proach, the other strategy to synthesise orthogonally protected BFCAs involves the synthesis 
of orthogonally protected compound 4 when R ≠ tert-butyl in which the carboxylic acids can 
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be selectively deprotected under different conditions and reagents. Although the use of metal 
protection avoids subsequent cleavage of the ester groups using reagents that are not suitable 
for fragile biomolecules, this approach has limited application and could not be applied for 
nuclear imaging, as the complexation of radiometals should be performed in the last step to 
minimise unnecessary loss of radioactivity. A literature review has revealed that DOTASA19 
and DOTAGA24 have been synthesised by Mäcke and co-workers. The multistep synthesis of 
DOTASA involved synthesis of diphenylmethyldiester of commercially available bromosuc-
cinic acid, whereas multistep synthesis of DOTAGA included orthogonally protected 4 
wherein R is benzyl group. DOTAAA has not been synthesised although the synthesis of or-
thogonally protected bromo-adipic acid has been established.25 
2.2.1 Formation of Protected DO3A (3) 
DOTA-based chelates are generally synthesised from the alkylation between the protected 
DO3A 3 and an appropriate pendant arm. The precursor tBu-DO3A 3 can be synthesised from 
cyclen and tert-butyl bromoacetate via two methods: stirring in dimethylacetamide (DMA) (i) 
at room temperature (rt) for 19 days giving a yield ranging between 56-80%26 or (ii) at lower 
temperature for 24 h giving a much higher yield of 95%.27 
 
Scheme 2-3 Synthesis of protected DO3A, 3. 
Compound 3 is the building block for vast majority of metal chelates used in bioimaging. The 
initial attempts to prepare 3 were to react cyclen with sodium acetate with stirring at -20 °C 
and tert-butyl bromoacetate was added dropwise over 30 min (Scheme 2-3). Following the 
complete reaction, water and potassium hydrogen carbonate were added to precipitate the 
product. The crude product was collected by filtration and recrystallised from diethyl ether 
gave a white solid with 95% yield. The product was confirmed via 1H, 13C NMR spectroscopy 
and MS (ESI +ve), which are compared to those in the literature.27 
2.2.2 Synthesis Towards α-Bromo Dicarboxylic Acid Diester (4) 
A retrosynthesis of compound 4 is shown in Scheme 2-4. Compound 4 is formed by esterifica-
tion using appropriate reagents from α-bromocarboxylic acid 5, which is an important 
synthetic intermediate. There are two classical methods to prepare 5: the Hell-Volhard-
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Zelinsky reaction from aliphatic carboxylic acids (Scheme 2-4, method 1) or diazotisation of 
α-amino acids (Scheme 2-4, method 2). 
 
Scheme 2-4 Retrosynthesis analysis of orthogonally protected α-bromo dicarboxylic acid diester 
4. 
The Hell-Volhard-Zelinsky reaction (Figure 2-1) is α-halogenation of carboxylic acids. Car-
boxylic acids do not react with Br2 unlike aldehydes and ketones, thus bromination is 
performed using a mixture of Br2 and inorganic halide such as thionyl chloride, phosphorus 
tribromide or organic halide such as oxalyl chloride. The halides convert carboxylic acids to 
acid halides, which can enolise to react with Br2. Subsequent hydrolysis terminates the bro-
mination reaction forming α-halocarboxylic acid. Monoesterification of the symmetrical 
dicarboxylic acids 8 is required to avoid di-halogenation. However, monoesterification can 
result in the formation of mono- and di-substituted products, thus to simplify and minimise the 
reaction procedure commercially available monoester e.g. 6 (n = 2, R = ethyl) was used and 
the synthesis to 4 (n = 2, R = ethyl) was attempted according to the literature.25  
 
Figure 2-1 Reaction mechanism of Hell-Volhard-Zelinsky reaction. 
Diazotisation of primary aromatic amines with nitrous acid generated in situ from sodium ni-
trite and a strong acid leads to the formation of isolable diazonium salts. When aliphatic 
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primary amines are employed, the resultant diazonium salts are unstable and yield various 
products according to the reaction conditions and reagents. Treatment of α-amino acids using 
sodium nitrite in aqueous hydrobromic acid results in diazotisation-bromination (Figure 2-2).5 
The nucleophilic substitution of the diazonium salt proceeds with retention of configuration, 
which is the result of double inversion associated with anchimeric assistance by the neigh-
bouring carboxyl group in the amino acid.28 In addition, the presence of multiple carboxylic 
acids within the same molecule does not have any impact on diazotisation compared to the 
Hell-Volhard-Zelinsky reaction. Therefore, 4 can be formed directly from 9 when R = tert-
butyl in a two-step synthesis i.e. diazotisation-bromination followed by diesterification. 
 
Figure 2-2 Reaction mechanism of diazotisation-bromination of α-amino acid with anchimeric 
assistance. 
2.2.2.1 Attempted Synthesis of 2-Bromoadipic Acid 1-tert-Butyl Ester 6-Ethyl Ester 
(11) 
Conversion of 10 to 11 was attempted via the Hell-Volhard-Zelinsky reaction with thionyl 
chloride according to the literature (Scheme 2-5).25 A variety of conditions was explored in an 
attempt to synthesise and isolate the desired compound. These included an increase in reaction 
time and temperature, and a substitution of thionyl chloride with oxalyl chloride as the acylat-
ing agent. These changes did not show positive results whilst the reaction was monitored via 
1H NMR spectroscopy and MS. Both MS (CI) and 1H NMR spectra indicated that α-
bromination did not occur and 10 remained unreacted.  
 
Scheme 2-5 Attempted synthesis of 11. 
The true cause of the unsuccessful synthesis of 11 could not be definitely ascertained. It was 
probably due to the presence of water in the bromine source which could hamper the bromina-
tion reaction. Alternative bromine sources such as N-bromosuccinimide can be considered 
which has been employed to α-brominate carbonyl compounds.29-30 However, due to the syn-
thetic difficulties and complications in preparing 11, the simpler diazotisation of commercially 
available α-amino acid was considered. 
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2.2.2.2 Formation of Bromoglutamic Acid Diester (15, 17) 
Initial attempt to prepare 15 was to diazotise L-glutamic acid (GA) 12 using in situ nitrous 
acid generated from sodium nitrite and aqueous hydrobromic acid in the presence of sodium 
bromide followed by esterification using the method adapted from the literature (Scheme 2-
6).31-32 
 
Scheme 2-6 Formation of 15 and reaction side product 14. 
The first step involved conversion of the amino functional group without the change of carbon 
chain skeleton, both 1H and 13C NMR spectroscopy were therefore inconclusive, MS (CI) and 
IR spectroscopy were employed to monitor and analyse the reactions. MS (CI +ve) showed 
peaks at m/z = 252 and 254 representing [M-H+Na+NH4]+ with the correct Br isotopic split-
ting. IR spectroscopy shows the characteristic peaks for different functional groups; this is 
particular useful for this reaction as the diazotisation-bromination and subsequent esterifica-
tion of 12 can be observed (Figure 2-3). The characteristic bands at 3021 and 2743 cm-1 
corresponding to νN-H disappeared and a broad band at 3200 cm-1 corresponding to carbox-
ylic OH group was observed in 13. The broad νO-H band disappeared in 15 and the 
characteristic bands for νC-H at 2979 and 2934 cm-1 corresponding to the tert-butyl group 
were observed, indicating successful conversion of 12 to 15. 
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Figure 2-3 IR spectra comparing 13 (black) and 15 (blue) (neat on KBr disc). 
Although the desired product 15 had been synthesised and isolated, there were issues with the 
reaction reproducibility. It was found that when the conversion of 12 to 13 was performed 
with aged hydrobromic acid, bromination did not occur and the only product observed was γ-
butyrolactone-γ-carboxylic acid 14 (Scheme 2-6). The formation of the lactone as the side 
product is common due to the hydrolysis of the carbocation in water. Following investigation 
by varying reaction conditions, it was found that hydrobromic acid has to be prepared prior to 
the reaction as the presence of the impurity, Br2 generated in aqueous solution over time could 
impede the reaction. It was also found that slow addition of sodium nitrite using a syringe 
pump is essential in obtaining 13 in high yield as Br2 formation is minimised during the reac-
tion. In addition, sodium nitrite has no impact on yield or side product formation whether it is 
anhydrous or not. 
The crude product 13 was further reacted without purification. Subsequent reaction with tert-
butyl acetate and perchloric acid as a catalyst was conducted according to Kielar et al. and 
yielded the desired product 15.31 Isolation of pure compound 15 using silica gel, eluting with 
dichloromethane (DCM), gave a pale yellow oil with 15% yield, which is comparable to the 
literature (19% yield).31  
 
Scheme 2-7 Synthesis of orthogonally protected 2-bromoglutamic acid diester 17. 
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Compound 17 was prepared from commercially available 16 according to the method similar-
ly used for 15, using freshly prepared hydrobromic acid prior to the reaction (Scheme 2-7). 
Esterification with tert-butyl acetate and perchlorate acid successfully modified the carboxylic 
acid without any reaction on the methyl ester. Analysis by 1H NMR spectroscopy showed 
peaks indicative of the methyl ester at 3.73 ppm integrating to three protons; MS (CI +ve) 
gave peaks at m/z = 242 and 244 representing [M+NH4]+ with the correct Br isotopic distribu-
tion. The overall yield was 33% after purification on silica. It was postulated that the improved 
yield as compared to the synthesis 15 (15% yield) is attributed to the presence of the methyl 
ester, which minimises the formation of the side product. 
2.2.3 Synthesis Towards Protected DOTAGA (18-19) 
Initial attempt to prepare compound 18 was to react 3 with 15 in the presence of potassium 
carbonate as a base in acetonitrile (Scheme 2-8). It was found that purification after esterifica-
tion from 13 to 15 was crucial as it removed acetic acid generated during the esterification 
reaction using perchloric acid, which could inhibit the alkylation reaction. The crude product 
was purified on 5% deactivated alumina with a gradient elution of 0 to 3% methanol in DCM 
giving a pale yellow oil (80% yield). MS (ESI +ve) showed peaks at m/z = 757 and 779 repre-
senting [M+H]+ and [M+Na]+ respectively, indicating the formation of the desired product; 1H 
NMR spectrum exhibited peaks indicative of the desired product with the alkane CH2 on the 
GA chain and the tert-butyl at 2.18 and 1.47 ppm respectively. 
 
Scheme 2-8 Synthesis of protected DOTAGA (18, 19). 
The orthogonal protected DOTAGA 19 (R = Me) was synthesised in the same manner giving 
a pale yellow oil with 43% yield (Scheme 2-8). Analysis by 1H NMR spectroscopy showed 
peaks indicative of the methyl ester at 3.66 ppm integrating to three protons; MS (ESI +ve) 
gave peaks at m/z = 715 and 737 representing [M+H]+ and [M+Na]+ respectively. 
As demonstrated by Levy et al., ligand 18 synthesised via diazotisation-bromination followed 
by alkylation resulted in a 2:1 mixture of diastereoisomers as a result of partial racemisation of 
alkylating agent or racemisation during the alkylation reaction.33 Thus it is assumed that both 
ligand 18 and 19 synthesised in this project are not optically pure. A multistep synthesis has 
been established to obtain optically pure DOTAGA chelate.33 In this project, diazotisation-
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bromination method is preferred as the synthesis is less complicated with fewer synthetic steps 
and the chirality in DOTAGA would not affect the receptor binding since the DOTA unit is 
not directly involved in the receptor-ligand interaction. However, the synthesis of optically 
pure ligand 20 should be considered for future clinical applications. 
2.2.4 Formation of DOTAGA (20) 
To synthesise DOTAGA 20, the protected ligand 18 was treated with a mixture of trifluoroa-
cetic acid (TFA) in DCM, and the tert-butyl esters were cleaved to afford the final product as a 
hydroscopic powder in near quantitative yield (Scheme 2-9). 
 
Scheme 2-9 Cleavage of tert-butyl esters from 18. 
In the 1H NMR spectrum, the peaks indicative of tert-butyl ester at 1.47 ppm were not ob-
served, confirming successful cleavage of tert-butyl esters. The final product 20 was further 
characterised via HRMS and IR, which are compared to the findings in the literature.31 
2.2.5 Selective Deprotection of DOTAGA-tBu4, Me 
The orthogonally protected 19 was treated with a mixture of 1 M sodium hydroxide and meth-
anol, and the methyl ester was cleaved without cleavage of tert-butyl esters to give the desired 
product 21 as a pale yellow oil with 90% yield (Scheme 2-10). 
 
Scheme 2-10 Methyl ester cleavage of 19. 
In the 1H NMR spectrum, the peaks indicative of tert-butyl ester at 1.47 ppm were observed, 
whereas the peaks representing the methyl ester at 3.66 ppm were not observed confirming 
successful selective cleavage of methyl ester over tert-butyl ester. The final product 21 was 
further characterised via MS and IR spectroscopy. The MS (ESI +ve) showed a peak at m/z = 
701 representing [M+H]+. 
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2.2.6 Lanthanide Complexation with DOTAGA (Ln.20) 
Despite a growing interest in employing DOTAGA 20 to conjugate with biomolecules for bi-
oimaging application, little is known for metal complexes of 20 except Gd(III) and Y(III).32 
Other lanthanide complexes, such as Eu(III) and Tb(III) have not been synthesised and their 
photophysical properties have not been investigated. The primary aim was to obtain a Gd(III) 
complex from ligand 20 in order to produce novel MRI contrast agents by conjugating to bio-
molecules containing an amino functional group via the smart metal protection approach, and 
analogous Tb(III) and Eu(III) complexes enable for luminescence and NMR studies, and to 
elucidate the solution behaviour or Gd.20. 
 
Scheme 2-11 Lanthanide complexation with ligand 20. 
All lanthanide complexes were synthesised via the same method (Scheme 2-11), reacting 20 
with an excess of LnCl3.6H2O in water at pH 5.5 for 18 h. To ensure successful metal com-
plexation, the control of pH is vital as the lanthanide starts to precipitate at a pH above 7.34 
The pH of the reaction mixture solution was maintained between 5.5 and 6 throughout the re-
action time. 
Free lanthanide ions were removed as lanthanide hydroxide by centrifugation after stirring at 
pH 11 for 30-40 min. The supernatant was collected and tested for the presence of free lantha-
nide ions using acetate buffered solution of xylenol orange at pH 5.8.35 The xylenol orange 
assay is a colourimetric assay whereby a colour change from orange to purple indicates the 
presence of free lanthanide ions. The reaction was monitored via MS (ESI) for the specific 
mass and lanthanide isotopic pattern of the desired complex. 
2.2.7 Characterisation of Ln.20 
2.2.7.1 NMR studies of Eu.20 
Eu.20 was synthesised from 20 and EuCl3.6H2O, giving a white solid in 96% yield. MS (ESI –
ve) of the complex gave peaks at m/z = 625 representing [M]- with the correct isotopic split-
ting pattern for a Eu(III) complex. 
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With paramagnetic Ln(III) complexes, the spectral range increases as the protons near the 
Ln(III) are paramagnetically shifted through dipolar coupling, as shown in the 1H NMR spec-
trum of Eu.20 (Figure 2-4). The peaks are found between -25 to +40 ppm, which is within the 
expected range for Eu(III) complexes of DOTA derivatives. Ligand 20 is an asymmetrical de-
rivative of DOTA, thus the signal degeneracy is removed due to lack of C4 symmetry leading 
to a large number of resonances for each isomer in the 1H NMR spectrum. 
Previous studies has demonstrated that the introduction of a site of asymmetry and a chiral 
centre on one of the acetate α-C results in four possible diastereoisomers upon chelation. The 
presence of the substituent on the acetate α-C slows the acetate arm rotation and thus only two 
diastereoisomers are observed.20, 36-37 Derivatisation of one acetate α-C with a GA substituent 
led to two isomers as detected in the 1H NMR spectrum. The axial ring protons gave two sets 
of four resonances well separated from all the others peaks, corresponding to the SAP (or M) 
or TSAP (or m) isomers. The peaks observed at higher frequency (δ = 33-38 ppm) corre-
sponded to four axial ring protons of the SAP geometry, while, for the TSAP geometry, the 
same axial ring protons were observed at lower frequencies (δ = 13-19 ppm). Integration of 
these resonances gave the isomer ratio M/m of 1:0.9 as shown in Table 2-2. 
DOTA functionalisation at the α-C of the acetate arms affects the M/m isomer ratio in which 
the configuration at the chiral carbon determines the least sterically hindered helical form of 
the complex. The dependence of the M/m ratio on the ionic radius of the lanthanide ions for 
DOTA complexes was observed and interpolation gave an approximate value of M/m = 1:0.3 
for Gd.DOTA.38 It is well known that the m isomers of lanthanide DOTA-type chelates have 
considerably faster water exchange kinetics than those of the M isomers.22, 39 This has im-
portant implications to the design of DOTA-based contrast agents, as it is preferable to 
synthesise complexes which exist mainly in the fast exchanging m isomer in solution. More 
importantly, the m isomer population of ligand 20 is 3-4 times increased relative to Gd.DOTA 
as postulated from Eu.20, indicating that ligand 20 with Gd(III) forms stable complexes for 
MRI with a higher ratio of M/m and the extra acetate group is available for further modifica-
tion without affecting the M/m ratio.  
- 63 - 
 
Figure 2-4 1H NMR spectrum of Eu.20 showing the axial protons of the SAP and TSAP isomers 
(D2O, pH 7.0, 298 K). 
Complex TSAP or m isomer/ppm SAP or M isomer/ppm M/m 
Eu.20 18.61, 17.08, 14.01, 13.32 37.31, 36.74, 36.73, 33.17 1:0.9 
Table 2-2 1H NMR shifts, δ  of the ax1 protons of the paramagnetic Eu.20 in the M and m isomeric 
forms. 
2.2.7.2 Luminescent Studies of Eu.20 
The luminescent properties of Eu.20 were investigated and its hydration number, q was de-
termined. The complex was excited at 395 nm to give an emission spectrum as depicted in 
Figure 2-5, which is typical for an eight-coordinated Eu(III) complex with q = 1. The excita-
tion spectrum showed weak peaks at 395 nm representing pseudo-direct excitation of the 
Eu(III) ion. The emission was weak because there is no chromophore within ligand 20 for sen-
sitised emission to increase emission intensities. 
The peaks at 590, 615, 650 and 695 nm corresponded to the 5D0 → 7F1, 7F2, 7F3 and 7F4 (ΔJ = 1, 
2, 3 and 4) transitions respectively. The most intense emission bands are usually ΔJ = 1 and ΔJ 
= 2 bands. ΔJ = 1 is recognised as being “insensitive” to ligand field effect and thus the coor-
dination environment of the Eu(III) ion, while ΔJ = 2 is hypersensitive to the site symmetry of 
Eu(III) ion.40 The non-degenerate nature of 5D0 state simplifies the splitting of the Eu(III) 
TSAP 
m 
SAP 
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emissions, thus the energy spacing, line splitting and relative intensities of the transitions ΔJ = 
1 and ΔJ = 2 reveal valuable information about the coordination geometry of the complex.41 
However, owing to the limitation of spectral resolution, line splittings of ΔJ = 0-2 transitions 
are not discussed. For Eu.20, the ratio of the intensities of ΔJ = 2/ΔJ = 1 is 0.7 indicating that 
the Eu(III) is in a high symmetry environment, however it is in conflict with the 1H NMR 
spectrum, which showed that there is no symmetry due to presence of M and m isomers. 
The hypersensitive 5D0 → 7F2 transition at 612 nm was monitored for lifetime studies in H2O 
and D2O to determine 𝑘!!! and 𝑘!!! in order to calculate q of Eu.20 (Figure 2-6). The rec-
orded data were fitted to a first-order exponential decay using GraphPad Prism (version 5.0c, 
GraphPad Software, Inc., San Diego, CA). It was found that the rate of decay was faster in 
H2O than in D2O owing to less effective coupling with O-D oscillators than in the O-H oscilla-
tors, and q of Eu.20 was calculated to be 1.0 from the lifetime studies (Table 2-3). 
The results show that Eu.20 will bind one water molecule and ligand 20 is an octadentate lig-
and featuring an eight-donating DOTA unit for strong coordination to a Ln(III) ion and an 
extra acetate arm for further modification. 
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Figure 2-5 Luminescent excitation and emission spectra of Eu.20, (λ ex = 395 nm, H2O, 298 K, pH 
7.4).  
 
Figure 2-6 Excited state lifetime studies for Eu.20 at 298 K, pH 7.4, λ ex = 395 nm, λ em = 590 nm. 
Complex λex/nm λem/nm 𝑘!!!/ms-1 𝑘!!!/ms-1 q (±0.2) 
Eu.20 395 612 1.56 0.49 1.0 
Table 2-3 Rate constants, k, for depopulation of the excited state and derived hydration number, q 
of Eu.20. 
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2.2.7.3 Luminescent Studies of Tb.20 
Tb.20 was synthesised in the same manner as Eu.20 from TbCl3.6H2O, giving a peach col-
oured solid in 95% yield. MS (ESI -ve) showed peaks at m/z = 631 representing [M]- with the 
correct isotopic splitting for a Tb(III) complex. Its luminescent properties were investigated 
and the hydration state, q of the complex was determined. 
Due to the absence of a chromophore within ligand 20, there is no sensitised emission and the 
emission spectrum was recorded at λex = 355 nm, which is a pseudo-direct excitation of the 
Tb(III) ion (Figure 2-7). The emission spectrum is typical for a Tb(III) emission, showing var-
ious transitions from 5D4 to 7FJ (ΔJ = 2 to -2). Although the relative intensities of 5D4 → 7FJ 
show some structuring to the detailed nature of the ligand environment, it is not hypersensitive 
compared to Eu(III) owing to the higher energy of the excited state of Tb(III), thus being less 
effected by the ligand environment.41 
The 5D4 → 7F5 transition at 545 nm was monitored for lifetime studies in H2O and D2O to de-
termine 𝑘!!! and 𝑘!!! in order to calculate q of Tb.20 (Figure 2-8). The rate constants for 
Tb.20 are lower than that of Eu.20, as deactivation of Tb(III) emission is less affected by O-H 
and O-D oscillators (Table 2-4). The hydration state, q of Tb.20 was calculated to be 0.8, indi-
cating that ligand 20 is an octadentate chelate. This corresponds with the results from Eu.20, 
indicating that ligand 20 forms stable eight-coordinated complexes for these lanthanide ions 
including Gd(III) ions. 
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Figure 2-7 Luminescent excitation and emission spectra of Tb.20, (λ ex = 355 nm, H2O, 298 K, pH 
7). 
 
Figure 2-8 Excited state lifetime studies for Tb.20 at 298 K, pH 7, λ ex = 355 nm, λ em = 545 nm. 
Complex λex/nm λem/nm 𝑘!!!/ms-1 𝑘!!!/ms-1 q (±0.2) 
Eu.20 395 612 1.56 0.49 1.0 
Tb.20 355 545 0.57 0.35 0.8 
Table 2-4 Rate constants, k, for depopulation of the excited state and derived hydration number, q 
of Eu.20 and Tb.20. 
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2.2.7.4 Relaxometric Investigation of Gd.20 
Gd.20 was synthesised from GdCl3.6H2O and 20 giving a white hydroscopic solid in 90% 
yield. MS (ESI –ve) spectrum of the complex gave peaks at m/z = 630 representing [M]- with 
the correct isotopic splitting pattern for a Gd(III) complex. The relaxometric properties of 
Gd.20 were investigated.  
As elucidated from previous luminescent studies, Gd.20 is expected to be an octadentate com-
plex and it will behave similarly to Gd.DOTA forming an octadentate complex which allows 
for one coordinated inner-sphere water molecule. A preliminary relaxivity study on Gd.20 was 
investigated using a spin recovery experiment recorded on a 400 MHz NMR spectrometer, T1 
was measured and r1 was calculated to be 4.6 mM-1s-1 (298 K, pH 7.0) suggesting an octaden-
tate ligand compared to the ‘gold standard’, i.e. Gd.DOTA (r1 = 4.7 mM-1s-1, 400 MHz).18 The 
concentration of Gd(III) was subsequently determined by magnetic susceptibility shifts in the 
NMR spectra for further experiment.42 
An MRI phantom investigation upon Gd.20 was performed by Dr Marzena Wylezinska-
Arridge at Biomedical Imaging Centre, Imperial College London, Hammersmith Campus us-
ing 9.4 T (400 MHz) MRI scanners. As the Gd concentration increased, the MR signals were 
enhanced as revealed by the increasing brightness, as presented in Figure 2-9. Quantitative 
analysis using ImageJ (version 1.46q, National Institute of Health, USA) showed a linear rela-
tionship between the longitudinal relaxation rate (1/T1) and Gd concentration (Figure 2-10). 
The relaxivity, r1 of Gd.20 was calculated to be 4.1 mM-1s-1 (298 K, pH 7.0). The linearity be-
tween r1 and Gd concentration implies that Gd(III) ion has been successfully complexed with 
ligand 20. 
 
Figure 2-9 T1-weighted image of six microfuge tubes immersed in a snap cap vial filled with water 
and Gd.20 with various concentrations at 9.4 T (400 MHz), 298 K. 
water      0.1          0.5           1.0            1.5           2.0 mM 
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Figure 2-10 A) Exponential fitting for measuring the T1 relaxation time at various concentrations 
of Gd.20. B) A graph of the longitudinal relaxation (1/T1) vs. Gd concentration gives a linear rela-
tionship from which the r1 can be extracted. 
2.3 Summary and Conclusions 
A reliable synthesis for DOTAGA 20 and orthogonally protected DOTAGA 19 has been 
demonstrated. Ligand 19 can be selectively deprotected to remove the methyl ester without 
cleavage of tert-butyl esters under different reaction conditions. Both ligands 20 and 19 can 
therefore find applications in biomedical imaging. 
Ln.20 has a hydration state q = 1 from luminescent studies indicating that the stable eight-
coordinated complexes were formed leaving one vacant site to bind with one water molecule. 
In addition, relaxometric studies of Gd.20 gave the relaxivity of 4.1 mM-1s-1 (298 K, 
400 MHz). This is within the range of the relaxivity of Gd.DOTA (3.5-4.8 mM-1s-1) which is 
frequency dependent, indicating that Ln.DOTA core is preserved with all four anionic oxygen 
donors leaving one acetate arm for conjugation with amino functional groups of biomolecules. 
Furthermore, derivatisation on the α-C at one of the acetate arms is not accompanied by the 
lengthening of the mean residence lifetime, τM of the coordinated water molecule that is ob-
served in the case of DOTAM derivatives. More importantly, functionalisation at α-C of the 
acetate arm in ligand 20 affected the M/m ratios in solution. There is a 3-4 times increase in 
the m isomer population relative to Gd.DOTA as postulated from Eu.20, implying that Gd.20 
would have a relatively fast water exchange kinetics. 
Studies on these various lanthanide DOTA type complexes (Eu, Gd and Tb) have confirmed 
that the ligand 20 forms a kinetically stable complex featuring an extra acetate arm as a stable 
coordinating linker to biomolecules of interest which contains amino functional groups. 
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3 Peptide-Based MRI Contrast Agents Targeting FPR1 
3.1 FPR1 Antagonists and cFLFLF-based Imaging Agents 
FPR1 is a member of the FPR family and it is functionally expressed on a variety of cell types 
as discussed in Chapter 1. FPR1 was originally identified by the ability to bind and be stimu-
lated by N-formyl peptides, such as fMLF produced by bacteria. FPR1 is known to be 
important in neutrophilic inflammatory disorders e.g. ischaemic stroke, rheumatoid arthritis.1-2 
Therefore, FPR1 has become a diagnostic and therapeutic target for the detection and devel-
opment of novel drugs that may be used to treat inflammatory diseases. The highly selective 
FPR1 agonist, fMLF had been investigated for imaging infection and inflammation in vivo.3-4 
However, using FPR1 agonists leads to the activation of FPR1 and thus stimulating neutrophil 
and macrophage pro-inflammatory response as part of the innate immune response, which is 
critical to the detection of inflammatory disease progression.  
 
Figure 3-1 A selection of known FPR1 antagonists. 
Novel contrast agents targeting FPR1 are designed with the criteria to avoid undesirable FPR1 
activation, which leads to neutropenia. Hence peptide-based FPR1 antagonists are employed 
as the targeting motif for FPR1 since antagonists do not provoke a biological response. Using 
short-chained peptides (< 10 residues) in synthesising imaging agents offer several advantages 
over small molecules. Peptides are readily synthesised and generally retain high binding af-
finity to the receptor and are less likely to produce immunogenic response. Unlike small 
molecule chemical entities (molecular weight < 500 Da) in which any modification to the 
chemical structure may result in the loss of receptor selectivity and activity, modification to 
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the peptides of interest without impairing their binding affinity and biological activity is 
achievable by conjugating the side chain of amino acid which is not involved in binding. A 
selection of peptide-based FPR1 antagonists that have been reported is shown in Figure 3-1.5-6 
The hexapeptide, cFLFLFK is potent and specific to FPR1 with a pKi of 8.7.3 It is a derivative 
of the non-selective FPR antagonist Boc2.7 It was shown that substitution of a cinnamoyl 
group to t-Boc group not only improved the receptor affinity, but more importantly made it 
highly selective to FPR1 and not to FPR2 and FPR3.3, 8  
 
Figure 3-2 Structures of cFLFLF-based imaging agents used in PET and SPECT.9-11 
Locke et al. have demonstrated the applications of cFLFLFK conjugated with a DOTA chelate 
or a hydrazinonicotinamide (HYNIC) chelate for 64Cu or 99mTc through the lysine residue for 
PET and SPECT imaging, respectively (Figure 3-2).9-12 Both ligands exhibited high binding 
affinity towards FPR1, and visualisation of focal sites of bacteria infection and phorbol 12-
myristate 13-acetate-induced inflammation in mice have been successfully conducted. It has 
indicated that cFLFLFK is a highly selective biomarker for imaging inflammation. 
This chapter features the development of novel MRI contrast agents employing the previously 
synthesised ligand DOTAGA 20 as the chelating unit for Gd(III) and using cFLFLFK as the 
targeting motif towards FPR1 for imaging acute inflammation in the brain. 
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It was hypothesised that the resultant contrast agents synthesised will retain their photophysi-
cal and relaxometric properties as well as the biological and pharmacological properties of the 
targeting peptide. However, introducing a chelating unit to the cFLFLFK can result in a signif-
icant impact on the biological and pharmacological properties of the targeting peptide, in 
particular the binding affinity towards FPR1 as this will have a significant impact on the sensi-
tivity of the desired imaging agents. It is therefore important to assess the biological effects of 
the novel contrast agents upon FPR1 and neutrophils, and to identify any undesirable effect 
using various in vitro assays. 
3.2 Synthesis Towards Peptide-Based Contrast Agents Targeting FPR1 
As shown in Scheme 3-1, there are two approaches to synthesise the desired contrast agent 
Ln.23, which features a DOTA unit and the FPR1 antagonist cFLFLFK. In both methods, the 
starting ligands 20 and 21 have been synthesised and discussed in Chapter 2. Method A high-
lights a ‘one-step’ synthesis to Ln.23 from Ln.20, in which the Ln(III) ion act as a protecting 
group leaving only one extra acetate arm for the subsequent amide coupling reaction. Com-
plexation from 20 to Ln.20 was previously discussed in Chapter 2. In contrast, method B 
employs the orthogonally protected chelate 21, which requires removal of tert-butyl esters us-
ing TFA after peptide conjugation. The highly acidic deprotection conditions could cause 
peptide degradation during the reaction. Therefore, it would be preferable to synthesise Ln.23 
via method A and method B has not been attempted. 
- 76 - 
 
Scheme 3-1 General scheme for the synthesis of novel peptide-based MRI agent, Ln.23. 
The targeted FPR1 antagonist, cFLFLFK contains an amino functional group from the lysine 
residue and modification can be achieved via amide coupling reaction between an amine and a 
carboxylic acid in the presence of a coupling reagent, which is commonly employed in peptide 
synthesis. Several review articles have been published devoted to a vast choice of peptide cou-
pling reagents.13-14 
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3.2.1 Synthesis of Ln.DOTAGA-cFLFLF (Ln.23) 
 
Scheme 3-2 Synthesis of Ln.DOTAGA-cFLFLF (Ln.23). 
Ln.23 was synthesised via the ‘active ester’ approach in which Ln.20 was activated in situ in 
the presence of O-benzotriazol-1-yl-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
(HBTU) and triethylamine (TEA) prior to the addition of cFLFLFK (Scheme 3-2). The solu-
tion was stirred at ambient temperature for 1 h. Borate buffer (pH 8.5) was added to ensure 
complete conversion and removal of unreacted HBTU. Purification was achieved by flash col-
umn chromatography on Sephadex G-25, eluting with MilliQ water. HBTU activation of 
excess carboxylic acid Ln.20 with a base, such as TEA and diisopropylethylamine (DIEA), 
resulted in high yield (> 85%) after purification. The reaction was monitored via MS for the 
specific mass and lanthanide isotope pattern for the desired complex. 
3.2.2 Characterisation of Ln.23 
3.2.2.1 Luminescence Studies of Eu.23 
Eu.23 was isolated as a white hydroscopic solid in 91% yield. MS (ESI -ve) spectrum showed 
peaks at m/z = 1550 representing [M]-. Its luminescent properties were investigated and hydra-
tion number, q was determined. 
Upon excitation at 260 and 395 nm, Eu.23 depicted emissions as illustrated in Figure 3-3, 
which arise from transitions 5D0 → 7FJ (ΔJ = 0 to 4). The presence of hexapeptide containing 
phenyl groups, which act as an antenna for sensitised emission, resulted in energy transfer to 
Eu(III) thus enhancing the emission intensity upon excitation at 260 nm. However, the sensiti-
sation from the phenyl groups was not very efficient as the emission resulting from the 
pseudo-direct excitation to Eu(III) ion at 395 nm was still observed. 
The hypersensitive band 5D0 → 7F2 at 613 nm was monitored for lifetime studies in H2O and 
D2O to determine 𝑘!!! and 𝑘!!! in order to calculate q using both pseudo-direct and sensi-
tised excitation at 395 and 260 nm respectively (Table 3-1). The hydration state, q of Eu.23 
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was calculated to be 1.1, which is similar to that obtained from Eu.20 indicating that modifica-
tion on the chelate with the extra acetate arm has not altered the photophysical properties of 
the bound Eu(III) ion. Eu.23 have retains its eight coordination with the ligand after coupling 
reaction and subsequent purification. In addition, the complex will bind one water molecule. 
  
 Figure 3-3 Luminescent excitation and emission spectra of Eu.23, (λ ex = 260 and 395 nm, H2O, 
298 K, pH 7.0).  
3.2.2.2 Luminescence Studies of Tb.23 
Tb.23 was synthesised from Tb.20 as per previous methodology, giving a white solid (94% 
yield). Tb.23 is expected to be an eight coordinate complex with a negative charge. MS (ESI -
ve) spectrum showed the peak at m/z = 1556 representing [M]-. Its luminescent properties were 
investigated and the hydration state, q of the complex was determined. 
The complex was excited at 240 and 290 nm to give emission spectra as shown in Figure 3-4 
which were typical for Tb(III) emissions, showing various transitions from 5D4 to 7FJ (ΔJ = 2 
to -1). The excitation spectrum showed strong peaks at 240 and 290 nm which could be sensi-
tisation from the phenyl and cinnamoyl groups of the hexapeptide to the Tb(III) ion, 
respectively. 
The 5D4 → 7F5 transition at 545 nm was monitored for lifetime studies in H2O and D2O to de-
termine 𝑘!!! and 𝑘!!! in order to calculate q (Table 3-1). It was found that luminescence of 
both Eu.23 and Tb.23 had q unchanged from the unmodified complexes Ln.20. These indi-
cate that modification of the extra acetate arms of complexes Ln.20 has not influenced the 
luminescence properties of Eu(III) and Tb(III) ions. This also implies that the Ln(III) ion will 
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remain encapsulated within the DOTA unit during the reaction and the novel contrast agent 
Gd.23 will bind one water molecule for MRI applications. 
  
Figure 3-4 Luminescent excitation and emission spectra of Tb.23, (λ ex = 240 and 290 nm, H2O, 
298 K, pH 7.0). 
Complex λex/nm λem/nm 𝑘!!!/ms-1 𝑘!!!/ms-1 q (±0.2) 
Eu.23 260, 395 613 1.80 0.67 1.1 
Tb.23 290, 355 545 0.82 0.59 0.9 
Table 3-1 Rate constants, k for depopulation of the excited states and q for the decay of Ln.23. 
3.2.2.3 Relaxometric Investigation of Gd.23 
Gd.23 was synthesised from Gd.20 giving a white hydroscopic solid. MS (ESI -ve) spectrum 
of the complex gave peaks at m/z = 1555 representing [M]- with the correct isotopic splitting 
pattern for a Gd(III) complex. 
It is expected that Gd.23 will behave similarly to Gd.20 as discussed in Chapter 2, forming an 
octadentate complex which allows for one coordinated inner-sphere water molecule. A prelim-
inary relaxivity study on Gd.23 was investigated using a spin recovery experiment recorded 
on a 400 MHz NMR spectrometer. T1 was measured (139 ms) and r1 was calculated to be 
5.23 mM-1s-1 (298 K, pH 7.0, 400 MHz). The r1 of Gd.23 is higher compared to Gd.20 due to 
an increase in both molecular weight and rotational correlation time, τR. 
An MRI phantom study upon Gd.23 using a 9.4 T (400 MHz) MRI scanner was performed in 
collaboration with Dr Marzena Wylezinska-Arridge at Biomedical Imaging Centre, Imperial 
College London, Hammersmith Campus. Figure 3-5 shows the result of the preliminary MR 
200 300 400 500 600 700
excitation
emission at λex = 240 nm
Δ
J 
= 
2
Δ
J 
= 
1
Δ
J 
= 
0
Δ
J 
= 
-1
emission at λex = 290 nm
Wavelength (nm)
In
te
ns
ity
 (a
.u
.)
N
H
H
N N
H
O
O
OPh
Ph
Ph
H
N
O
O
N
H
Ph
H
N
O
NH2
O
NH
iPr iPr
N
NN
N
O
O
O O
O
O
O O
Tb
O
OH2
λex = 240 or 290 nm
λem Tb
sensitisation
Tb.23
- 80 - 
study in water. As the Gd concentration increased, there was a prominent increase in the MR 
signals as revealed by the increasing brightness. Quantitative analysis using ImageJ (version 
1.46q, National Institute of Health, USA) showed a linear relationship between the longitudi-
nal relaxation rate (1/T1) and Gd concentration (Figure 3-6). The relaxivity r1 of Gd.23 was 
determined from the graph, to be 5.24 ± 0.08 mM-1s-1 (298 K, pH 7.0). The linearity between r1 
and Gd concentration implies that Gd(III) ion remains encapsulated in the DOTA unit after 
coupling reaction and purification. 
 
Figure 3-5 T1-weighted image of six microfuge tubes immersed in a snap cap vial filled with water 
and Gd.23 with various concentrations at 9.4 T (400 MHz), 298 K. 
 
Figure 3-6 A) Exponential fitting for measuring the T1 relaxation time at various concentrations 
of Gd.23. B) A graph of the longitudinal relaxation (1/T1) vs. Gd concentration gives a linear rela-
tionship from which the r1 can be extracted. 
Complex r1/mM-1s-1 at 9.4 T 
Gd.20 4.10 ± 0.06 
Gd.23 5.24 ± 0.08 
Table 3-2 Relaxivities, r1 of Gd.20 and Gd.23 obtained from MRI phantom studies at 9.4 T 
(400 MHz), 298 K. 
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3.3 In Vitro Evaluation of Gd.23 
It is essential that any labelling protocol used for imaging does not substantially alter the im-
munological properties of the targeted cells i.e. neutrophils. Thus, it is important to assess the 
biological functions of neutrophils as introducing a chelating unit to cFLFLFK can result in a 
significant impact on the biological and pharmacological properties of the targeting peptide. 
The biological effects of cFLFLFK and Gd.23 upon FPR1 and neutrophils were assessed us-
ing various in vitro assays. The results were compared in order to identify any undesirable 
effect prior to in vivo experiments. 
3.3.1 Radioligand Binding Assay 
A radioligand binding assay was performed using HEK cells stably expressing FPR1 and 125I-
labelled fnLLFnLYK chemotactic peptide, which was labelled in-house in collaboration with 
Andrew Hogben and Dr James Minnion (Commonwealth Building, Imperial College London, 
Hammersmith campus).  
Competitive binding experiments were performed to measure the binding of a single concen-
tration of [125I]-fnLLFnLYK in the presence of various concentrations of unlabelled ligands. 
Data were subjected to non-linear progressive analysis using GraphPad Prism (version 5.0k, 
GraphPad Software Inc., San Diego, USA) to determine the inhibitory concentration 50%, IC50 
which is the concentration that inhibits 50% of the binding. This is a measure of the competi-
tor’s potency for interacting with the receptor against the radioligand. 
The unlabelled fnLLFnLYK, cFLFLFK and Ln.23 were subjected to a radioligand binding 
assay. Data collected for cFLFLFK were inconclusive owing to its insolubility in the buffer, 
thus its Kd value (2 nM) was obtained from the literature3 and included in Table 3-3 for com-
parison to Ln.23. Poor solubility of cFLFLFK in water has limited its biological applications 
as various in vitro and in vivo experiments often require drugs to be water soluble for easy 
administration and maximal bioavailability. Although some organic solvents such as dime-
thylsuphoxide (DMSO) may be used, the solvents might be toxic to cells thus affecting the 
biological activities.15 The synthesised complexes Ln.23 are water-soluble and the use of toxic 
solvents such as DMSO could be avoided, which is beneficial for biomedical applications. 
The binding affinity profiles of Ln.23 and fnLLFnLYK are shown in Figure 3-7, IC50 and 
pIC50 values obtained from the graph are tabulated in Table 3-3. Unlabelled fnLLFnLYK has a 
high binding affinity (Kd = 2 nM)16-17 towards FPR1 and its pIC50 value of 7.1 ± 0.2 was de-
termined. The hexapeptide cFLFLFK has comparable binding affinity to fnLLFnLYK for 
FPR1. The pIC50 values of all conjugated Ln.23 complexes are of the same order of magnitude 
- 82 - 
as the potent agonist fnLLFnLYK, indicating that modification to the native peptide cFLFLFK 
does not have a significant impact on the binding towards FPR1. 
 
Figure 3-7 Competitive binding profiles of Ln.23 and fnLLFnLYK. Various concentrations of 
Ln.23 were incubated together with [125I]-fnLLFnLYK (1000 cts/s) and FPR1 expressed HEK 
cells. 
Complex pIC50 IC50 (nM) 
cFLFLFK 8.7a 2.0a 
fnLLFnLYK 7.1 ± 0.2 74 
Eu.23 7.2 ± 0.1 71 
Tb.23 7.0 ± 0.2 106 
Gd.23 7.3 ± 0.2 73 
Table 3-3 Comparison of pIC50 from competition of Ln-labelled or unlabelled peptides with [125I]-
fnLLFnLYK. a Reported as Kd values from the literature [3]. 
3.3.2 Chemotaxis 
To determine whether modification on cFLFLFK has any undesirable effect on neutrophil 
functions, a chemotaxis assay was used to study locomotor activity of freshly isolated neutro-
phils from healthy volunteers using 96-well ChemoTx® chemotaxis plate (NeuroProbe Inc., 
Gaithersburg, USA), which consists of a polycarbonate membrane on top of a customised 96-
well plate (Figure 3-8). The results were expressed as the chemotaxis index calculated as the 
mean number of cells that migrated towards the chemoattractants divided by the mean number 
of cells migrated towards the medium control. Statistical significance of the results was evalu-
ated by ANOVA and Bonferroni post-test using GraphPad Prism (version 5.0k, GraphPad 
Software Inc., San Diego, USA). 
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Figure 3-8 Experimental set-up of chemotaxis assay using ChemoTx® chemotaxis plate (Neuro-
Probe Inc., Gaithersburg, USA). The lower wells contain chemoattractant solution to make 
contact with the underside of the membrane creating a gradient between the well and cell-
containing droplet on the surface of the membrane. Cells migrate from the droplet through the 
membrane and may drop into the lower well. Two experiments were performed to study a) the 
chemotactic effects of ligands or b) the biological effects of ligands on cells towards chemotaxis. 
The native peptide cFLFLFK is an FPR1 antagonist, it has little biological activity and previ-
ously has been shown to have little effect on neutrophil chemotactic ability. This is in 
agreement with the data obtained, as seen in Figure 3-9A. It shows that cFLFLFK was not 
chemotactic to neutrophils, compared to the exposure of isolated circulating neutrophils to the 
chemoattractant fMLF which caused a characteristic migration response towards the basement 
chamber. fMLF is one of the most extensively studied chemoattractants. It is probably the 
most commonly-used activator of neutrophils in vitro to study receptor-mediated processes18 
and it has been shown to induce neutrophil migration in a dose-dependent fashion.19 Chemo-
taxis did not occur at concentrations (0.1-100 nM), but cFLFLFK exhibited chemotactic effect 
at the highest concentration (300 nM), this could result from non-specific receptor activation. 
Gd.23 did not possess chemoattractant properties at all concentrations (0.1-300 nM) as shown 
in Figure 3-9B.  
Figure 3-10 depicts the neutrophil responses towards the basement wells containing the chem-
oattractant fMLF after incubation with cFLFLFK or Gd.23. It was found that both cFLFLFK 
and Gd.23 did not affect the ability of neutrophils to respond to the chemotactic signals in-
duced by fMLF. 
These experiments demonstrated that modification to cFLFLFK at the ε-lysine residue with a 
rather bulky DOTA chelate did not substantially affect the peptide activity over neutrophil 
functions at doses of 0.1-100 nM, when compared to vehicle and fMLF, which is the desired 
response of neutrophils. At 300 nM, Gd.23 showed a reduced chemotactic effect compared to 
cFLFLFK, which is a desirable effect. 
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Figure 3-9 Effect of cFLFLFK and Gd.23 to induce neutrophil chemotaxis. Neutrophils isolated 
from healthy volunteers were re-suspended at 4 x 106 cells/ml and chemotaxis to A) cFLFLFK or 
B) Gd.23 was assessed over a 90-min period. fMLF (10 nM; bottom well) were used as controls. 
Cell migration is expressed as the average chemotaxis index (mean ± SEM) of 3 separate experi-
ments; each experiment was run in duplicate. **P < 0.01, ***P < 0.001 vs. vehicle (ANOVA and 
Bonferroni). 
 
 
Figure 3-10 Effect of cFLFLFK and Gd.23 on fMLF-induced human neutrophil chemotaxis. Neu-
trophils isolated from healthy volunteers were incubated with A) cFLFLFK or B) Gd.23 for 
10 min prior to loading on a chemotaxis plate where the bottom wells were loaded with vehicle or 
fMLF (10 nM). Cell migration is expressed as the average chemotaxis index (mean ± SEM) of 4 
separate experiments; each experiment was run in duplicate. *P < 0.05 vs. vehicle (ANOVA and 
Bonferroni). 
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3.3.3 TNF-α  Induced IL-1β  Production 
During acute inflammation, it has been shown that FPR1 is activated on neutrophils, which are 
the most abundant leukocytes. In response to a range of pathogens, noxious stimuli or pro-
inflammatory cytokines such as lipopolysaccharide (LPS) and TNF-α, neutrophils have been 
shown to produce chemokines and cytokines including IL-1β in mediating inflammation.20-21 
TNF-α is a pro-inflammatory cytokine that mediates inflammatory response and innate im-
munity. It has been shown to be implicated in the pathogenesis of several diseases, such as 
cancer, sepsis, Alzheimer’s disease, inflammatory bowel disease and ischaemic stroke.22-24 
TNF-α can stimulate expression and production of many cytokines including IL-1β, which is a 
potent pro-inflammatory cytokine. Increased levels of IL-1β have been found in several in-
flammatory diseases, such as ischaemic stroke, inflammatory bowel disease and sepsis.25-26 
TNF-α induced IL-1β production level is measured and employed to assess the functions of 
neutrophils and to determine inflammation index. IL-1β level was measured using enzyme-
linked immunosorbent assay (ELISA, referred to Chapter 9) and statistical significance of the 
results was evaluated by ANOVA and Bonferroni post-test using GraphPad Prism (version 
5.0k, GraphPad Software Inc., San Diego, USA). 
In this project, the modulatory effects of cFLFLFK and Gd.23 were examined on cytokine 
production by TNF-α stimulated neutrophils obtained from healthy volunteers (Figure 3-11). 
Both cFLFLFK and Gd.23 in the absence of TNF-α had no impact on IL-1β release compared 
to the basal condition, in which human neutrophils produced a 10-fold increase in the release 
of IL-1β in response to TNF-α. Pre-incubation with cFLFLFK or Gd.23 in the presence of 
TNF-α resulted in similar effects to the basal condition. An AnxA1 N-terminal derived pep-
tide, Ac2-26 was used as a control to compare the effects of cFLFLFK and Gd.23. Similar 
results to both compounds were observed. Ac2-26 alone did not affect IL-1β production. 
When TNF-α was presence, a 10-fold increase in the release of IL-1β level was observed. 
These experiments demonstrated that modification to cFLFLFK at the ε-lysine residue with a 
DOTA unit had no effect on the neutrophil TNF-α inflammatory responses at doses of 0.1-
300 nM. This suggests that Gd.23 would be suitable for imaging inflammation, as it has not 
significantly affected neutrophil inflammatory functioning.  
Both in vitro assays suggest that neutrophils labelled with Gd.23 would be conserved in the 
blood for extravasation and chemokinesis to the site of inflammation, since Gd.23 does not 
activate and significantly change the function of neutrophils. In addition, administration of 
Gd.23 would not be detrimental to the patients and Gd.23 would not affect the inflammatory 
process during the imaging, which is a desirable outcome for imaging applications. 
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Figure 3-11 Effect of cFLFLFK and Gd.23 on human neutrophil-derived TNF-α  induced IL-1β  
production. Human neutrophils isolated from healthy volunteers were incubated with A) 
cFLFLFK, B) Gd.23 or Ac2-26 (1 µM) for 10 min prior to incubation in the presence or absence 
of TNF-α  (10 ng/ml) for 18 h. Cell-free supernatants were tested by ELISA for human IL-1β . Da-
ta represents mean ± SEM of 3 separate experiments; each experiment was run in duplicate. *P < 
0.05 vs. TNF-α  alone (ANOVA and Bonferroni). 
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3.4 Application of Gd.23 for In Vivo MRI of Inflammation in Mice 
In the framework of aiming at the application of the novel MRI contrast agents to the diagno-
sis of acute inflammation in the brain, the chapter presents the study of the synthesised Gd.23 
as a contrast agent in MRI pre-clinical experiments. This was performed in collaboration with 
Professor Stuart Allan, University of Manchester by Grace MacGregor and Katie Murray with 
the exception of Section 3.4.2. 
LPS is an endotoxin molecule and it evokes multiple pathophysiological processes in vivo, 
such as fever, sepsis and multiple organ dysfunctions. These effects are associated with the 
stimulation of LPS to the receptors that mediate the signalling cascades leading to the activa-
tion of neutrophils and macrophages and the release of inflammatory cytokines.27 It was 
hypothesised that the FPR1 on the surface of neutrophils resulting from LPS-mediated in-
flammation could be targeted by Gd.23, which could serve as a biomarker for the diagnosis of 
inflammatory processes. MRI was used to visualise the T1-positive contrast enhancement in-
duced by the paramagnetic Gd.23 in an LPS-induced neuronal inflammation in C57/BL6 mice 
and compare it with the contrast produced by Gd.DOTA (Dotarem®) and Gd.20. The biodis-
tribution profiles of Gd.23 and Gd.20 were also determined after MRI experiments. 
3.4.1 Imaging of Inflammation using Gd.23 
C57/BL6 mice (male, 25-30 g) were injected intrastriatally with 2 µl of phosphate buffered 
saline (PBS) as a control or LPS (4 mg/ml) 24 h prior to MRI to induce inflammation in the 
brain. Neutrophil infiltration and blood brain barrier (BBB) breakdown were confirmed by 
immunohistochemical techniques at 24 h in the striatum of LPS-treated animals (data shown 
in Appendix, Figure I). At 24 h, mice were intravenously (tail vein) injected with Gd.DOTA, 
Gd.20 or Gd.23 as a bolus injection (150 µl, 0.2 mmol Gd/kg) for dynamic contrast enhance-
ment (DCE)-T1 MRI studies. Images obtained were analysed using ImageJ (version 1.46q, 
National Institute of Health, USA) and signal intensity was quantified in a region of interest 
(ROI). 
Figure 3-12 shows signal intensity analysis on the DCE-T1 images in the striatum after contrast 
agent administration 24 h after LPS injection. For Gd.DOTA, the signal increased dramatical-
ly and reached a plateau during the times the images were taken. This pattern suggested a 
constant uptake of Gd.DOTA by the striatum, which then remained within the brain. 
Gd.DOTA injected mice demonstrated a significant increase in signal intensity within the site 
of BBB breakdown whereas both Gd.20 and Gd.23 injected mice did not demonstrate a sig-
nificant contrast enhancement.  
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Figure 3-13 depicts signal analysis on T1-weighted images before and after contrast agent ad-
ministration. The control Gd.DOTA showed a significant contrast enhancement of 85% in the 
striatum (p < 0.05) whereas both Gd.20 and Gd.23 showed no significant enhancement. 
The BBB is a selectively permeable layer lining cerebral microvessels, which restricts the en-
try of polar solutes into the brain, as a consequence of tight junctions between the endothelial 
cells. It poses an impenetrable obstacle to leukocytes attempting to enter the vasculature.28-31 
During CNS inflammatory responses, entry of leukocytes is enhanced by both BBB disruption 
and cerebrovascular inflammation.32-33 intrastriatal LPS induced inflammation characterised by 
the recruitment of neutrophils to the brain after 24 h had concomitant increase in BBB perme-
ability. This BBB breakdown was neutrophil–dependent as demonstrated by 
immunohistochemistry and MRI using Gd.DOTA, which crossed the BBB and retained in the 
striatum. 
Both Gd.DOTA and Gd.20 are ionic and have similar structure; it was hypothesised that 
Gd.20 would behave similarly to Gd.DOTA and uptake of Gd.20 could be imaged in MRI. 
However, Gd.20 did not show any contrast enhancement within the striatum. This emphasised 
its inability to cross the BBB even though there was a BBB disruption caused by LPS. Similar 
to Gd.20, Gd.23 did not show signal enhancement within the striatum. This suggested that 
Gd.23 could not cross the BBB and it was very likely to be deposited elsewhere within the 
body instead of labelling neutrophils in vivo. 
It was speculated that the neutrophil concentration within the vessels would have a significant 
impact on signal enhancement using Gd.23. Preliminary studies from Giles et al. demonstrat-
ed that there was a highly significant difference in neutrophil concentration between 6 h and 
24 h after LPS injection.34 Neutrophil concentration within the vessels is most likely to be low 
at 24 h, as the majority of activated neutrophils have migrated to the site of injury. It could be 
inferred that Gd.23 might be required to bind to neutrophils prior to neutrophil migration 
across the BBB. However, the results from Gd.23 injected 18 h prior to MRI scanning in a 
separate cohort of animals were similar and no signal enhancement was observed within the 
striatum. 
At this stage, it cannot be validly concluded whether the failure in mapping neutrophil infiltra-
tion using Gd.23 is due to its inability to cross the BBB or low concentrations of circulating 
neutrophils.  Further studies with Gd.23 are required to evaluate and optimise the technique to 
successfully map the neutrophil infiltration into the brain. 
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Figure 3-12 Time-course curves at striatum (red circle) obtained from the quantification of DCE-
T1 images using ImageJ. Each curve displays the average contrast enhancement obtained for each 
group (Gd.DOTA, Gd.20 and Gd.23). Values correspond to the results obtained from 2 or 3 mice 
per group. Mean data plotted with SD. 
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Figure 3-13 A) Signal intensity obtained from ROI (ipsilateral hemisphere normalised against the 
contralateral hemisphere) on T1-weighted images, *P < 0.05 (Paired t test). B) Representative axi-
al DCE-T1-weighted images after administration of MRI contrast agents (Gd.DOTA, Gd.20 or 
Gd.23) at 7 T. 
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3.4.2 Biodistribution of Gd.20 and Gd.23 
Mice were euthanised after each MRI experiment, main organs (liver, spleen, kidney, lung, 
brain, muscle and heart) were collected, weighted and frozen until needed. The Gd content 
was determined by inductively coupled plasma mass spectrometry (ICP-MS) by Dr Stanislav 
Strekopytov at the Natural History Museum, London. 
ICP-MS is a highly sensitive technique for elemental determination and analysis of the Gd 
content by ICP-MS in different tissues has been used extensively as a way of tracking Gd-
based small chelates.35-37 The amount of Gd in spleen, kidney, heart, muscle, liver and lung 
was determined in the LPS-injected mice. The most important organ, the brain was taken for 
immunohistochemical analysis and therefore it was not submitted for the analysis of Gd con-
tent. 
 
Figure 3-14 Gd concentrations in various organs as measured by ICP-MS post MRI scans. 
Excised tissue concentrations of Gd using Gd.20 and Gd.23 in the MRI experiments are pre-
sented in Figure 3-14. All small Gd-chelate-based MRI agents show renal clearance by 
glomerular filtration into the urine.38 It was hypothesised that Gd.20 would behave similarly to 
Gd.DOTA, which is a well known extracellular fluid agent.38 However, tissue biodistribution 
of Gd content indicated that Gd was mainly accumulated in the kidney and liver for Gd.20. 
This indicated the retention of Gd.20 in the reticule-endothelial system (RES). The result ob-
tained for Gd.20 correlates to the MRI experiment; no uptake of Gd.20 within the site of BBB 
breakdown as Gd.20 was deposited to liver and kidney. 
Unlike Gd.20, Gd.23 showed lower uptake in both kidney and liver owing to its increased 
molecular weight and size as compared to Gd.20. It appeared that Gd.23 had deposited to oth-
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er organs not submitted for ICP-MS study. To further clarify the biodistribution of Gd.23 and 
determine how it is eliminated from the body, a whole body scan and longitudinal biodistribu-
tion should be performed in both healthy and LPS-injected mice. At this stage, the true cause 
of the failure of Gd.23 to target neuronal neutrophils could not be fully elucidated. It was ap-
peared that the unsuccessful MRI of Gd.23 was solely due to its inability to cross the BBB. 
Further studies are required to evaluate the ability of Gd.23 to cross the BBB prior to MRI 
experiments using in vitro BBB models, which will be the subject of the future work.  
3.5 Summary and Conclusions 
Complex Gd.23 is a novel MRI contrast agent targeting inflammation via FPR1 expressed on 
neutrophils that has been designed and synthesised, using the common method of amide cou-
pling reaction from DOTAGA 20 and the desired FPR1 antagonist, cFLFLFK. Luminescence 
studies of the analogous Ln.23 revealed that the complex has a hydration state q = 1, indicat-
ing highly stable eight-coordinated complexes have been formed. Relaxometric studies of 
Gd.23 gave a relaxivity of 5.24 ± 0.08 mM-1s-1 (298 K, 9.4 T), which is typical for small Gd-
based contrast agents. 
Radioligand binding assays using [125I]-fnLLFnLYK and FPR1 transfected HEK cells gave 
pIC50 of 7.3 ± 0.23 for Gd.23, which is comparable to the potent agonist fnLLFnLYK (pIC50 = 
7.1 ± 0.15). In vitro assays relevant to the inflammatory process involving neutrophils were 
performed to determine the effect of Gd.23 on neutrophil functions: chemotaxis using fMLF 
as stimulants and IL-1β production induced by TNF-α. Gd.23 did not exhibit chemotactic ef-
fects on neutrophils and did not induce cellular response on neutrophils to the desired effects 
when stimulated with fMLF at concentrations 0.1-300 nM. Neutrophils produce IL-1β upon 
activation and thus IL-1β release is characteristic of inflammation. Gd.23 had no impact on 
neutrophil functions with respect to IL-1β production at concentrations 0.1-300 nM. 
These studies suggest that modification on ε-lysine of cFLFLFK has negligible effects on 
binding affinity towards FPR1 and Gd.23 would not alter neutrophil functions. This is an im-
portant feature for MRI contrast agents targeting neutrophils since avoiding activation would 
conserve neutrophils labelled in the blood for extravasation and chemokinesis to the site of 
inflammation. 
In MRI studies, inflammation induced by intrastriatal injection of LPS was investigated. Im-
munohistochemitry showed neutrophil intakes after 6 h and 24 h. BBB breakdown was 
observed using Gd.DOTA but not Gd.20 and Gd.23. Although MRI experiments of Gd.23 
with murine model of LPS-induced inflammation on the brain have shown disappointing re-
sults, Gd.23 is believed to have the potential for early diagnosis for inflammation. The most 
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important question that has still to be answered is in vivo labelling of cells by Gd.23 in a MRI 
setting. This issue demands to address the study of its uptake and the monitoring of its fate 
into the cells. To achieve this goal, a fluorescent labelled Gd.23 has been developed and will 
be discussed in Chapter 6. 
For further extension to this work, a novel MRI contrast agent similar to Gd.23 has been de-
signed to target FPR2 using the FPR2 agonist WKYMVm, and this is described in the next 
chapter. In addition, work is ongoing with nuclear imaging using the same ligand 23, which 
features a DOTA unit that is suitable for binding various radiometals. This work is described 
in Chapter 5. 
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4 Peptide-Based Contrast Agents Targeting FPR2 
4.1 Introduction 
In addition to FPR1, neutrophils also express the closely related FPR2, which is a low affinity 
receptor for fMLF, despite relatively high levels of sequence homology with FPR1. FPR2 ex-
hibits 69% amino acidic homology to FPR1.1 FPR1 and FPR2 have a similar distribution in 
various tissues and cells involved in inflammation, such as endothelial cells, dendritic cells 
and platelets. FPR2 is also expressed in a range of other cell types including phagocytic leuko-
cytes and hepatocytes.2  
FPR2 is the first receptor family to be shown to interact with ligands including lipids, proteins 
and peptides. FPR2 has been reported to bind LXA4, a lipid metabolite with high affinity. Un-
like fMLF, a peptide chemotactic agonist, LXA4 is reported to induce an anti-inflammatory 
signalling cascade inhibiting neutrophil transmigration.3 Furthermore, a pro-inflammatory 
acute phase protein SAA, has been reported to induce phagocyte migration and calcium mobi-
lisation through FPR2.4 SAA has also been found to greatly induced angiogenesis via 
proliferation, migration, and tube formation of endothelial cells in vitro.5 These results have 
suggested that FPR2 may play important pathophysiological roles in addition to host defence. 
 
Figure 4-1 A selection of known FPR2 agonists. 
A screening of natural and synthetic peptide libraries has allowed the identification of potent 
agonists for FPR2 as illustrated in Figure 4-1. Among them, the hexapeptide WKYMVm was 
found to be a potent agonist to FPR1 (EC50 = 25 nM) and FPR2 (EC50 = 75 pM).6 Several stud-
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ies on WKYMVm have been reported for activation of human neutrophils, monocytes, B lym-
phocyte and endothelial cells.7-9 In recent years, much attention has focused on the therapeutic 
effects of WKYMVm. It has been reported to promote ischaemic neovascularisation in murine 
model of limb ischaemia via FPR2-dependent mechanism.10 These studies have suggested that 
WKYMVm is a suitable target for developing FPR2-targeted imaging agents. 
This chapter features the development of novel MRI contrast agents employing WKYMVm as 
the targeting motif towards FPR2 for imaging inflammation, owing to its high affinity towards 
FPR2 and the presence of a lysine residue for chemical modifications similar to cFLFLFK.  
4.2 FPR2 Targeted MRI Contrast Agent 
4.2.1 Synthesis of Ln.DOTAGA-WKYMVm (Ln.24) 
 
Scheme 4-1 Synthesis of Ln.DOTAGA-WKYMVm (Ln.24) is not regioselective and results in two 
isomers. 
Initial attempts to prepare the novel MRI contrast agent Gd.24 involved the reaction of Gd.20 
with WKYMVm using the HBTU/DIEA approach similar to Ln.23. In brief, Gd.20 was acti-
vated by HBTU and DIEA in situ prior to the addition of WKYMVm. The solution was stirred 
at ambient temperature for 1 h before borate buffer (pH 8.5) was added. Purification was 
achieved by flash column chromatography on Sephadex G-25 with high yields (85-90%). The 
product was confirmed by MS (MALDI -ve) which gave a peak at m/z = 1468 representing 
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[M]-. Spin recovery experiments were performed on a 400 MHz NMR spectrometer, r1 was 
calculated to be 3.89 mM-1 s-1 (298 K, 400 MHz), which is within the range for Gd(III) com-
plexes with q = 1.11  
As shown in Scheme 4-1, WKYMVm features two amino functional groups and the amide 
coupling employing HBTU is not regioselective. LC-MS showed an almost 1:1 product ratio, 
indicating that the reaction was not regioselective and purification on Sephadex G-25 did not 
result in high purity product. Alternatives such as RP-HPLC should be considered. Moreover, 
the solvents employed for HPLC requires careful selection due to the presence of Gd(III) ions, 
as metal decomplexation could occur under acidic conditions during purification processes. 
However, due to time constraints, optimising RP-HPLC as an alternative purification method 
could not be completed and this mixture was tested in photophysical and in vitro experiments 
without further purification. 
4.2.2 Characterisation of Ln.24 
4.2.2.1 Luminescence Studies of Eu.24 
Eu.24 was isolated as a white hydroscopic solid in 96% yield, MS (MALDI -ve) gave a peak 
at m/z = 1463 representing [M]-. Similar to Eu.23, Eu.24 is expected to be eight-coordinate 
with respect to ligand 24. Its luminescent properties were investigated and q was determined. 
Upon excitation at 370 and 395 nm, Eu.24 depicted emissions as seen in Figure 4-2, which 
arise from the transitions 5D0 to 4FJ (ΔJ = 0 to 4). Sensitisation at 370 nm could result from the 
indole ring of the hexapeptide to the Eu(III) ion displaying a more intense spectrum compared 
to the emissions resulted from the pseudo-direct excitation to Eu(III) ion at 395 nm. 
The hypersensitive band 5D0 → 7F2 transition at 612 nm was monitored for lifetime studies in 
H2O and D2O to determine 𝑘!!! and 𝑘!!! in order to calculate q (Table 4-1). It was found that 
q of Eu.24 was 1.07, which is similar to that obtained from Eu.20 indicating Eu.24 has re-
tained its eight coordination after peptide coupling reaction and purification.  
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Figure 4-2 Luminescent excitation and emission spectra of Eu.24, (λ ex = 370 and 395 nm, H2O, 
298 K, pH 7.0).  
4.2.2.2 Luminescence Studies of Tb.24 
Tb.24 was isolated as a white hydroscopic solid in 92% yield, MS (MALDI) gave a peak at 
m/z = 1468 representing [M]-. Similar to Tb.23, Tb.24 is expected to be eight-coordinate and 
binds one inner sphere water molecule. Its luminescent properties were investigated and q was 
determined. 
Upon excitation at 255 and 355 nm, Tb.24 showed emission spectra (Figure 4-3) arising from 
the transitions 5D4 to 7FJ (ΔJ = 2 to -1). The excitation spectrum showed a strong peak at 
250 nm which could be due to the sensitisation from the phenol of the hexapeptide to the 
Tb(III) ion, resulting in a more intense emission spectrum compared to the emission resulting 
from the pseudo-direct excitation to Tb(III) at 355 nm. 
The 5D4 → 7F5 transition at 545 nm was monitored for lifetime studies in H2O and D2O to de-
termine 𝑘!!! and 𝑘!!! in order to calculate q (Table 4-1). The hydration state, q of Tb.24 was 
calculated to be 0.71. This correlates to Eu.24 indicating that Tb.24 has retained its eight co-
ordination after coupling reaction and purification. This also implies that the Ln(III) ion will 
remain encapsulated within the DOTA unit during the reaction and the novel contrast agent 
Gd.24 will bind one water molecule for MRI applications. 
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Figure 4-3 Luminescent excitation and emission spectra of Tb.24, (λ ex = 250 and 355 nm, H2O, 
298 K, pH 7.0).  
Complex λex/nm λem/nm 𝑘!!!/ms-1 𝑘!!!/ms-1 q (±0.2) 
Eu.24 370, 395 613 1.61 0.47 1.07 
Tb.24 255, 355 545 0.82 0.59 0.71 
Table 4-1 Rate constants, k for depopulation of the excited states and q for the decay of Ln.24. 
4.3 In Vitro Evaluation 
4.3.1 Chemotaxis 
A chemotaxis assay was performed to study the chemotactic effects of WKYMVm and Gd.24 
using freshly isolated neutrophils from healthy volunteers and 96-well ChemoTx® chemotaxis 
plates (NeuroProbe Inc., Gaithersburg, USA) as described in Chapter 3. 
The chemotactic activity of WKYMVm has been reported to be very potent and it is very effi-
cient even at pM concentrations for both monocytes and neutrophils.7 This is in agreement 
with the data obtained as WKYMVm has been shown to be chemotactic to neutrophils at low 
concentrations (0.1-10 nM) in Figure 4-4A. At the higher concentrations (100-300 nM), there 
was competition between two potent chemoattractants i.e. fMLF and WKYMVm, thus the 
cells stopped crossing the membrane. In contrast, Gd.24 exhibited a chemotactic effect in a 
dose-dependent manner (Figure 4-4B). 
Figure 4-5 depicts the neutrophil responses towards the basement wells containing the chemo-
attractant fMLF after incubation with WKYMVm or Gd.24. As shown in Figure 4-5A, 
WKYMVm did not further affect the cellular responses to fMLF at low concentrations (0.1-
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10 nM) owing to its chemotactic nature. However, it produced a marked inhibition in neutro-
phil response towards fMLF at high concentrations (100-300 nM) as a result of competition 
between two potent chemoattractants. Gd.24 did not affect the ability of neutrophils to re-
spond to the chemotactic signals induced by fMLF at all concentrations, which is a desirable 
effect (Figure 4-5B). 
These experiments demonstrated that modification to WKYMVm with a DOTA-based chelate 
had a significant impact on the peptide activity over neutrophil functions. Gd.24 induced neu-
trophil chemotaxis in a dose-dependent fashion but did not affect neutrophil responses to 
fMLF.  
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Figure 4-4 Effect of WKYMVm and Gd.24 to induce neutrophil chemotaxis. Neutrophils isolated 
from healthy volunteers were re-suspended at 4 x 106 cells/ml and chemotaxis to A) WKYMVm or 
B) Gd.24 was assessed over a 90-min period. fMLF (10 nM; bottom well) was used as controls. 
Cell migration is expressed as the average chemotaxis index (mean ± SEM) of 3 separate experi-
ments; each experiment was run in duplicate. *P < 0.05, ***P < 0.001 vs. vehicle (ANOVA and 
Bonferroni). 
 
 
Figure 4-5 Effect of WKYMVm and Gd.24 on fMLF-induced human neutrophil chemotaxis. Neu-
trophils isolated from healthy volunteers were incubated with either A) WKYMVm or B) Gd.24 
for 10 min prior to loading on a chemotaxis plate where the bottom wells were loaded with vehicle 
or fMLF (10 nM). Cell migration is expressed as the average chemotaxis index (mean ± SEM) of 4 
separate experiments; each experiment was run in duplicate. **P < 0.01, ***P < 0.001 vs. vehicle 
(ANOVA and Bonferroni). 
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4.3.2 TNF-α  Induced IL-1β  Production 
Neutrophils produce IL-1β upon activation and thus IL-1β release is characteristic of inflam-
mation. Therefore, TNF-α induced IL-1β production levels are measured and employed for 
assessing the function of neutrophils and to determine inflammation index. In this project, the 
modulatory effects of WKYMVm and Gd.24 were examined on cytokine production by TNF-
α stimulated neutrophils obtained from healthy volunteers (Figure 4-6). Both WKYMVm and 
Gd.24 in the absence of TNF-α had no impact on IL-1β release compared to the basal condi-
tion, in which human neutrophils produced a 20-fold increase in the release of IL-1β in 
response to TNF-α. Pre-incubation with WKYMVm or Gd.24 in the presence of TNF-α re-
sulted in a similar effect to the basal condition. An AnxA1 N-terminal derived peptide, Ac2-26 
was used as a control to compare the effects of WKYMVm and Gd.24. Similar results to both 
compounds were observed. Ac2-26 alone did not affect IL-1β production. When TNF-α was 
presence, a 20-fold increase in the release of IL-1β level was observed. 
These experiments demonstrated that modification to WKYMVm with a DOTA unit did not 
affect the neutrophil TNF-α inflammatory responses at doses of 0.1-300 nM. This suggests 
that Gd.24 would be suitable for imaging inflammation, as it has not significantly affected the 
function of the neutrophil during inflammation. 
Both in vitro assays suggest that neutrophils labelled with Gd.24 would be conserved in the 
blood for extravasation and chemokinesis to the site of inflammation, since Gd.24 does not 
activate and significantly change the function of neutrophils. In addition, administration of 
Gd.24 would not be detrimental to the patients and Gd.24 would not affect the inflammatory 
process during the imaging, which is the desirable outcome.  
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Figure 4-6 Effect of WKYMVm and Gd.24 on human neutrophil-derived TNF-α  induced IL-1β  
production. Human neutrophils isolated from healthy volunteers were incubated with A) 
WKYMVm, B) Gd.24 or Ac2-26 (1 µM) for 10 min prior to incubation in the presence or absence 
of TNF-α  (10 ng/ml) for 18 h. Cell-free supernatants were tested by ELISA for human IL-1β . Da-
ta represents mean ± SEM of 3 separate experiments; each experiment was run in duplicate. *P < 
0.05 vs. TNF-α  alone (ANOVA and Bonferroni). 
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4.4 Summary and Conclusions 
Complex Gd.24, a novel MRI contrast agent targeting inflammation via FPR2 has been de-
signed and synthesised using the common method of amide coupling reaction between 
DOTAGA 20 and the desired FPR2 agonist, WKYMVm. Luminescence studies of the analo-
gous Ln.24 showed that the complex has a hydration state q = 1, indicating highly stable 
eight-coordinated complexes have been formed. Preliminary relaxometric studies of Gd.24 
gave relaxivity of 3.89 mM-1s-1 (298 K, 400 MHz), which is typical for small Gd-based con-
trast agents. 
In vitro assays relevant to the inflammatory process involving neutrophils were performed to 
determine the effect of Gd.24 on neutrophil functions: chemotaxis using fMLF as stimulants 
and IL-1β production induced by TNF-α. Although Gd.24 exhibited chemotactic effects on 
neutrophils, it did not induce cellular response on neutrophils to the desired effects when stim-
ulated with fMLF at concentration 0.1-300 nM. Gd.24 had no impact on neutrophil function 
with respect to IL-1β production at concentration 0.1-300 nM. These studies suggest that 
Gd.24 might have the potential to image FPR2 expressing cells in addition to inflammation. 
Work is ongoing with nuclear imaging using the same ligand 24 and featuring a DOTA unit, 
which is suitable for chelation to various radiometals. This work is described in Chapter 5. 
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5 Synthesis Towards Nuclear Imaging Applications 
5.1 DOTA-based Chelates and Nuclear Imaging 
In the last few decades, extensive research has been expanded to develop and synthesise met-
al-based radiopharmaceuticals by conjugating a metal chelate with biomolecules such as 
peptides and monoclonal antibodies.1-2 Depending on the selected metal ion, these species 
have found applications as diagnostic or therapeutic agents in nuclear imaging. For example, 
complexes of gamma or positron emitting radionuclides such as 99mTc, 111In or 68Ga, 64Cu ions 
are employed in SPECT or PET, respectively. 
There are two strategies for conjugating a chelate to a biomolecule of interest. In one strategy, 
the pre-labelling approach involves formation of the metal complexes prior to the conjugation 
to synthetic peptides. This is especially suited for when complex formation can only be 
achieved under non-aqueous conditions and the biomolecule is sensitive to these conditions. 
However, this method is not suitable for routine clinical applications as it is time-consuming 
and radioactivity of the final products is reduced. In contrast, the post-labelling strategy is the 
most practical for developing commercial peptide-based radiopharmaceuticals as radioactive 
metal ions are introduced after the chelates have been attached to the biomolecules to ensure 
maximal radioactivity. This post-labelling approach has been utilised with the use of BFCAs 
such as DOTA-based chelates.3 
DOTA derivatives are the most favourable and widely used BFCAs over acyclic chelates ow-
ing to their compatibility with a variety of potentially useful radionuclides and their high 
stability (Table 5-1).4 In addition, metal complexes of DOTA have favourable clearance prop-
erties in vivo making them highly favourable for in vivo imaging.5  
Cation Radioisotopes Ionic radius/Å kex in H2O/s-1 
𝐥𝐨𝐠  𝐊𝒔𝒕 with 
DOTA 
Cu(II) 62Cu, 64Cu 0.57-0.73 2 x 108 22.7 
Ga(III) 67Ga, 68Ga 0.47-0.62 7.6 x 102 21.3 
In(III) 111In 0.62-0.92 4.0 x 104 23.9 
Y(III) 86Y 0.90-1.02 1.3 x 107 24.9 
Table 5-1 Stability constants for DOTA with various metal ions. Table adapted from ref [6]. 
The initial aim of this chapter was to utilise previously synthesised DOTAGA for the post-
labelling strategy and development of peptide-linked ligands for imaging inflammation using a 
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nuclear imaging modality. Complexation with Ga(III) and Cu(II) was of interest because of 
the access to different radioisotopes for imaging. 
5.2 Synthesis of Peptide-based Imaging Agents for Nuclear Imaging 
As discussed in Chapter 3, previously synthesised ligand 21 can be employed in the prepara-
tion of peptide-conjugated ligands via activation of the extra carboxylic acid (Scheme 5-1 
method A). However, an alternative approach was investigated as the deprotection of tert-
butyl esters using TFA might not be compatible with the integrity of the peptides cFLFLFK 
and WKYMVm for FPR1 and FPR2, respectively. 
 
Scheme 5-1 Synthetic routes to peptide-conjugated ligands for nuclear imaging. 
Bernhard and co-workers have reported a simple and facile synthesis of DOTAGA-anhydride 
25.7 It was achieved by using the method similar to that reported for the synthesis of DTPA-
bisanhydride (Scheme 5-2).8-9 Acetic anhydride is used as a dehydrating agent for the for-
mation of cyclic anhydrides from the dicarboxylic acids. 
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Scheme 5-2 Formation of DTPA-bisanhydride. 
The reaction mechanism is shown in Figure 5-1. The key step in the dehydration reaction is 
the formation and cyclisation of the mixed anhydride formed from the dicarboxylic acids and 
acetic anhydride, in which both reaction steps have the same mechanism. The carboxylic acid 
attacks at an anhydride in both steps but the second step is intramolecular. The reaction is en-
tropically favoured as the cyclisation reaction involves two molecules reacting to give three 
molecules i.e. the cyclic anhydride and two molecules of acetic acid. 
 
Figure 5-1 Reaction mechanism for the formation of a cyclic anhydride. 
25 was synthesised and employed for conjugating to the peptidies, cFLFLFK and WKYMVm 
for FPR1 and FPR2 respectively (Scheme 5-1, method B). The resultant ligands 23 and 24 
consist of a DOTA unit for subsequent complexation with the radiometals of interest i.e. 
Ga(III) and Cu(II) ions in this project. 
5.2.1 Synthesis of DOTAGA-anhydride (25) 
 
Scheme 5-3 Synthesis of DOTAGA-anhydride 25. 
25 was synthesised according to the reported method,7 which involved the reaction of previ-
ously synthesised 20 with acetic anhydride in the presence of pyridine acting as a base catalyst 
according to Bernhard et al. (Scheme 5-3).7 The precipitate collected was washed with acetic 
anhydride and dried in vacuo to give the desired product 25. The product was confirmed via 
1H NMR and MS (ESI +ve) gave a peak at m/z = 497 representing [M+K]+, which are compa-
rable to the literature.7 Owing to its poor solubility in deuterated organic solvents, 1H NMR 
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spectrum was recorded in D2O (Figure 5-2). The spectrum showed a mixture of 20 and 25 
identified by the characteristic peaks at 3.85 and 4.44 ppm respectively, which was obtained 
systematically as a result of rapid hydrolysis in D2O. 
 
Figure 5-2 1H NMR spectrum of 25 showing a mixture of 25 and 20 due to rapid hydrolysis 
(298 K, 400 MHz, D2O). 
Ligands 23 and 24 were subsequently produced from conjugation with cFLFLFK and 
WKYMVm using the HBTU/DIEA approach. The products were isolated in high purity from 
column chromatography on Sephadex G-25. The products were confirmed via MS (MALDI) 
which gave a peak at m/z = 1403 and 1315 representing [M+H]+ for 23 and 24 respectively. 
5.2.2 Metal Complexation Protocols 
To minimise the risks and hazards, radionuclides are often produced in minimal quantity, with 
concentrations typically lower than 1 µM used for radiolabelling. In addition, radioisotopes are 
generally short-lived so it is essential to choose the optimal complexation conditions for effi-
cient and rapid formation of radiopeptides. In general, the efficiency of radiolabelling largely 
depends on the concentration of DOTA-peptide conjugates, concentration of trace metal con-
taminants, pH, temperature and reaction time. 
Despite the high stability and inertness of DOTA-based chelates with various metal ions, they 
have a potential limitation for nuclear imaging applications owing to their slow complexation 
rate.10 Thus, harsh labelling conditions such as high temperatures are often required for effi-
cient labelling in high yields. Using elevated temperatures can be problematic with the 
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presence of heat sensitive biomolecules, as this can result in a loss of bioactivity and thus low-
ering the specificity of the imaging agents. 
Radiolabelling with 68Ga(III) and 64Cu(II) is of interest in this project because of the access to 
different radioisotopes for nuclear imaging. Due to the ability of DOTA-based chelates to co-
ordinate various metal ions, they are particularly sensitive to metallic impurities and 
contaminants. The optimal complexation conditions such as the reaction time and tempera-
tures were investigated for efficient labelling of ligands 23 and 24 prior to labelling in the 
radiochemistry lab. 
5.2.2.1 Copper Complexation 
Copper is a first-row transition metal and its solution chemistry in aqueous media is restricted 
to two oxidation states +I and +II. Cu(II) remains as the prominent state for radiocopper label-
ling in aqueous media. Cu(II) exists as d 9 metal ions of borderline softness, which has high 
affinity for borderline nitrogen donors and is an ideal candidate for DOTA-based complexes. 
 
Scheme 5-4 Cu(II) complexation with ligands 23 and 24. 
DOTA-based conjugates are readily radiolabelled within 30 min at relatively ambient tempera-
tures (30-40 °C) and pH 3-7 using citrate or acetate buffer. Cu(II) complexation was attempted 
according to the literature method used for radiolabelling (Scheme 5-4).11 Both ligands 23 and 
24 were successfully complexed with Cu(II) in acetate buffer (pH 5.5) at 40 °C for 30 min. 
MS (MALDI) gave a peak at m/z = 1488 and 1397 representing [M+Na]+ for Cu.23 and Cu.24 
respectively. Radiolabelling with 64Cu(II) will be discussed in Section 5.4. 
5.2.2.2 Gallium Complexation 
Gallium is a non-physiological metal and the solution chemistry in aqueous media is exclu-
sively represented by the stable +III oxidation state. In aqueous solution, the freely hydrated 
Ga(III) ion is only stable under acidic conditions and hydrolysis to insoluble Ga(OH)3 occurs 
in the absence of stabilising ligands in pH 3-7.12 At pH > 7, Ga(III) hydroxides re-dissolve as 
[Ga(OH)4]-. Since Ga(III) is highly charged, the slow kinetics of multidentate ligands and rap-
id hydrolysis of Ga(III) ions to insoluble Ga(OH)3 remain significant challenges for 
radiolabelling. Moreover, a fast and efficient radiolabelling protocol is especially critical for 
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68Ga(III) due to its short half-life (t1/2 = 68 min). Therefore, it is crucial to optimise the reaction 
conditions for radiolabelling of radioactive Ga(III) ions. 
 
Scheme 5-5 Ga(III) complexation with ligands 23 and 24. 
Ga(III) ions are generally stabilised in the presence of weakly coordinating buffer anions such 
as citrate, acetate or oxalate. Thus, an acetate buffer of different pH was employed as the 
aqueous media for complexation of 23 and 24 with Ga(III) ions (Scheme 5-5). Radiolabelling 
with Ga(III) ions is generally performed at pH 5.5 and high temperatures (80-90 °C) for 
10 min.13 With the knowledge that peptides are susceptible to high temperatures, complexation 
of Ga(III) ions was initially attempted at lower temperature i.e. 50 °C for 10 min using acetate 
buffer (pH 5.5). Ligand 23 was successfully complexed with Ga(III) without peptide degrada-
tion as indicated by MS (MALDI) giving a peak at m/z = 1465 representing [M]-. However, 
peptide degradation was observed in the MS (MALDI) spectrum for ligand 24 featuring 
WKYMVm. It was proven that WKYMVm is susceptible to high temperatures and Ga(III) 
complexation was attempted at a lower temperature of 40 °C using acetate buffer at pH 4.5. 
Ga.24 was successfully synthesised and MS (MALDI) gave a peak at m/z = 1402 representing 
[M]-. 
5.3 In Vitro Evaluation 
5.3.1 Chemotaxis: Chemotactic effects of Cu.23 and Cu.24 
A chemotaxis assay was performed to study the chemotactic effects of Cu.23 and Cu.24 using 
freshly isolated neutrophils from healthy volunteers and 96-well ChemoTx® chemotaxis 
plates (NeuroProbe Inc., Gaithersburg, USA) as described in Chapter 3. 
The chemotactic effects of the native peptides cFLFLFK and WKYMVm were compared to 
Cu.23 and Cu.24, respectively (Figure 5-3). As previously discussed, cFLFLFK is an FPR1 
antagonist which has been shown to have little effect on neutrophil chemotactic ability, com-
pared to the exposure of neutrophils to the potent chemoattractant fMLF, which caused a 
characteristic migration response towards the basement chamber (Figure 5-3A). As seen in 
Figure 5-3C, Cu.23 did not possess chemoattractant properties at all concentrations (0.1-
300 nM), which is a desirable outcome. 
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WKYMVm exhibited chemotactic effects at low concentrations (0.1-10 nM), which is in 
agreement with the literature as WKYMVm has been reported to be very efficient even at pM 
concentrations for both monocytes and neutrophils.14 At higher concentrations (100-300 nM), 
there were competitions between two potent chemoattractants i.e. fMLF and WKYMVm, thus 
the cells stopped crossing the membrane (Figure 5-3B). In contrast, Cu.24 exhibited chemo-
tactic effects in a dose-dependent manner, which is a desirable effect (Figure 5-3D). 
 
 
Figure 5-3 Effect of Cu.23 and Cu.24 to induce neutrophil chemotaxis. Neutrophils isolated from 
healthy volunteers were re-suspended at 4 x 106 cells/ml and chemotaxis to A) cFLFLFK, B) 
WKYMVm, C) Cu.23 or D) Cu.24 was assessed over a 90-min period. fMLF (10 nM; bottom well) 
was used as controls. Cell migration is expressed as the average chemotaxis index (mean ± SEM) 
of 3 separate experiments; each experiment was run in duplicate. *P < 0.05, **P < 0.01, ***P < 
0.001 vs. vehicle (ANOVA and Bonferroni). 
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5.3.2 Chemotaxis: Effect of Cu.23 and Cu.24 on fMLF-induced neutrophil 
chemotaxis 
Figure 5-4 shows the neutrophil responses towards the basement wells containing the potent 
chemoattractant fMLF after incubation with cFLFLFK, WKYMVm, Cu.23 or Cu.24. It was 
found that both cFLFLFK and Cu.23 did not affect the ability of neutrophils to response to the 
chemotactic signals induced by fMLF (Figure 5-4A and C). 
As shown in Figure 5-4B, WKYMVm did not further affect the cellular responses to fMLF at 
low concentrations (0.1-10 nM) owing to its chemotactic nature. However, it produced a 
marked inhibition in neutrophil response towards fMLF at high concentrations (100-300 nM) 
as a result of competition between two potent chemoattractants. Cu.24 did not affect the abil-
ity of neutrophils to respond to the chemotactic signals induced by fMLF at all concentrations, 
which is a desirable effect (Figure 5-4D). 
These experiments demonstrated that modification to cFLFLFK at the ε-lysine residue with a 
rather bulky DOTA chelate did not substantially affect the peptide activity over neutrophil 
functions at doses of 0.1-100 nM, when compared to the vehicle and fMLF, which is the de-
sired response of neutrophils. At 300 nM, Cu.23 showed reduced chemotactic effects 
compared to the cFLFLFK, which is a desirable outcome. In contrast, modification to 
WKYMVm with a DOTA chelate had an impact on the peptide activity over neutrophil func-
tions. Cu.24 induced neutrophil chemotaxis in a dose-dependent fashion but did not affect 
neutrophil responses to fMLF.  
 
- 116 - 
 
Figure 5-4 Effect of Cu.23 and Cu.24 on fMLF-induced human neutrophil chemotaxis. Neutro-
phils isolated from healthy volunteers were incubated with either A) cFLFLFK, B) WKYMVm, 
C) Cu.23 or D) Cu.24 for 10 min prior to loading on a chemotaxis plate where the bottom wells 
were loaded with vehicle or fMLF (10 nM). Cell migration is expressed as the average chemotaxis 
index (mean ± SEM) of 4 separate experiments; each experiment was run in duplicate. *P < 0.05, 
**P < 0.01, ***P < 0.001 vs. vehicle (ANOVA and Bonferroni). 
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5.3.3 TNF-α  Induced IL-1β  Production 
Neutrophils produce IL-1β upon activation and thus IL-1β release is characteristic of inflam-
mation. Thus, TNF-α induced IL-1β production levels are measured and employed to assess 
the functions of neutrophils and determine inflammation index. The modulatory effects of 
Cu.23 and Cu.24 were examined on cytokine production by TNF-α stimulated neutrophils 
obtained from healthy volunteers (Figure 5-5). Both Cu.23 and Cu.24 in the absence of TNF-
α had no impact on IL-1β release compared to the basal condition, in which human neutro-
phils produced a 10-fold increase in the release of IL-1β in response to TNF-α. Pre-incubation 
with Cu.23 or Cu.24 in the presence of TNF-α resulted in similar effects to the basal condi-
tion. Ac2-26 was used as a control to compare the effects of Cu.23 and Cu.24. Similar results 
to both compounds were observed. Ac2-26 alone did not affect IL-1β production. When TNF-
α was presence, a 10-fold increase in the release of IL-1β level was observed. 
These experiments demonstrated that modification to either cFLFLFK or WKYMVm with a 
DOTA unit did not affect the neutrophil TNF-α inflammatory response at doses of 0.1-
300 nM. These suggest that both Cu.23 and Cu.24 would be suitable for imaging inflamma-
tion, as they have not significantly affected neutrophil inflammatory functioning.  
Both in vitro assays suggest that neutrophils labelled with Cu.23 or Cu.24 would be conserved 
in the blood for extravasation and chemokinesis to the site of inflammation, since they do not 
activate and significantly change the function of neutrophils. In addition, administration of 
Cu.23 or Cu.24 would not be detrimental to the patients and both complexes would not affect 
the inflammatory process during the imaging, which is a desirable outcome. 
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Figure 5-5 Effect of Cu.23 and Cu.24 on human neutrophil-derived TNF-α  induced IL-1β  pro-
duction. Human neutrophils isolated from healthy volunteers were incubated with A) Cu.23, B) 
Cu.24 or Ac2-26 (1 µM) for 10 min prior to incubation in the presence or absence of TNF-α  
(10 ng/ml) for 18 h. Cell-free supernatants were tested by ELISA for human IL-1β . Data repre-
sents mean ± SEM of 3 separate experiments; each experiment was run in duplicate. *P < 0.05 vs. 
TNF-α  alone (ANOVA and Bonferroni). 
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5.4 In Vivo PET Imaging of [64Cu].23 
Towards the application of the novel radiopharmaceuticals to the diagnosis of acute inflamma-
tion, this chapter features the study of the synthesised ligand 23 as an imaging agent in pre-
clinical PET experiments after complexation with 64Cu(II) ions. 
Radiometal labelling and PET imaging experiments were performed by Dr Felicity Gavins and 
Dr Graeme Stasiuk at Louisiana State University Health Center, Shreveport, US. C57/BL6 
mice were injected with LPS in the left thigh to induce inflammation and PBS as control in the 
right thigh. At 24 h, mice were injected [64Cu].23 (200 µCi) via tail vein for PET imaging. 
 
Figure 5-6 PET-CT image of mouse with LPS and PBS injected on the left and right thigh respec-
tively, at 200 µCi. 
The imaging properties of [64Cu].23 were studied using mice with LPS-induced inflammation. 
Several studies have shown that LPS-mediated inflammation is primarily neutrophilic in the 
early stages,15-18 thus it has been used in this project for proof of concept studies of [64Cu].23, 
which would label neutrophils via FPR1. 
Figure 5-6 shows representative PET-CT image of [64Cu].23 after injection. Uniform uptake 
was observed in the PET images and this indicated good biodistribution of [64Cu].23 but poor 
targeting to the site of inflammation. However, a higher uptake in the left thigh was observed 
compared to the control. These preliminary studies have shown that imaging of [64Cu].23 as a 
proof of concept of the target for which [64Cu].23 was being tested for receptor occupancy 
mechanism of action. Although the preliminary PET experiments have not shown a significant 
uptake at the site of inflammation, [64Cu].23 is believed to have potential uses for nuclear im-
aging of inflammation. However, several issues need to be addressed for a positive outcome in 
imaging inflammation, such as selection of a suitable inflammation model and experimental 
design to determine the time course for injection and scanning. 
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5.5 Summary and Conclusions 
A reliable synthesis for DOTAGA-anhydride 25 has been demonstrated. Novel peptide-based 
imaging agents 23 and 24 have been designed and synthesised to target FPR1 and FPR2 using 
the FPR1 and FPR2 ligands respectively. Subsequent conjugation with peptides containing an 
amino functional group has been successfully performed and 25 can therefore find applica-
tions in biomedical imaging depending on the metal of choice, at the centre of the chelate 
ligand. 
In vitro assays relevant to the inflammatory process involving neutrophils were performed to 
determine the effects of Cu.23 and Cu.24 on neutrophil functions: chemotaxis using fMLF as 
stimulants and IL-1β production was induced by TNF-α. Cu.23 did not exhibit chemotactic 
effects on neutrophils and did not induce cellular response on neutrophils when stimulated 
with fMLF at all concentrations (0.1-300 nM). In contrast, Cu.24 exhibited chemotactic ef-
fects in a dose-dependent fashion but it did not induce cellular response on neutrophils to the 
desired effects when stimulated with fMLF. Neutrophils produce IL-1β upon activation and 
thus IL-1β release is characteristic of inflammation. Both Cu.23 and Cu.24 had no impacts on 
neutrophil functions with respect to IL-1β production. These results suggest that both Cu.23 
and Cu.24 would be an ideal imaging agent for inflammation as they do not activate and sig-
nificantly change the function of the targeted cells i.e. neutrophils. 
As a proof of concept, PET imaging of 64Cu(II) labelled 23 with a murine model of LPS-
induced inflammation on the right thigh has been investigated. 23 is believed to have the po-
tential for early diagnosis for inflammation. The most important question remains to be 
answered is whether the labelling of live cells by Cu.23 can be successfully conducted in a 
PET setting. Ligand 24 has not been further investigated for PET imaging due to time con-
straints and this will be the subject of future studies. 
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Chapter 6 
 
Synthesis Towards Dual-Modal Contrast Agents 
Targeting Inflammation 
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6 Synthesis Towards Dual-Modal Imaging Agents Target-
ing Inflammation 
6.1 Introduction 
To date, indocyanine green (ICG) is the only Food and Drug Administration approved long 
wavelength dye for direct administration in medical diagnostics for over 30 years with an ex-
cellent safety record.1-3 It is one of the dyes in the cyanine family and can be used as a 
fluorescence imaging agent. Classical cyanine dyes are cationic molecules in which two ter-
minal nitrogen heterocyclic subunits are linked by a polymethine bridge as shown in Figure 6-
1.  
 
Figure 6-1 General structure for a cyanine. 
Their common names denote the number of methine groups in the polyene chain e.g. n = 1 and 
n = 2 are referred to as trimethine (Cy3) and pentamethine (Cy5) cyanines, respectively. The 
length of the polymethine chain determines the spectral range of absorption and emission, and 
with each extension of one vinylene unit, the spectra shift to longer wavelengths by about 
100 nm. For example, Cy3 emits visible light while Cy5 and Cy7 emit in the far-red and NIR 
regions, respectively.4 
In general, cyanine dyes have narrow absorption bands and extremely high extinction coeffi-
cients, often reaching 200000 M-1cm-1. Cyanine dyes are weakly fluorescent owing to its 
conformational flexibility, thus fluorescence quantum yields are low from 1-18%. The fluo-
rescence quantum yield decreases with increasing length of the polymethine chain. However, 
the fluorescence efficiency of some NIR cyanines is enhanced upon immobilisation in com-
plexes with biomolecules. 
Owing to their structural diversity through varying the nitrogen substituents, polyene chain or 
the heterocycles, cyanines are employed for the synthesis of novel optical and dual-modal im-
aging agents that target inflammation. In particular, Cy5 exhibits bright fluorescence in the far 
red region around 670 nm and its spectroscopic and photophysical properties do not change 
significantly after covalent attachment. Cy5 has been demonstrated in the imaging of living 
cells,5-6 and is widely used to label biomolecules e.g. nucleic acids, proteins and peptides.7-8 
N
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6.1.1 Multimodal Imaging 
Multimodal imaging has drawn much attention within biomedical applications.9-11 Each imag-
ing modality has its own advantages and disadvantages in sensitivity, spatial and temporal 
resolution, and depth of penetration. Multimodal imaging offers the advantage of coupling the 
high sensitivity of one technique with the high resolution of another, providing more accurate 
and reliable information on diagnosis. Fluorescence imaging has high sensitivity and spatial 
resolution but limited depth penetration. In contrast, MRI offers excellent spatial resolution 
and unlimited depth of penetration but has at an inherently low sensitivity. 
Over the past few years, there has been an increasing interest in the development of multimod-
al imaging agents e.g. integrating within the same molecular entity the requirements of MRI 
and a second imaging modality.12-14 The combination of fluorescence and MRI techniques of-
fers attractive synergistic advantages in biomedical imaging with high sensitivity, good spatial 
resolution and non-ionising radiation. 
This chapter describes the development of targeted optical and multimodal imaging agents 
employing Cy5 as the chromophore for fluoresecence imaging and a DOTA motif as the che-
lating unit for Gd(III). 
6.2 Synthesis Towards Cy5 Dyes 
The preparation of cyanine dyes is traditionally accomplished by a stepwise condensation re-
action of two nucleophilic aza-heterocycles containing an activated methyl group with a 
polyene precursor for desired chain length e.g. diphenylformamidine and malondialdehyde 
bis(phenylimine) monohydrochloride for Cy3 and Cy5 respectively, the resultant hemicyanine 
is isolated and purified prior to the addition of another indolinium salt (Scheme 6-1). Kvach et 
al. reported a convenient one-pot approach to synthesising Cy5 containing two different N-
substituents, in which the hemicyanine intermediate is not isolated and the N-substituents can 
be functionalised for further modifications.8  
 
Scheme 6-1 General synthetic route to cyanine dyes. 
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The primary aim was to synthesise a water soluble cyanine dye featuring a carboxylic acid 
reactive group for peptide labelling with the peptides of interest i.e. cFLFLFK and 
WKYMVm. In general, the functionalisation can be introduced in the first step through R1 and 
R2 as shown in Scheme 6-1. However, this general approach is not compatible with some reac-
tive groups, as only carboxylic and sulphonic acid reactive groups are completely inert 
towards the reagents and reaction conditions used for the general synthesis of cyanine dyes. A 
water-soluble cyanine 31 was synthesised where R1 and R2 feature a carboxylic acid functional 
group for peptide labelling and a sulphonic acid to increase water solubility, respectively 
(Scheme 6-2). 
 
Scheme 6-2 General synthesis of Cy5 showing the non-isolated hemicyanine intermediate 30. a) 6-
bromohexanoic acid, b) 1,3-propanesultone, c) N-(3-bromopropyl)phthalimide.  
The secondary aim was to synthesise a cyanine-based amino acid bridging the peptides of in-
terest and previously synthesised DOTAGA-anhydride for the evaluation of previously 
synthesised Gd.23, using various in vitro techniques and for the development of novel multi-
modal imaging agents. The same approach leads to the synthesis of a cyanine-based amino 
acid 32 where R2 features an amino functional group. This requires a protection step prior to 
the condensation with a polyene precursor as amino functional group is susceptible to the reac-
tion conditions. Chipon et al. published the first original synthetic route to a novel water 
soluble fluorescent amino acid derived from pentamethine cyanine.15 The synthesis involved 
N-(3-bromopropyl)phthalimide as a protected amine, which can be treated with an excess of 
hydrazine monohydrate to give the cyanine-based amino acid. The synthesis was adapted to 
prepare 32 (Scheme 6-2) and the development towards novel multimodal imaging agents em-
ploying 32 will be described later in this chapter. 
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6.2.1 Synthesis of Indolinium Salts (27-29) 
 
Scheme 6-3 General synthesis of indolinium salts 27-29. 
The first step towards the preparation of Cy5 (31 and 32) involved alkylating a Fischer base 26 
with the corresponding alkyl halides to afford the indolinium salts (27-29) under various reac-
tion conditions and temperatures, as tabulated in Table 6-1. The products were characterised 
by 1H and 13C NMR spectroscopy, elemental analysis and HRMS, which are consistent to the 
findings in the literature.8, 16-17 
The starting indole 26 was readily alkylated with 1,3-propanesultone and N-(3-
bromopropyl)phthalimide to give the salts 28 and 29, respectively, in high yields (80-95%) at 
elevated temperatures. In contrast, alkylation with 6-bromohexanoic acid afforded indolinium 
salt 27 in 32% yield, which is low compared to the literature (92%).8 The yield could be im-
proved by longer reaction times, addition of catalytic potassium iodide or a higher reaction 
temperature, as suggested by the literature.15  
Compound Reaction conditions Yield 1H NMR at 298 K/ppm 
   Aliphatic H Phenyl H 
27a 
 
6-bromohexanoic acid 
MeNH2, 80 °C, 7 h 
32% 1.35 (2H), 1.55, 
(2H) 1.88 (2H), 2.27 
(2H), 4.37 (2H) 
7.52 (2H), 7.62 
(1H), 7.67 (1H) 
28a 1,3-propanesultone 
toluene, 110 °C, 20 h 
82% 2.30 (2H), 3.01 
(2H), 4.56 (2H) 
7.55 (2H), 7.64 
(1H), 7.73 (1H) 
29b N-(3-bromopropyl)phthalimide 
140 °C, 18 h 
95% 1.48 (2H), 1.99 
(2H), 3.79 (2H), 
4.90 (2H) 
7.56 (4H), 7.75 
(1H), 7.83 (1H) 
Table 6-1 Summary table for compounds 27-29, 1H NMR spectra measured in a) D2O, b) CDCl3. 
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6.2.2 Synthesis of Cy5 Dyes (31-32) 
 
Scheme 6-4 Synthesis of Cy5 (31-32). 
To synthesise the desired cyanine acid 31 or 32 (Scheme 6-4), the salt 27 was first heated with 
malondialdehyde bis(phenylimine) in acetic anhydride to form a hemicyanine intermediate in 
situ, which was treated with the corresponding salts 28 or 29 in pyridine at ambient tempera-
ture, respectively. The resulting mixtures were separated by column chromatography to afford 
the desired cyanine acids in high yields (80-95%), which were characterised by 1H, 13C NMR, 
elemental analysis and HRMS. 
UV-vis and fluorescence of 31 and 32 were recorded as seen in Figure 6-2, strong absorptions 
at 647 and 643 nm for 31 and 32, respectively were observed due to the contribution of π → 
π* transitions, the fluorescence spectra showed emissions at the NIR region of 680 and 
668 nm, respectively. In general, Cy5 exhibits bright fluorescence around 670 nm, the λem is 
governed solely by the length of the polymethine chain and the substituents on the rings. 
However, cyanine 31 gave a fluorescence spectrum at a higher λem compared to 32 and it indi-
cates that λem has been influenced by the R group as the core structures of 31 and 32 remain 
unchanged. The λem of 31 is slightly red-shifted and this might be resulted from the presence 
of an electron-withdrawing group i.e. the sulphonic acid group in closer proximity than the 
phthalimide group in 32. 
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Figure 6-2 Normalised absorption (blue) and emission (red) spectra of compound A) 31 (λ ex = 
647 nm) and B) 32 (λ ex = 643 nm), (H2O, pH 7.0, 298 K). 
Compound Yield MS(ESI) λex, λem/nm ε/ M-1cm-1 1H NMR at 298 K/ppm 
     Vinylene H Phenyl H 
31 82% 591.29 647, 680 167000 6.29 (1H), 6.41 
(1H), 6.66 
(1H), 8.27 (2H) 
7.25 (2H), 7.34 
(4H), 7.48 (2H) 
32 95% 670.36 643, 668 165000 6.31 (2H), 6.63 
(1H), 8.23 (2H) 
7.38 (8H), 7.80 
(2H), 7.86 (2H) 
Table 6-2 Summary table for cyanines 31-32, 1H NMR spectra measured in MeOD. 
6.3 Development Towards Optical Imaging Agents 
6.3.1 Synthesis of Cy5-cFLFLF (33) 
 
Scheme 6-5 Synthesis of 33. 
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Cyanine 31 was activated by HBTU and DIEA in situ prior to the addition of cFLFLFK dis-
solved in acetonitrile (Scheme 6-5). The solution was stirred at ambient temperature for 2 h. 
Borate buffer (pH 8.5) was added to ensure complete conversion and removal of unreacted 
HBTU. Purification was achieved by flash column chromatography on Sephadex G-25, elut-
ing with MilliQ water. 33 was successfully synthesised in high yield (85%) and MS (MALDI) 
spectrum gave a peak at m/z = 1515 for [M]+. 
Photophysical properties of 33 were investigated, strong absorptions at 647 nm were observed 
due to the contribution of π → π* transitions from the conjugated polyene core, the fluores-
cence spectra showed emissions in the far red region of 678 nm (Figure 6-4A).  
6.3.2 Synthesis of Rhodamine B-cFLFLF (34) 
Rhodamine dyes are fluorophores that belong to the family of xanthene dyes containing a 2-
carboxyphenyl ring on the central carbon atom featuring high photostability, ε, and quantum 
yield (Figure 6-3).18 They were initially used in cloth colouration but soon found many appli-
cations owing to their unique optical properties such as water tracking agents, fluorescent 
markers and laser sensitisers.19-20 
 
Figure 6-3 Molecular structure of xanthene, rhodamines and rhodamine 6G. 
Rhodamine 6G (Figure 6-3) has been utilised to visualise and track leukocytes using IVM, 
which is an invasive technique to monitor leukocyte-endohethial cell interaction in vivo.21-23 
Rhodamine 6G features an ethyl ester on the carboxyphenyl ring and thus cannot be further 
functionalised without a deprotection step. Utilisation of bis-N-alkylated rhodamines (R1, R2 = 
alkyl) or protection is required to avoid side reactions of any active functional group with the 
unprotected amines of xanthene moiety. Thus, the bis-N-alkylated rhodamine B was consid-
ered as an alternative to rhodamine 6G. Moreover, a simple preparation of N-
hydroxysuccinimidyl ester from rhodamine B has been demonstrated and the subsequent con-
jugation reaction with an amine derivative was proven to be useful for labeling molecules of 
interest.24  
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Scheme 6-6 Synthesis of 34. 
Compound 34 was prepared and isolated from rhodamine B and cFLFLFK using the 
HBTU/DIEA approach (Scheme 6-6). The crude product was purified on silica eluting with 
10% methanol in DCM afforded the product in high purity (85% yield). The formation of 34 
was confirmed by MS (MALDI +ve) which showed peaks at m/z = 1368 representing [M]+. 
Photophysical properties of 34 were investigated, strong absorptions at 555 nm was observed 
due to the contribution of π → π* transitions, the fluorescence spectra showed emissions in 
the red region of 578 nm from the rhodamine B (Figure 6-4B). 34 was used in confocal fluo-
rescence imaging as a comparison to 33 in the subsequent section. 
 
Figure 6-4 Normalised absorption (blue) and emission (red) spectra of compound A) 33 (λ ex = 
647 nm) and B) 34 ((λ ex = 555 nm), (H2O, pH 7.0, 298 K). 
6.3.3 Confocal Fluorescence Imaging 
To demonstrate the ability of cFLFLFK to bind to FPR1, this section represents the study of 
the cFLFLFK conjugates 33 and 34 using HEK cells stably expressing FPR1 in confocal fluo-
rescence microscopy, performed by Dr Paul Holloway in Neuroscience Centre, Imperial 
College London, Hammersmith Campus. Cells were seeded in multi-chamber macroscopic 
slides (µ-Slide VI Treat, IBIDI, Integrated BioDiagnostics), which allow direct observations 
with inverted microscopes through its transparent plastic bottom. 
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6.3.3.1 Ligand Binding 
The cells grown in µ-Slide were incubated with either 33 or 34, followed by fluorescently la-
belled Concanavalin A (ConA) with either TRITC or Alexa Fluor® 488, respectively. ConA is 
a lectin and widely used to characterise glycoproteins on the surface of various cells. Cell nu-
clei were stained and visualised by 4',6-diamidino-2-phenylindole (DAPI). 
ConA staining exhibited localisation to the cell membranes and the classical pyramidal or 
rhombic morphology of HEK cells were observed (Figure 6-5 and 6-6). When the images 
were merged, extensive colocalisation was observed and 33 was accumulated on the cell sur-
faces indicating binding to FPR1 (Figure 6-5). Similarly to 33, a uniform distribution of 34 
was observed but internalisation of 34 to the cytoplasm was also observed compared to 33 
(Figure 6-6). Many GPCRs rapidly internalise upon ligand binding,25 FPR1 is internalised to 
prevent over activation upon stimulations with agonists such as fMLF.26 However, as 
cFLFLFK is an antagonist, it was believed that 34 was able to move across the membrane and 
bind to the proteins inside the cells rather than being internalised as some rhodamine deriva-
tives have been shown to accumulate inside the cells.27-30 
6.3.3.2 FPR1 Staining 
In order to verify the presence of FPR1 on the HEK cells stably expressing FPR1, immunocy-
tochemical staining was performed on the cells with rabbit anti human-FPR1 antibody 
followed by Alexa Fluor® 488 goat anti-rabbit IgG (Figure 6-7). An almost uniform mem-
brane distribution of FPR1 was observed indicating that FPR1 have been successfully 
transfected and expressed on HEK cells. When using HEK cells stably expressing FPR2, no 
cross reactivity of the antibody was observed, strongly suggesting that 33 and 34 are solely 
bound to FPR1. 
These confocal fluorescence studies showed that FPR1 was transfected steadily on HEK cells. 
Binding of the antibody was convincingly specific, thus it was believed that fluorescence of 33 
and 34 was originated from the binding to FPR1 on cell surfaces. Modification to the FPR1 
antagonist cFLFLFK has not affected the binding towards FPR1 and the fluorescent conju-
gates (33-34) can potentially be used as receptor labels to study FPR1 on various cell types. 
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DAPI 
nuclear stain 
ConA 
membrane stain 33 Merged 
    
Figure 6-5 From left to right, HEK cells stably expressing FPR1 were stained with DAPI (blue), 
TRITC-ConcA (red), 33 (yellow) and a merged image showing ligand binding of 33 on cell surfac-
es. 
DAPI 
nuclear stain 
ConA 
membrane stain 34 Merged 
    
Figure 6-6 From left to right, HEK cells stably expressing FPR1 were stained with DAPI (blue), 
Alexa Fluoro® 488-ConcA (red), 34 (red) and a merged image showing ligand binding of 34 on 
cell surfaces and internalisation by cells. 
 DAPI 
nuclear stain FPR1 IgG Merged 
FPR1 
   
FPR2 
   
Figure 6-7 From left to right, HEK cells stably expressing FPR1 or FPR2 were stained with DAPI 
(blue), Alexa Fluoro® 488-goat anti rabbit IgG (green) for FPR1 and merged images showing 
distribution of FPR1 and no cross reactivity to FPR2. 
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6.4 Development Towards Dual-Modal Imaging Agents 
6.4.1 Synthesis Towards Peptide-based Dual-Modal Imaging Agents 
Multistep synthesis towards novel dual-modal imaging agents targeting inflammation is illus-
trated in Scheme 6-7. Cyanine 32 featuring two orthogonal functional groups has been 
synthesised. Subsequent amide coupling reaction with cFLFLFK using HBTU/DIEA approach 
was performed. As the starting cyanine 32 is highly polar and tends to remain on alumina, 35 
was isolated by flash column chromatograph in near quantitative yield. 
 
Scheme 6-7 Synthetic scheme towards novel multimodal imaging agents. Reaction conditions: i) 
hydrazine monohydrate; ii) MeNH2, MeOH, 65°C. 
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Various methods for converting phthalimides to amines exist in the literature.7, 15, 31 The meth-
od using hydrazine monohydrate group was initially attempted. 35 was stirred in an excess of 
hydrazine monohydrate for 2-4 h and the reaction was monitored via TLC. Phthalimide was 
successfully converted to the amino functional group but hydrogenation at the alkene func-
tional group of cFLFLFK was observed in this reaction. The chemical shifts indicative of the 
alkene protons at 6.66 ppm in the 1H NMR spectrum were not observed and the resultant 
product recorded peaks in the HRMS at m/z = 1467 representing [M-2H]+ with no peak at m/z 
= 1465 representing [M]+. Reaction at the targeting peptide could affect the binding affinity 
towards FPR1 and more importantly the biological functions of the cells. As a result, methods 
using alternative reagents were investigated. 
The second method used a milder alternative to hydrazine monohydrate, which was methyla-
mine (2 M in methanol) in 3-5 equivalents. In order to optimise the reaction conditions and 
reduce the cost of the expensive peptides, a simple kinetic reaction was performed using cya-
nine 32 at 65°C and 1H NMR spectrum was recorded every 20 min for 4 h at 65°C in 
deuterated methanol (Figure 6-8). The chemical shift indicative of the starting cyanine 32 ob-
served at 3.78 ppm disappeared after 3 h while new chemical shifts at 2.72 and 3.14 ppm were 
observed representing the methylene protons and amine respectively. This showed that depro-
tection of 32 using methylamine was completed within 4 h at 65°C. 
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Figure 6-8 1H NMR spectra of 32 with MeNH2 showing region enlarged in 1.9-4.4 ppm every hour 
for 4 h at 65°C (MeOD, 338 K). 
With the knowledge that deprotection of 32 completed within 4 h, the same reaction condi-
tions were used to deprotect 35. Excess methylamine was removed under reduced pressure and 
the resultant compound 37 was characterised via 1H NMR and MS (MALDI). 37 was used 
without further purification in the subsequent reaction with DOTAGA-anhydride 25 in the 
presence of DIEA in DCM. Unfortunately, the formation of the desired product 39 was not 
observed and it was thought that impurities from previous reaction had impeded the reaction 
with 25. Various purification methods were investigated including extraction with basic solu-
tion to remove impurities and flash column chromatography. After purifying 37 on silica, the 
eventual ligand 39 was successfully synthesised from 25 and isolated in 80% yield after puri-
fication on Sephadex G-25. 39 was further characterised by MS (MALDI +ve), which showed 
peaks at m/z = 1923 corresponding to [M]+. Ln(III) complexation with 39 was performed and 
UV-vis spectra of Ln.39 showed characteristic peptide and cyanine absorbance bands at 280 
and 670 nm, respectively (Figure 6-9). 
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Figure 6-9 UV-vis spectra of cyanine 32 and its derivatives. (H2O, 298 K). 
Although the ligand 39 had been synthesised and isolated, the multistep synthesis showed sev-
eral synthetic difficulties. The critical amine deprotection step was extremely low yielding, 
impurities from this step had impeded the subsequent amide coupling reaction. In addition, 35 
is highly polar and tends to be retained on the alumina column. Thus, conventional chromato-
graphic methods are not economically viable in obtaining sufficient amounts for further 
reactions. Alternative purification methods should be considered such as RP-HPLC which 
generally has high compound recovery rate. However, due to time constraints, optimising RP-
HPLC as an alternative purification method could not be completed. 
Novel dual-modal imaging agents based on the FPR2 agonist WKYMVm were attempted in 
parallel to the synthesis using cFLFLFK (Scheme 6-7). However, WKYMVm is susceptible to 
high temperatures and deprotection of 36 using methylamine at 65°C resulted in peptide deg-
radation. The deprotection could be performed at lower temperatures with longer reaction 
times, but due to time constraints, this part of the project was suspended in favour of investi-
gating the more promising peptide cFLFLFK. The synthesis towards ligand 40 featuring 
WKYMVm could not be completed. 
6.4.2 Characterisation of Ln.39 
6.4.2.1 Relaxometric and Luminescence Studies of Gd.39 
Gd.39 was synthesised from ligand 39 and GdCl3.6H2O, giving a blue solid. MS (MALDI 
+ve) of the complex gave peaks at m/z = 1039 and 2078 representing [M]2+ and [M+H]+ re-
spectively. Spin recovery experiments were performed on a 400 MHz NMR spectrometer, r1 is 
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calculated to be 4.24 mM-1 s-1 (298 K, 400 MHz), which is within the range for Gd(III) com-
plexes with q = 1.32 
The luminescent properties of Gd.39 were investigated. It was found that Gd.39 exhibited flu-
orescence emission at 670 nm upon excitation at 643 nm (Figure 6-10), suggesting that 
modifications on the terminal carboxylic and amino functional groups do not lead to signifi-
cant changes in the luminescent properties of the chromophore, as there are no electronic or 
structural changes on the polymethine chain. Gd.39 can thus behave as a dual-modal 
MRI/fluorescence imaging agent. 
 
Figure 6-10 Normalised absorption (blue) and emission (red) spectra of Gd.39 ((λ ex = 643 nm, 
H2O, pH 7.0, 298 K). 
6.4.2.2 Luminescence Studies of Tb.39 
Tb.39 was synthesised from ligand 39 and TbCl3.6H2O, giving a blue solid. MS (MALDI +ve) 
of the complex gave peaks at m/z = 1039 and 2079 representing [M]2+ and [M+H]+ respective-
ly. The luminescent properties of Tb.39 were investigated and q was determined. 
Upon excitation at 642 nm, Tb.39 gave an emission at 670 nm, featuring fluorescence from 
the cyanine chromophore (Figure 6-11). Upon excitation at 210 and 355 nm, Tb(III) displayed 
emission spectra which arise from transitions 5D4 to 7FJ (ΔJ = 2 to 0). Sensitisation at 210 nm 
could result from the phenyl groups in cFLFLFK displaying a more intense spectrum com-
pared to the emission resulted from the pseudo-direct excitation to Tb(III) ion at 355 nm. 
Fluorescence resonance energy transfer (FRET) is a process where energy from one fluoro-
phore is transferred to a second one if they are in close proximity (typically 10-100 Å). The 
process involved a sensitised Ln(III) centre has been called luminescence resonance energy 
transfer (LRET).33 It has been reported that when a sensitised Tb(III) chelate is conjugated to 
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an organic fluorophore, LRET occurs from the donor Tb(III) chelate to the acceptor fluoro-
phores.34-35 The lifetime of Tb.39 is lower than Tb.23 which does not contain a second 
fluorophore, indicating LRET from the donor Tb(III) to the acceptor Cy5 dye (Table 6-3). 
Tb(III) emission lifetime is typically long (0.1-2 ms), whereas organic fluorophores such as 
Cy5 has short lifetime (ns) and its fluorescence emission is generally not observed in time-
gated detection unlike Tb(III) emission. In Tb.39, both sensitised and pseudo-direct excita-
tions to the donor Tb(III) at 210 and 355 nm respectively, resulted in an overlapped 
luminescence spectra of Tb(III) and Cy5 emissions, further confirming LRET of Tb(III) to 
Cy5.  
The 5D4 to 7F5 transition at 545 nm was monitored for lifetime studies in H2O and D2O to de-
termine 𝑘!!! and 𝑘!!! in order to calculate q (Table 6-3). The q of Tb.39 is 0.80 from the 
lifetime studies, which is similar to Tb.23. The results show that modification of the chelate 
complex with the extra acetate arm for conjugation does not alter the luminescence properties 
of the bound Tb(III) ion. Tb.39 exhibits LRET from Tb(III) to Cy5 which could allow for 
time-gated detection to eliminate background fluorescence. 
 
Figure 6-11 Emission spectra of Tb.36, (λ ex = 210, 355 and 643 nm, gated time = 0.1 ms, H2O, 
298 K, pH 7.0). Excitation at λ ex = 210 nm resulted in sensitisation to Tb(III) which give rise to 
LRET to neighbouring Cy5 showing emission at λ ex = 670 nm. 
Complex λex/nm λem/nm 𝑘!!!/ms-1 𝑘!!!/ms-1 q (±0.2) 
Tb.23 355 545 0.82 0.59 0.9 
Tb.39 355 545 0.64 0.42 0.8 
Table 6-3 Rate constants, k for depopulation of the excited states and q for the decay of Tb.39. 
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6.5 Summary and Conclusions 
A reliable synthesis for a water-soluble cyanine dye 31 has been demonstrated. The subse-
quent cFLFLFK conjugate 33 is water-soluble and it has exhibited binding with HEK cells 
stably expressing FPR1 via confocal imaging. Rhodamine B-cFLFLFK 34, which emits at λem 
= 555 nm, has been synthesised and immunocytochemical staining with a FPR1 antibody has 
confirmed binding of both 33 and 34 towards FPR1. 
Cyanine 32, featuring orthogonally functional groups, has been synthesised and a novel dual-
modal imaging agent targeting FPR1 39 using cyanine 32 has been demonstrated. Complexa-
tion with paramagnetic Gd(III) ions resulted in a dual-modal MRI/optical imaging agent. 
Relaxometric studies of Gd.39 gave a relaxivity of 4.24 mM-1s-1 (298 K, 9.4 T), which is typi-
cal for small Gd-based contrast agents with q = 1. In contrast, complexation with luminescent 
Tb(III) ions gave dual luminescent imaging agents. Tb.39 shows LRET from Tb(III) to Cy5 as 
the ground states are very close in energy, this could allow for time-gated detection to elimi-
nate autofluorescence and distinguish between target recognition and false-positive signal. 
Besides forming highly stable complexes with Ln(III) ions, ligand 39 could form stable com-
plexes with various divalent and trivalent radionuclei, e.g. 64Cu(II) and 68Ga(III) ions, giving 
novel dual-modal optical/PET or optical/SPECT imaging agents, respectively, and this will be 
the subject of future studies. 
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7 Synthesis Towards Non-Peptide Based Contrast Agents 
7.1 Introduction 
There are a few FPR1 antagonists that have been identified with most of them being proteins 
and short-chain peptides, e.g. cyclosporin H, t-Boc-MLF.1-2 A few examples of non-peptide 
(i.e. small molecule) FPR1 antagonists have been identified in the last few years through the 
use of small molecule high throughput screening (Figure 7-1).3-7 Pyrazole 20 is the most potent 
FPR1 antagonist identified to date with pIC50 of 8.4 in intracellular Ca(II) response determina-
tion.3  
 
Figure 7-1 A selection of known FPR1 antagonists. 
Peptides usually present poorer pharmacokinetics and shorter half-lives, making chronic ad-
ministration problematic and expensive. Therefore, there is a need to develop FPR1 targeted 
contrast agents employing small non-peptide organic molecules. As mentioned in previous 
chapters, the criteria for FPR1 targeting contrast agent is to avoid undesirable activation of 
FPR1, which leads to inflammation. Thus, non-peptide FPR1 antagonists are employed as the 
targeting motif for FPR1. At the beginning of this project, the Ugi diamide 41 was the most 
potent known FPR1 antagonist with pIC50 of 6.4 from a High Throughput Screen of the corpo-
rate AstraZeneca collection (800K) reported by Unitt and coworkers.4 Ugi diamide 41 can be 
obtained using a one-pot multicomponent reaction in methanol, which is a so-called Ugi con-
densation reaction from salicylic acid, 5-methyl-2-thiophenecarbaldehyde, 2,6-dimethylphenyl 
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isocyanide and ammonia (Scheme 7-1). This approach is particularly attractive and requires 
little effort to set up while accepting a broad variety of chemical functionality. Marcus et al. 
reported the synthesis of a series of DOTA-monoamide ligands using Ugi reaction employing 
orthogonal protected DOTA chelates, showing the complexity and feasibility of Ugi reaction 
in synthesising DOTA based ligands.8 This chapter features the development towards non-
peptide imaging agents is based on the Ugi reaction of 41 with amine- or acid-appended mac-
rocycles. 
 
Scheme 7-1 Synthesis of the FPR1 antagonist, Ugi diamide. 
7.2 Development Towards Non-peptide Imaging Agents 
First described by Ugi in 1959,9 the Ugi reaction or Ugi four-component reaction (Ugi-4CR) 
usually refers to the reaction between a primary or secondary amine, a carbonyl compound, an 
isocyanide and a carboxylic acid (Scheme 7-2). The combination of three or more different 
series of reagents allows the straightforward construction of large libraries while accepting a 
broad variety of chemical functionality. Ugi-4CR represents a powerful method to quickly 
assemble in one-pot α-acylaminocarboxamides from a primary amine, a carbonyl component, 
a carboxylic acid and an isocyanide as starting reagents. 
 
Scheme 7-2 The general scheme of Ugi four-component reaction. 
The reaction mechanism is shown in Figure 7-2. Condensation of an amine with a carbonyl 
gives the corresponding Schiff base. Upon proton activation, the Schiff base reacts with an 
isocyanide giving an intermediate nitrilium ion. Subsequent addition of carboxylate ensues an 
irreversible rearrangement by forming a CO double bond i.e. Mumm rearrangement, which 
drives the reaction forward giving acyclic α-acylaminocarboxamides, which form the classical 
skeleton of Ugi-4CR. 
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Figure 7-2 Reaction mechanism of Ugi-4CR with Mumm rearrangement. 
In this project, the Ugi reaction has been employed in the attempts to synthesise a series of 
FPR1 antagonist-based MRI contrast agents incorporating a DOTA unit for Gd(III) ion, and 
other lanthanide ions such as Eu(III) and Tb(III) for luminescent studies. Apart from the ease 
of performance, the other advantage of Ugi-4CR in the synthesis of imaging agents is that two 
of the components, the carboxylic acid and amine, can be substituted with appropriate carbox-
ylic acid- or amine-appended BFCAs to synthesise the target compounds, target I and II 
respectively, as shown in Scheme 7-3.  
 
Scheme 7-3 Synthetic approach to synthesise non-peptide based imaging agents using Ugi-4CR. 
Unitt et al. reported that the preliminary exploration of the structure-activity relationship of 
41, in which the replacement of hydrogen at the R4 with a methyl group resulted in a loss of 
FPR1 potency and the ortho-phenol at the R1 was required to maintain FPR1 activity.4 Modifi-
cations are therefore limited to the R1 and R2 positions. Substitution of carboxylic acid- or 
amine-appended BFCAs at R1 and R4 respectively is very likely to have a significant impact 
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on the binding affinity and selectivity towards FPR1. Having said this, the Ugi reaction still 
remains a synthetically useful reaction in the project owing to its straightforward experimental 
set up and the effects of modification at R1 and R4 on receptor affinity can be studied using 
radioligand binding assays. 
7.3 Target I: Modification at the R1-position 
There are two approaches to synthesise the desired contrast agents M.43 (when M = Gd) for 
MRI as shown in Scheme 7-4. Both chelate 20 and 21 were successfully synthesised and their 
syntheses are described in previous chapter. Method A highlights a ‘one-step’ synthesis to 
M.43 from M.20, in which the metal ion act as a protecting group to the acetate arms leaving 
only one extra acetate arm for reaction. In contrast, method B employs the orthogonally pro-
tected chelate 21, which requires removal of tert-butyl esters using TFA after Ugi-4CR. 
 
Scheme 7-4 Synthetic routes to novel non-peptide based imaging agents utilising the R1-position. 
7.3.1 Attempted Ugi-4CR towards 43 
Method A was investigated preferably owing to its simplicity. A Y(III) complex of 20 was 
employed; yttrium is non-paramagnetic and its 1H NMR spectra can be studied for structural 
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characterisation. The initial attempts to prepare Y.43 were to react Y.20 with ammonia in 
methanol for 30 min followed by the addition of 5-methyl-2-thiophenecarbaldehyde and 2,6-
dimethylphenyl isocyanide. The solution was heated in methanol at 45 °C for 72 h. Prelimi-
nary analysis using LC-MS showed two major peaks at 5.88 and 6.97 min but none of them 
represented the desired product. 
 
Figure 7-3 Major products obtained in Ugi-4CR involving ammonia in MeOH. 
Various reports commented upon the fact that the use of ammonia as the amine component 
often leads to irreversible side reactions e.g. Passerini reaction. Kazmaier and co-workers 
characterised the products of Ugi-4CR using ammonia as the amine component and postulated 
a reaction mechanism for the formation of the by-products (Figure 7-3).10-11 From the reaction 
mechanism, imine A formed in the first step can react with another nucleophile, methanol or 
ammonia leading to the formation of a semiaminal intermediate which can then react with a 
second equivalent of aldehyde component giving rise to intermediates C and D. Addition of 
the carboxylic acid and isocyanide generates the highly reactive intermediates E and F, which 
R1
O
OH R2
O
NH3R3 NC+ + +
R3
H
N
O
N
H
R2
R1
O
R2
O
+
NH3
H
H
NHR2
R2H2N
N R3O
OR1
R3
H
N
O
N
H
R2
R1
O
A
B Ugi-4CR product
NH3 NH2R2
NH2
R2CHO N
NH2
R2 R2
D
C E
F
H
N
O
R3
H
N
O
N
R2
R1
O
R2 NH2
R3
H
N
O
N
R2
R1
O
R2 OMe
R3 NH
R2
NH2
R2
R1
O
R2CHO
MeOH
N
OMe
R2 R2 R1COOH
R3 NC
6CC by-products
R3
N
OO
R1
R2
HN
MeO
R2
R1COOH
R3 NC
MeOH
Reaction mechanism
R3
H
N
O
N
R2
R1
O
R2 NH2
R3
H
N
O
N
R2
R1
O
R2 OMe
6CC by-products
Ugi-4CR product
R1COOH
R3 NC
- 148 - 
subsequently undergo Mumm rearrangement to the six-component coupling (6CC) by-
products. This has led to the identification of the peak at 5.88 min to be the side product 44 
without the metal ion at m/z = 858, representing [M]- (Scheme 7-5). 
 
Scheme 7-5 Attempted synthesis of Y.41 using Ugi-4CR. 
After unsuccessful attempts in methanol, 2,2,2-trifluoroethanol was employed as the solvent in 
an attempt to synthesise M.43. It was found that the 6CC by-products can be suppressed by 
using a non-nucleophilic solvent, as reported by Kazmaier et al.10-11 Preliminary analysis using 
LC-MS showed a complex reaction mixture and the desired product 43 at 15.65 min without 
the metal ions, indicating that prolonged heating at 40-50 °C in either methanol or 2,2,2-
trifluoroethanol resulted in metal decomplexation. Following unsuccessful attempts to prepare 
and isolate M.43 using metal protected BFCA 20, this one-step approach to synthesise the 
non-peptide based MRI contrast agent Gd.43 was deemed not feasible and an alternative route 
using the previously synthesised acid-appended BFCA 21 was attempted (Scheme 7-4 method 
B). 
As demonstrated in the previous chapter, the orthogonally protected ligand 19 can be selec-
tively deprotected according to reaction conditions. The methyl ester was cleaved to make 21 
with a carboxylic acid functional group, which was employed to substitute salicylic acid in the 
attempts to prepare 42 (Scheme7-6). 
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Scheme 7-6 Attempted Ugi-4CR synthesis from orthogonally protected 21 via method B. 
By switching from methanol to non-nucleophilic 2,2,2-trifluoroethanol, the side reactions of 
ammonia were reduced with an improved yield of the desired product. However, in the at-
tempts to prepare 42 via method B using 21 in 2,2,2-trifluoroethanol, the formation of the 
desired product 42 and the 6CC product was not observed in the preliminary LC-MS studies. 
A likely possibility was that 21 was a weak acid and this resulted in long reaction times owing 
to the low concentration of the imine intermediate in the reaction medium. In addition, ammo-
nia is not a suitable amine component for Ugi-4CR owing to the complexity resulting from the 
side reactions. It could be concluded that modification at R1 was not feasible with acid-
appended Y.20 and 21. The approach to derivatising R4 with an amine-appended BFCA was 
explored as an alternative to synthesise non-peptide based imaging agents, as discussed in the 
next section. 
7.4 Target II: Modification at the R4-position 
7.4.1 Synthesis of DOTAGA-tBu4, NH2 (45) 
The modification at the R4-position requires an amine-appended BFCA as the amine compo-
nent in Ugi-4CR (Scheme 7-3, Target II). Compound 45 was prepared according to the 
method adapted from Grogna et al. which employed ethylenediamine as a solvent as well as a 
reactant in an excess of about 30 equivalents.12 Compound 19 was dissolved in ethylenedia-
mine and the solution was stirred at rt for 72 hr. Following the completed reaction, which was 
evidenced by the complete disappearance of the peak representing the methyl ester at 3.66 
ppm, the excess ethylenediamine was removed under reduced pressure and the crude product 
was purified on alumina with a gradient elution of 0 to 20% methanol in DCM, giving a pale 
yellow oil with a yield of 75% (Scheme 7-7). 
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Scheme 7-7 Synthesis of amine-appended 45. 
In the 1H NMR spectrum, the peaks indicative of methyl ester at 3.66 ppm disappeared where-
as the peaks representing the ethylene chain at 2.14 ppm were observed, indicating the 
formation of the desired product. MS (ESI +ve) showed peaks at m/z = 743 and 765 represent-
ing [M+H]+ and [M+Na]+ respectively. 
7.4.2 Attempted Ugi-4CR of 46 
Ugi-4CR using the amine-appended 45 as the amine component was attempted in order to 
prepare 46 (Scheme 7-8). Compound 45 was heated with salicylic acid for 30 min at 40 °C for 
the formation of imine before reaction with the aldehyde and isocyanide for further 72 h. Pre-
liminary LC-MS studies of the Ugi-4CR showed disappointing results; both the desired 
product 46 and 6CC product were not observed. It was hypothesised that the amine-appended 
BCFA 45 was a weak nucleophile and this resulted in long reaction times owing to slow for-
mation of the imine intermediate during the reaction. 
  
Scheme 7-8 Attempted Ugi-4CR to prepare 46 using amine-appended pro-chelator 45. 
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Following unsuccessful attempts towards non-peptide based imaging agents (42, 46) from 
DOTAGA at both R1 and R4 positions, optimisation through the reaction conditions via syn-
thesis of 41 was investigated to clarify the true cause of these reactions and to investigate the 
effects of various reaction conditions on the product formation. 
7.5 Synthesis of Ugi Diamide (41) 
The success of Ugi-4CR clearly depends on various factors e.g. the strength of the basic amine 
component, reagent concentrations and temperature. A review article has been published with 
more detailed discussions on each factor.13 Following investigation from the attempts in syn-
thesising 42 and 46, the effects of using methanol and non-nucleophilic 2,2,2-trifluoroethanol, 
and the reagent concentrations were investigated in the synthesis of 41 (Scheme 7-1). The re-
sults are tabulated in Table 7-1. 
Initial attempt to prepare 41 involved the reaction at 0.01 M concentration using methanol at 
40°C. The mixture was stirred for 7 days and the reaction was monitored via TLC and LC-MS. 
The crude product was purified on silica with a gradient elution of 0 to 3% methanol in DCM 
giving an orange oil (10% yield). The MS (ESI +ve) showed peaks at m/z = 395 and 417 rep-
resenting [M+H]+ and [M+Na]+ respectively, indicating the formation of the desired product. 
Although the reaction conditions to form the desired product had been established, the reaction 
performed in methanol was extremely slow and low yielding after purification on silica.  
The synthesis was attempted with identical reaction conditions but the less nucleophilic 2,2,2-
trifluoroethanol was used. Preliminary LC-MS showed less side reactions and the formation of 
the desired product was evident. However, the yield was not significantly improved after puri-
fication on silica. With the knowledge that less side reaction occurs in 2,2,2-trifluoroethanol, 
the Ugi-4CR was attempted at a much higher concentration of 0.5 M in 1:1 MeOH:2,2,2-
trifluoroethanol. The yield was increased from 10% to 44% and the desired compound 41 pre-
cipitated from the solution. No tedious purification was needed and 41 was isolated in a 
reasonably high purity after simple workup by filtration and washing with cold methanol and 
diethyl ether. 
Concentration Solvent Temperature Yield 
0.01 M MeOH 40 °C 11% 
0.01 M CF3CH2OH 40 °C 10% 
0.5 M CF3CH2OH 40 °C 44% 
Table 7-1 Summary table for the Ugi-4CR of 41. 
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Although the synthesis of 41 has been reported, no spectroscopic data have been detailed in 
the literature. Successful synthesis of 41 in high yield and purity allowed for detailed analysis 
and structural characterisation via 1H, 13C NMR, MS and IR spectroscopy. The 1H NMR spec-
trum (Figure 7-4) exhibited a singlet at 2.15 and 2.50 ppm attributed to the methyl groups on 
the phenyl and thiophene ring, respectively. The CH at the chiral centre was allocated to the 
singlet at 6.06 ppm. The phenyl and thiophene protons were unambiguously assigned by 2D 
COSY NMR analysis. This would be useful for structural characterisation of compound 42 
and 46 using NMR if the syntheses were successful. 
 
Figure 7-4 1H NMR of Ugi diamide 41 with insert showing the aromatic region (298 K, 400 MHz, 
MeOD). 
7.6 Radioligand Binding Assay 
A radioligand binding assay was performed using FPR1 expressed HEK cells and the 125I-
labelled fnLLFnLYK chemotactic peptide, which was labelled in-house in collaboration with 
Andrew Hogben and Dr James Minnion (Commonwealth Building, Imperial College London, 
Hammersmith campus).  
41 was subjected to radioligand binding assay against [125I]_fnLLFnLYK as shown in Figure 7-
5, the pIC50 value obtained from the graph was 6.7 ± 0.3 which is comparable to the literature 
(pIC50 = 6.4).4 It can be used as a reference against 42 and 46 if the synthesis was successful. 
This would give an indication as to whether modification at various positions of 41 with a 
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large DOTA unit would have a significant impact on binding affinity towards FPR1. With the 
knowledge that replacement of hydrogen at R4 resulted in a loss of FPR1 potency, 42 would be 
expected to have lower affinity to FPR1. For 46, it was shown than the ortho-phenol at R1 was 
essential to maintain FPR1 activity and it will be interesting to look at the effect of substituting 
the ortho-phenol to a rather bulky DOTA motif at the R1 position would have any impact on 
FPR1 potency and selectivity. 
 
Figure 7-5 Representative competitive binding profile of 41. Various concentrations of 41 were 
incubated together with [125I]-fnLLFnLYK (1000 cts/s) and FPR1 transfected HEK cells. pIC50 
values were determined by non-linear progressive analysis and compared to the literature.4 
7.7 Summary and Conclusions 
The FPR1 antagonist 41 was successfully prepared and isolated in high yield by Ugi-4CR us-
ing ammonia as amine component. The less nucleophilic solvent, 2,2,2-trifluoroethanol proved 
to be superior over methanol for Ugi-4CR giving a cleaner reaction. The desired compound 41 
was isolated in high purity without the need of chromatographic separation. 
The Ugi building blocks consisting of a DOTA unit with an appended functional group such 
as carboxylic acid, 21 and an amine, 45 was successfully prepared and isolated. Ugi-4CR us-
ing these building blocks has been attempted but without success. The true cause of this 
reaction has not been fully elucidated. Synthesis of 41 at 0.5 M compared to at 0.1 M resulted 
in improved yield from 10% to 44% without tedious purification, implying that the reaction 
rate was affected by the reagents’ concentrations and thus the Ugi-4CR should be performed at 
0.5-2 M for successive coupling reactions and a more successful outcome. 
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Although the synthesis of these non-peptide based Ugi chelates would have established novel 
contrast agents for targeting FPR1, time constraints meant that this part of the project had to 
be suspended in favour of investigating the more promising peptide-based imaging agents us-
ing the targeted peptides cFLFLFK and WKYMVm for FPR1 and FPR2 respectively, as 
described in the previous chapters. 
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8 Conclusions and Future Work 
8.1 General Conclusions and Future Prospects 
Present clinical and medical imaging technologies rely on macroscopic physical, physiological 
or metabolic changes that differentiates pathological from normal tissues rather than identify-
ing specific molecular events responsible for the diseases. In this project, FPRs are selected as 
a biomarker for inflammation as FPRs have been shown to play pathophysiological roles in 
many inflammatory disorders.1-4 Despite large amount of research on imaging inflammation, 
the daily routine to image inflammation is to label leukocytes ex vivo, which is laborious and 
possesses potential hazards due to human blood handling. Thus, the development of novel im-
aging agents for imaging inflammation in clinical settings would provide further information 
and better understanding of various mechanistic pathways undertaken by inflammation. 
8.1.1 Synthesis of BFCAs 
A reliable synthesis has been established for DOTAGA 20 according to the method reported in 
the literature, as discussed in Chapter 2. It was demonstrated that complexation of 20 with var-
ious Ln(III) ions gave highly stable complexes with hydration state q = 1. Further 
derivatisation of 20 led to established syntheses of 21 and 25 for use towards other imaging 
modalities. 
 
Figure 8-1 The structures of synthesised BFCAs in Chapter 2 and 5. 
DOTAGA-anhydride 25 is particularly useful for synthesising novel imaging agents with bio-
molecules of interest via post-labelling approach as various metals or radionuclides can be 
introduced in the last step of the synthesis minimising the possibility of metal decomplexation 
and unnecessary loss in radioactivity. Moreover, an overall negative charge after metal com-
plexation has enhanced water solubility and thus allows for rapid and efficient purification 
using Sephadex G-25. This can be advantageous for routine use in clinical settings without the 
need of HPLC.  
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8.1.2 FPRs-based Imaging Agents 
FPRs are classic GPCRs, which are first known for causing leukocyte chemotaxis towards 
formylated peptides.5 In the decades since the discovery, its members have become more 
clearly defined and it has been revealed that they have been associated in various inflammato-
ry disorders.1-4 FPRs represent diagnostic and therapeutic targets for inflammation and thus 
they were targeted in this project for imaging of inflammation in acute phase. In Chapter 3-5, 
novel imaging agents targeting FPR1 and FPR2 were synthesised either from ligand 20 or 25 
via “smart metal protection” or post-labelling approach respectively. 
8.1.2.1 FPR1 
The hexapeptide cFLFLFK is a highly selective and potent FPR1 antagonist among many 
known FPR1 antagonists. The presence of a lysine residue allows for simple and straightfor-
ward reactions. The resultant ligand 23 gave highly stable Ln(III) complexes while 
maintaining their photophysical properties without a significant loss in binding affinity to-
wards FPR1. Results from chemotaxis and TNF-α induced IL-1β release have suggested that 
Ln.23 is suitable for imaging inflammation. However, MRI experiment using Gd.23 as the 
contrast agent and LPS-induced neuroinflammation model did not show contrast enhancement 
in the brain as compared to Gd.DOTA. 
Metal complexation with Cu(II) and Ga(II) ions have shown the potential uses of ligand 23 in 
nuclear imaging. Although a radioligand binding assay was not performed with these com-
plexes, it was believed that M.23 would behave similarly to Ln.23 without a significant loss in 
receptor binding affinity and efficacy towards FPR1. Both chemotaxis and TNF-α induced IL-
1β production of M.23 resembled similar results obtained from Ln.23 suggesting M.23 is 
suitable for imaging inflammation in vivo without undesired biological responses on the tar-
geted cells and processes involved in inflammation. Preliminary PET imaging of [64Cu].23 
was performed with murine model of LPS-induced inflammation, in which an increased signal 
intensity was observed at the site of inflammation although it was not significant. 
Overall, several questions on the imaging experiments need to be answered for positive out-
comes, such as imaging time course after injury and suitable models of inflammation. More 
specifically for MRI, Gd.23 did not show significant contrast enhancement in the MRI exper-
iment using mice with neuronal inflammation ascribed by its inability to cross the BBB. To 
further assess its ability to cross the BBB, in vitro BBB models could be used prior to imaging 
experiments to avoid high cost and the use of animal. The primary aim is to focus on ligand 
permeability across the BBB and hence a suitable model should be selected for this purpose. 
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Many detailed reviews have been published dedicated to the use of in vitro BBB models fo-
cusing at different functions of BBB.6-11  
8.1.2.2 FPR2 
The hexapeptide WKYMVm is a highly selective and potent FPR2 agonist. Similar to 
cFLFLFK, the presence of a lysine residue allows for simple and straightforward reactions. 
The resultant ligand 24 gave highly stable Ln(III) complexes while maintaining their photo-
physical properties while metal complexation with Cu(II) and Ga(III) ions have shown its 
potential use in nuclear imaging. Results from chemotaxis and TNF-α induced IL-1β release 
suggested that complexes of 24 retain their biological activity. However, the binding affinity 
towards FPR2 is unknown, radioligand binding assays with the metal or Ln(III) complexes of 
24 should provide further information on receptor binding affinity towards FPRs. 
Further expanding to in vivo imaging experiments, MRI and nuclear imaging could be per-
formed. Initial efforts should be aimed towards the selection of animal models of 
inflammation and experiment design to determine the time course for injection and scanning. 
8.1.3 Optical and Multi-Modal Imaging Agents 
In Chapter 6, reliable syntheses have been established for cyanine-based organic fluorophores 
31-32 according to the methods reported in the literature. The FPR1 antagonist cFLFLFK was 
fluorescently conjugated to Cy5 31 and a rhodamine dye for use in cellular studies. Confocal 
imaging of both compounds demonstrated their potential uses in labelling FPR1 for various 
biological studies. 
Multi-modal imaging agent 39 featuring cFLFLFK, a Cy5 and DOTA chelate were synthe-
sised from Cy5 32 and 25. The photophysical properties were investigated. Further testing 
with in vitro assays described in this thesis for biological characterisation and in vivo imaging 
experiments can be performed using various optical/MRI modalities. To further develop for 
multimodal imaging, ligand 39 could undergo metal complexation with various radionuclides 
such as 64Cu(II), 68Ga(III), 111In(III) and 86Y(III) for novel optical/nuclear imaging agents. 
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Scheme 8-1 Synthetic scheme towards novel multimodal imaging agents. 
More specifically for FPR2, synthesis towards analogous 40 featuring WKYMVm could be 
further investigated and it would provide a diagnostic tool for imaging molecular processes 
involving FPR2 (Scheme 8-1). As mentioned previously, WKYMVm is susceptible to high 
temperatures and amine deprotection using methylamine at 65 °C resulted in peptide degrada-
tion. The deprotection could be performed at transient temperature with longer reaction times. 
Unlike cFLFLFK that contains a reactive alkene functional group, deprotecting using hydra-
zine monohydrate could be attempted. 
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8.1.4 Non-Peptide Based Imaging Agents 
In Chapter 7, it was demonstrated that a known FPR1 antagonist 41 was synthesised using 
Ugi-4CR. Following unsuccessful attempts in synthesising ligand 43 from M.20 and 21, the 
amine-appended macrocycle 45 was synthesised and subsequent Ugi reaction towards 46 was 
attempted. 45 could not be successfully used in the Ugi reaction and this is ascribed to the 
amine being a weak nucleophile and slow formation of the imine intermediates during the re-
action. The result indicates that Ugi-4CR is not feasible for obtaining the desired compounds. 
To date, a few non-peptide based FPR1 antagonists have been reported as discussed in Chap-
ter 7 and it is desirable to design novel non-peptide based imaging agents based on these 
recently reported FPR1 antagonists. 
8.2 Final Remarks 
Overall, the studies of this thesis have made a significant contribution to the development of 
inflammation targeting imaging agents. The compounds synthesised would allow for imaging 
inflammation using various non-invasive imaging modalities depending on the metals or radi-
onuclides. Combined with future in vitro cell studies and in vivo observations of image 
enhancement using appropriate animal models, the novel imaging agents have the potential to 
be developed as general and targeted agents making a significant contribution in the efficacy 
of MRI and nuclear imaging. 
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9 Experimental 
9.1 Materials 
All commercially available starting materials were used without further purification unless 
otherwise stated. 
9.2 General Methods and Instrumentation 
Unless otherwise stated all reactions that required anhydrous conditions or involved moisture 
sensitive compounds were performed under an atmosphere of dry nitrogen gas using oven-
dried glassware. 
TLC was performed on Kieselgel 60 F254 plates (Merck) and the spots were visualised in UV 
fluorescence (254 and 366 nm) or I2 vapour. 
Flash column chromatography was carried out with Merck silica gel (0.040-0.063 mm), 5% 
deactivated Brockman Type I Al2O3 (neutral) or Sephadex G-25, with either anhydrous or 
non-anhydrous solvents. 
1H and 13C NMR spectra were recorded in specified deuterated solvents on a Bruker 2 channel 
DRX-400 spectrometer at Imperial College London, Department of Chemistry, NMR Service 
Facility, using the residual protic solvent signal as internal reference. Chemical shifts (δ) are 
reported in parts per million (ppm). Coupling constants (J) were measured in hertz (Hz) and 
NMR multiplicity are abbreviated as followed: s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet, br = broad. 
ESI, MALDI and CI mass spectra were recorded by John Barton or Lisa Haigh at Imperial 
College London, Department of Chemistry, Mass Spectrometry Service Facility: ESI on a Mi-
cromass LCT Premier spectrometer, MALDI mass spectra on a Micromass MALDI Micro 
MX spectrometer and CI on a Micromass Platform II using ammonia as the regent gas. 
Elemental analysis was performed by the Elemental Analysis Service, courtesy of Stephen 
Boyer at the Department of Health and Human Sciences, London Metropolitan University. 
UV-vis absorption spectra were recorded on a Perkin Elmer 650 UV-vis spectrometer using 
quartz cuvettes (10 x 10 mm) or semi-micro polystyrene disposable cuvettes (1.5 ml, 12.5 x 
0.45 mm, BRAND). 
FT-IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR Spectrometer fitted with 
an ATR cell. 
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Fluorescence spectra were recorded on a Varian Cary Eclipse fluorescence spectrophotometer 
using quartz cuvettes (10 x 4 mm).  
pH measurements were carried out using a Jenway Model 3510 pH/mV/Temperature meter, 
calibrated against ‘NIST’ pH 11.00, pH 7.00 and pH 4.00 buffers. 
9.3 Measurement of Photophysical Properties 
9.3.1 Molar Extinction Coefficients, ε  
Molar extinction coefficients were obtained from the slope of a graph of absorbance vs. con-
centration for each dye with five different concentrations (10-6 M). Data was fitted to a linear, 
least square function using Prism (version 5.0c, GraphPad Software, Inc., San Diego, CA). 
9.3.2 Luminescence and Lifetime of Ln(III) Complexes 
The number of coordinated water molecules was determined from luminescence lifetime 
measurements using Eu(III) or Tb(II) analogues. In brief, 1 mg/ml solutions of a test Ln(III) 
complex were prepared in H2O and the other in D2O. The integrated intensity of the transition 
ΔJ = 2 unless stated) was monitored during a fixed gate time of 0.1 ms, at a delay time 
(0.1 ms) for lifetime determination at direct excitation of Ln(III) unless stated. The determina-
tion of Ln(III) excited state lifetime is achieved by fitting Ln(III) luminescence decay data to a 
first order exponential decay function using Prism (version 5.0c, GraphPad Software, Inc., San 
Diego, CA). The calculated k values are then applied to the following equation to calculate the 
hydration number, q: 𝑞!" = 1.2 𝑘!!! −   𝑘!!! − 0.25  𝑞!" = 5 𝑘!!! −   𝑘!!! − 0.06  
where 𝑘!!! and 𝑘!!! are the excited state rate constants in H2O and D2O, respectively. 
9.4 Relaxometric Measurement of Gd(III) Complexes 
9.4.1 T1 measurement at 400 MHz 
T1 values were measured with a Bruker 2 channel DRX-400 spectrometer and carried out in 
collaboration with Peter Haycock, Imperial College London. The 90o pulse was calibrated for 
each sample. Samples were measured in a 60 µl NMR tube coaxial insert within a 5 mm NMR 
tube containing D2O. The concentration of Gd(III) was subsequently measured by magnetic 
susceptibility shifts in the NMR spectra.1 
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9.4.2 MRI phantom studies at 9.4 T MRI scanner 
MRI phantom experiments were performed using a 9.4 T (400 MHz) MRI scanner in collabo-
ration with Dr Marzena Wylezinska-Arridge at Brain Imaging Centre, Imperial College 
London, Hammersmith Campus Samples were measured in a 120 µl snap cap vials with five 
different concentrations (0-2 mM) and water was used as a control. 
9.5 Synthesis of Compounds 
9.5.1 Chapter 2 
1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane hydrobromide 
(3)2 
To a solution of cyclen (5.00 g, 29 mmol, 1 eq) and sodium acetate 
(7.86 g, 96 mmol, 3.3 eq) in DMA (60 ml) at -20 °C was added a solution 
of t-butyl bromoacetate (14.1 ml, 96 mmol, 3.3 eq) in DMA (20 ml) 
dropwise over 30 min under N2. The solution was stirred at rt for 24 h. 
Water (300 ml) was added to dissolve the white precipitate. NaHCO3 (12.6 g, 150 mmol, 
5.2 eq) was added in portions, white precipitate was collected by filtration and washed with 
water. The precipitated was dissolved in CHCl3 (250 ml), washed with water (100 ml) and 
dried over MgSO4 and concentrated to 20-30 ml. Ether (250 ml) was added and the product 
(12.2 g, 71% yield) was collected by filtration. 1H NMR (CDCl3) δ/ppm: 4.20 (NCH2, t, 3JHH = 
7.6 Hz, 4H), 4.08 (NCH2, t, 3JHH = 7.6 Hz, 4H), 3.79 (COCH2, s, 6H), 2.60 (NCH2, m, 8H), 
1.73 (CH3, s, 18H), 1.61 (CH3, s, 9H); 13C NMR (CDCl3) δ/ppm: 170.5, 169.7 (CO), 81.8, 81.6 
(C(CH3)3), 58.1 (COCH2), 51.3, 49.2, 48.6, 47.4 (NCH2), 28.3 (C(CH3)3); IR (KBr) νmax/cm-1: 
3420 (br νO-H), 2975, 2577 (νC-H), 1707, 1622 (νC=O), 1411 (O-H bending), 1261 (νC-O); 
MS (ESI +ve) m/z: 515.4 [M+H]+, 537.4 [M+Na]+ calc. for [C26H51N4O6]+ 515.37, 
[C26H5oN4O6Na]+ 537.36. 
General procedure for synthesis of α-bromoglutamic acid diester (15, 17) 
 
L-glutamic acid 12 or L-glutamic acid 5-methyl ester 16 (56 mmol, 1 eq) and NaBr (20 g, 
194 mmol, 3.5 eq) in freshly prepared 2 M HBr (60 ml) were cooled to 0 °C. NaNO2 (7.0 g, 
101 mmol, 1.8 eq) in water (15 ml) was added dropwise using a syringe pump over 2 h. After 
adding NaNO2, the reaction mixture was stirred at 0 °C for 2 h. Conc. H2SO4 (3.0 ml) was 
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added dropwise at 0 °C and the reaction mixture was stirred for 10 min. The solution was ex-
tracted with Et2O (3 x 100 ml), washed with brine (2 x 150 ml), dried (Na2SO4), and 
concentrated to oil, and used without further purification. 
The resultant brominated compound 13 or 13i (8.9 mmol) in t-butyl acetate (50 ml) was added 
70% perchloric acid (50 μl). The solution was stirred at rt under N2 for 24 h. The solution was 
washed with water (2 x 15 ml), 5% NaHCO3 (neutral pH, 25 ml), dried (Na2SO4), and evapo-
rated to give pale yellow oil. The purification was achieved by silica gel chromatography 
eluting with DCM. 
S-2-Bromo pentadioic acid 1,5-(1,1-dimethylethyl) diester (15)3 
13, pale yellow oil (5.49 g, 47% yield). 1H NMR (CDCl3) δ/ppm: 10.05 (COOH, s, 2H), 4.30 
(CHBr, dd, 3JHH = 8.4, 5.9 Hz, 1H), 2.45 (CH2, m, 2H), 2.30 (CH2, m, 2H); 13C NMR (CDCl3) 
δ/ppm: 174.5, 173.6 (COOH), 44.1 (CBr), 31.1 (CH2CBr), 29.6 (CH2CH2Br); IR (KBr) 
νmax/cm-1: 3420 (br νO-H), 2975, 2577 (νC-H), 1707, 1622 (νC=O), 1411 (O-H bending), 
1261 (νC-O); MS (CI +ve) m/z: 252 (254) [M+NH4]+ calc. for [C5H7BrNO4]+ 252. 
15, pale yellow oil (0.96 g, 35% yield). 1H NMR (CDCl3) δ/ppm: 4.25 (CHBr, dd, 3JHH = 8.4, 
5.9 Hz, 1H), 2.43 (CH2, m, 2H), 2.27 (CH2, m, 2H), 1.50 (CH3, s, 9H), 1.47 (CH3, s, 9H); 13C 
NMR (CDCl3) δ/ppm: 171.5 (COOtBu), 168.5 (COOtBu), 82.6 (C(CH3)3), 80.9 (C(CH3)3), 
46.9 (CBr), 32.8 (CH2CBr), 29.9 (CH2CH2Br) 28.1 (C(CH3)3), 27.6 (C(CH3)3). IR (KBr) 
νmax/cm-1: 2979, 2934 (νC-H tBu), 1727 (νC=O), 1460 (δCH2), 1368 (δCH3), 1139 (νC-O-C); 
MS (CI +ve) m/z: 340 (342) [M+NH4]+ calc. for [C13H27BrNO4]+ 340. 
S-2-Bromo pentadioic acid 1-(1,1-dimethylethyl)-5-methyl diester (17) 
13i, pale yellow oil (7.98 g, 64% yield). 1H NMR (CDCl3) δ/ppm: 4.43 (CHBr, dd, 3JHH = 8.4, 
5.7 Hz, 1H), 3.73 (CH3, s, 3H) 2.59 (CH2, m, 2H), 2.43 (CH2, m, 1H), 2.32 (CH2, m, 1H); 13C 
NMR (CDCl3) δ/ppm: 174.4 (COOH), 172.7 (COOMe), 52.0 (COOCH3), 44.2 (CBr) 31.1 
(CH2CBr), 29.5 (CH2CH2Br); IR (KBr) νmax/cm-1: 2962, 2875 (νC-H), 1718 (νC=O), 1437 
(CH bend), 1368 (δCH3 tBu), 1144 (νC-O), 508 (νC-Br); MS (CI +ve) m/z: 242 (244) 
[M+NH4]+ calc. for [C6H12NO4]+ 242. 
17, pale yellow oil (1.32 g, 52% yield). 1H NMR (CDCl3) δ/ppm: 4.26 (CHBr, dd, 3JHH = 8.7, 
5.5 Hz, 1H), 3.71 (COOCH3, s, 3H), 2.53 (CH2, m, 2H), 2.31 (CH2CBr, m, 2H), 1.50 
(C(CH3)3, s, 9H); 13C NMR (CDCl3) δ/ppm: 172.7 (COOtBu), 172.4 (COOMe), 82.7 
(C(CH3)3), 51.9 (COOCH3), 46.8 (CBr), 31.4 (CH2CBr), 29.7 (CH2CH2Br) 27.8 (C(CH3)3); IR 
(KBr) νmax/cm-1: 2980, 2939 (νC-H), 1730 (νC=O), 1438 (δCH2), 1368 (δCH3), 1140 (νC-O-
C); MS (CI +ve) m/z: 298 (300) [M+NH4]+ calc. for [C10H22NO4]+ 298. 
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DOTAGA-tBu5 (18)3 
A solution of 15 (0.52 g, 1.61 mmol, 1.1 eq), tBu-DO3A (0.78 g, 
1.52 mmol, 1 eq) and anhydrous K2CO3 (0.58 g, 4.20 mmol, 2.8 eq) 
in MeCN (10 ml) was heated under reflux for 24 h. The solvent was 
removed under reduced pressure. The residue was dissolved in anhy-
drous DCM (40 ml), the suspension was filtered to remove the salts and the solvent was re-
moved under reduced pressure. The purification was achieved by flash chromatography on 
alumina (gradient elution: 0 to 3% MeOH in DCM) to give the desired product as a pale yel-
low oil (980 mg, 80% yield). 1H NMR (CDCl3) δ/ppm: 3.40 (COCH2, *CH, m, 7H), 2.86 
(*CHNCH2, m, 4H), 2.55 (NCH2CH2N, m, 12H), 2.18 (*CHCH2CH2COOtBu, m, 4H), 1.47 
(C(CH3)3 m, 45H); 13C NMR (CDCl3) δ/ppm: 175.0, 173.1, 172.9, 172.4, (CO), 82.4, 81.8, 
81.6, 80.6 (C(CH3)3), 60.1 (COCH), 56.0, 55.9. 55.6 (COCH2), 52.7, 52.3, 48.7, 48.4, 47.4, 
44.5 (NCH2), 33.8 (NCHCH2), 28.3, 28.0, 27.6 (C(CH3)3); IR (KBr) νmax/cm-1: 3402 (νN-H), 
2978, 2935 (νC-H), 2836 (νC-H, amine), 1722 (νC=O), 1456 (δCH2), 1367 (δCH3), 1227 (C-
N bending), 1143 (νC-O-C), 1118, 1106 (νC-N-C), 755 (δNH); HRMS (ESI +ve) m/z: 
757.5362 [M+H]+ calc. for [C39H73N4O10]+ 757.5367. 
DOTAGA-tBu4, Me (19) 
A solution of 17 (1.32 g, 4.70 mmol, 1.2 eq), tBu-DO3A (2.30 g, 
3.86 mmol, 1 eq) and anhydrous K2CO3 (1.82 g, 13.2 mmol, 3.4 eq) 
in MeCN (20 ml) was heated under reflux for 24 h. The solvent was 
removed under reduced pressure. The residue was dissolved in anhy-
drous DCM (80 ml), the suspension was filtered to remove the salts and the solvent was re-
moved under reduced pressure. The purification was achieved by flash chromatography on 
alumina (gradient elution: 0 to 3% MeOH in DCM) to give the desired product as pale yellow 
oil (1.28 g, 46% yield). 1H NMR (CDCl3) δ/ppm: 3.66 (CH3, s, 3H), 3.44 (COCH2, *CH, m, 
7H), 2.87 (*CHNCH2, m, 4H), 2.45 (NCH2CH2N, m, 12H), 2.36 (*CHCH2CH2COOtBu, m, 
4H), 1.46 (C(CH3)3 m, 36H); 13C NMR (CDCl3) δ/ppm: 174.8 (CH2CO), 173.1, 172.9, 172.4, 
(CO), 82.7, 82.2, 81.9 (C(CH3)3), 59.9 (COCH), 55.9, 55.5, 52.5 (COCH2), 51.7 (COOCH3), 
49.8, 48,6, 48.1, 47.2, 44.3 (NCH2), 32.3 (CHCH2CH2), 28.1, 27.9, 27.8 (C(CH3)3), 19.0 
(NCHCH2); IR (KBr) νmax/cm-1: 3352 (νN-H), 2978, 2939 (νC-H), 2831 (νC-H, amine), 1723 
(νC=O), 1456 (δCH2), 1368 (δCH3), 1226 (C-N bending), 1140 (νC-O-C), 1118, 1106 (νC-N-
C), 730 (δNH); HRMS (ESI +ve) m/z: 715.4855 [M+H]+ calc. for [C36H67N4O10]+ 715.4857. 
DOTAGA (20)3  
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The solution of 18 (130 mg, 0.172 mmol) in TFA (3 ml) and DCM 
(1.5 ml) was stirred at rt for 18 h. The solvents were removed in vacuo. 
The residue was repeatedly (3x) dissolved in DCM and the solvent re-
moved in vacuo. The residue (170 mg, >100%) was analyzed by NMR 
and used without purification. 1H NMR (D2O) δ/ppm: 4.11-3.64 (NCH2CO, NCHCO, m, 7H), 
3.64-3.01 (NCH2, m, 16H), 2.76-2.31 (CHCH2CH2, m, 2H), 2.11-1.68 (CHCH2, m, 2H); 13C 
NMR (D2O) δ/ppm: 177.3 (CH2CO), 175.1, 174.2, 170.4, (CO), 59.8 (COCH), 55.9. 53.8, 51.1 
(COCH2), 48.5, 45.6, 44.3 (NCH2), 31.4 (CHCH2CH2), 21.7 (NCHCH2); IR (KBr) νmax/cm-1: 
3445 (νN-H), 3090 (νC-H), 2858 (νC-H, amine), 1670 (νC=O), 1462 (δCH2), 1387 (δCH3), 
1179 (C-C-N bending), 1127 (νC-O-C), 1092 (νC-N-C); HRMS (ESI +ve) m/z: 477.2194 
[M+H]+ calc. for [C19H33N4O10]+ 477.2197. 
DOTAGA-tBu4 (21)4-5 
To a solution of 19 (556 mg, 0.793 mmol) in MeOH (50 ml) was added 
1 M NaOH (50 ml). The reaction was stirred at rt for 18 h. MeOH was 
removed in vacuo and pH was adjusted to pH 5 using 1 M HCl. The 
solution was freeze-dried to give white solid. The white solid was dis-
solved in 20% anhydrous MeOH:DCM (20 ml) and filtered. The filtrate was collected and 
concentrated to give a pale yellow oil (491 mg, 90%). 1H NMR (CDCl3) δ/ppm: 3.44 (COCH2, 
COCH, m, 7H), 2.87 (*CNCH2, m, 4H), 2.45 (NCH2, m, 12H), 2.36 (CH2CH2COOtBu, m, 
4H), 1.46 (C(CH3)3 m, 36H); 13C NMR (CDCl3) δ/ppm: 175.2 (CH2CO), 172.8, 172.7, 172.6, 
(CO), 82.4, 82.1, 82.0, 81.9 (C(CH3)3), 60.0 (COCH), 55.8, 55.7, 52.6 (COCH2), 48.5, 48.4, 
47.1, 44.1 (NCH2), 32.4 (CHCH2CH2), 27.9, 27.9, 27.8 (C(CH3)3), 20.1 (NCHCH2); HRMS 
(ESI +ve) m/z: 701.4722 [M+H]+ calc. for [C35H65N4O10]+ 701.4701. 
General Procedure for Ln Complexation (Ln.20)3 
To a solution of 20 (100 mg, 0.21 mmol, 1 eq) in MilliQ water (5 ml) 
was added LnCl3.xH2O (0.25 mmol, 1.2 eq). The pH of the solution was 
adjusted to pH 5.5 using 1 M NaOH solution. The reaction mixture was 
stirred at rt for 10 min while monitoring the changes of pH and adjusting 
it to 5.5. The reaction mixture was stirred for 18 h. After adjusting the pH to 11, the reaction 
mixture was stirred for 40 min. The reaction mixture was centrifuged (13 g, 2 min, rt) to re-
move the Ln(OH)3 precipitate. The supernatant was collected and pH was adjusted to 7.0. The 
solution was freeze-dried to give the product as hydroscopic powder. Removal of salts was 
achieved by flash column chromatography on Sephadex G-25 eluting with MilliQ water. 
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Eu.20, white powder (126 mg, 96% yield). 1H NMR (D2O) δ/ppm: multiple resonances from δ 
-20 to 40 ppm indicative of DOTA-like complexes of Eu(III), 18.61, 17.08, 14.01, 13.32 (4Hax 
of TSAP), 37.31, 36.74, 36.73, 33.17 (4Hax of SAP); HRMS (ESI –ve) m/z 625.1044 [M]- calc. 
for [C19H28N4O10Eu]- 625.1018. 
Tb.20, pale peach powder (125 mg, 95% yield). HRMS (ESI –ve) m/z 631.1062 [M]- calc. for 
[C19H28N4O10Tb]-631.1059. 
Gd.20, white solid (119 mg, 90% yiel). HRMS (ESI –ve) m/z 630.1068 [M]- calc. for 
[C19H28GdN4O10]- 630.1047. 
9.5.2 Chapter 3 
General Procedure for Amide Coupling Reaction 
To a solution of Ln.20 (7.1 µmol, 3.4 eq) in MeCN (500 µl) was added HBTU (7.1 µmol, 
3.4 eq) and NEt3 (7.1 µmol, 3.4 eq). The reaction mixture was stirred at rt for 10 min before 
added the solution of cFLFLFK or WKYMVm (2.1 µmol) in MeCN (500 µl). The mixture 
was stirred at rt for 4 h and borate buffer (pH 8.5, 1 ml) was then added. The mixture was fur-
ther stirred at rt for 18 h. The solvent was removed in vacuo. Purification was achieved on 
Sephadex G-25 column chromatography eluting with MilliQ water to give the product as a 
white powder. 
Eu.23, white powder (3.0 mg, 91%). MS (ESI -ve) m/z: 1549.59 [M]-, calc. for 
[C73H96EuN12O16]- 1549.63. 
Tb.23, white powder (3.1 mg, 94%). MS (ESI -ve) m/z: 1555.65 [M]-, calc. for 
[C73H96TbN12O16]- 1555.63. 
Gd.23, white powder (2.9 mg, 88%). MS (ESI -ve) m/z: 1554.62 [M]- calc. for 
[C73H96GdN12O16]- 1554.63. 
9.5.3 Chapter 4 
General Procedure for Amide Coupling Reaction 
To a solution of Ln.20 (7.1 µmol, 3.4 eq) in MeCN (500 µl) was added HBTU (7.1 µmol, 
3.4 eq) and DIEA (7.1 µmol, 3.4 eq). The reaction mixture was stirred at rt for 10 min before 
adding the solution of WKYMVm (2.1 µmol) in MeCN (500 µl). The mixture was stirred at rt 
for 4 h and borate buffer (pH 8.5, 1 ml) was then added. The mixture was further stirred at rt 
for 18 h. The solvent was removed in vacuo. Purification was achieved on Sephadex G-25 
column chromatography eluting with MilliQ water to give the product as a white powder. 
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Eu.24, white powder (2.9 mg, 96%). MS (MALDI -ve) m/z: 1462.6 [M]-, calc. for 
[C60H87EuN13O16S2]+ 1462.5. 
Tb.24, white powder (2.8 mg, 92%). MS (MALDI -ve) m/z: 1468.4 [M]-, calc. for 
[C60H87TbN13O16S2]+ 1468.5. 
Gd.24, white powder (2.7 mg, 89%). MS (MALDI -ve) m/z: 1467.5 [M]-, calc. for 
[C60H87GdN13O16S2]+ 1467.8. 
9.5.4 Chapter 5 
DOTAGA-anhydride (25)6 
To a solution of DOTAGA 20 (500 mg, 1.05 mmol, 1 eq) in acetic anhy-
dride (5 ml) was added pyridine (509 µl, 6.29 mmol, 6 eq) under N2 gas. 
The reaction was heated at 65 °C for 18 h. The solution was cooled to rt and 
stirred for 30 min. The precipitate was filtered and washed with acetic an-
hydride (5 ml), MeCN (10 ml) and Et2O (20 ml) to give a light brown hydroscopic solid 
(82.9 mg, 18%). It was used without further purification. 1H NMR (D2O) δ/ppm: 4.44 (NCH, 
dd, 3JHH = 13.2, 5.2 Hz, 1H), 3.80-3.52 (NCH2CO, NCHCO, m, 7H), 3.50-2.75 (NCH2, m, 
16H), 2.52 (CO CH2CH2, m, 4H); IR (KBr) νmax/cm-1: 3404 (νN-H), 2876 (νC-H, amine), 
1723 (νC=O), 1456 (δCH2), 1368 (δCH3), 1226 (C-N bending), 1140 (νC-O-C), 1118, 1106 
(νC-N-C), 730 (δNH); HRMS (ESI +ve) m/z: 497.1631 [M+K]+ calc. for [C19H30N4O9K]+ 
497.1650. 
General Procedure for Peptide Conjugation from 25 
To a solution of cFLFLFK or WKYMVm (11 µmol, 1 eq) in anhydrous MeCN (1 ml) was 
added 25 (6.25 mg, 14 µmol, 1.2 eq) and DIEA (4.4 µl, 3 eq). The reaction mixture was stirred 
at rt for 2 h. Borate buffer (pH 8.5, 1 ml) was added and the reaction mixture was stirred at rt 
for 18 h. The purification was achieved by Sephadex G-25 eluting with MilliQ water, the ly-
ophilisation gave the desired product. 
23, white powder (14.9 mg, 96%). 1H NMR (MeCN-d3) δ/ppm: 7.30 (Ph, m, 20H), 6.42 
(C=CH, s, 1H), 6.37 (C=CH, s, 1H), 4.5-2.9 (COCH2, NCH2, NH2, very broad signal, 24H), 
2.63 (CH, m, 4H), 2.27 (CH2, m, 12H), 1.79 (CH2, CH, m, 7H), 0.52 (CH2, C(CH3)2, br, 16H); 
MS (MALDI) m/z: 1402.75 [M+H]+ calc. for [C73H101N12O16]- 1402.67. 
24, white powder (14.6 mg, 95%). 1H NMR (MeCN-d3) δ/ppm: 7.51 (Ph, m, 1H), 7.38 (Ph, m, 
1H), 7.14 (Ph, m, 3H), 7.01 (Ph, m, 4H), 6.72 (Ph, m, 2H), 4.5-2.9 (COCH2, NCH2, NH2, very 
N N
NN
HO
O
O OH
O
OH
O O
O
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broad signal, 33H), 2.31 (CH2, CH, m, 11H), 1.96 (CH2, m, 20H), 0.84 (SCH3, C(CH3)2, m, 
12H); MS (MALDI) m/z: 1315.11 [M+H]+ calc. for [C60H92N13O16S2]+ 1314.61. 
General Procedure for Cu(II) Complexation 
CuCl2.H2O (1 mg/ml, 200 µl) in 0.1 M acetate buffer (pH 5.5) was added to 23 or 24 (1 mg). 
The mixture was incubated at 40 °C for 30 min. The mixture was purified by flash column 
chromatography on Sephadex G-25 eluting with MilliQ water, the lyophilisation gave the de-
sired product. 
Cu.23, pale blue powder (1.0 mg, 97%). MS (MALDI +ve) m/z: 1484.7 [M+Na]+ calc. for 
[C73H98CuNaN12O16]+ 1484.6. 
Cu.24, pale blue powder (0.9 mg, 87%). MS (MALDI +ve) m/z: 1397.1 [M+Na]+ calc. for 
[C60H89CuNaN13O16S2]+ 1397.5. 
Ga(III) Complexation with 23 
GaCl3.H2O (1 mg/ml, 200 µl) in 0.1 M acetate buffer (pH 5.5) was added to 23 (1 mg). The 
mixture was incubated at 50 °C for 10 min. The mixture was purified by flash column chroma-
tography on Sephadex G-25 eluting with MilliQ water, the lyophilisation gave the desired 
product Ga.23 as a white powder (0.5 mg, 49%). MS (MALDI -ve) m/z: 1465.0 [M]- calc. for 
[C73H96GaN12O16]- 1465.6. 
Ga(III) Complexation with 24 
GaCl3.H2O (1 mg/ml, 200 µl) in 0.1 M acetate buffer (pH 4.5) was added to 24 (1 mg). The 
mixture was incubated at 40 °C for 10 min. The mixture was purified by flash column chroma-
tography on Sephadex G-25 eluting with MilliQ water, the lyophilisation gave the desired 
product Ga.24 as a white powder (0.6 mg, 61%). MS (MALDI -ve) m/z: 1401.8 [M]- calc. for 
[C60H87GaNaN13O16S2]- 1401.5. 
9.5.5 Chapter 6 
2,3,3-Trimethyl-1-(5-carboxypentyl)-3H-indolium Bromide (27)7 
2,3,3-Trimethyl-3H-indole (8.03 ml, 50 mmol, 1 eq) and 6-bromohexanoic 
acid (9.75 g, 50 mmol, 1 eq) in nitromethane (30 ml) were heated to 80 °C 
for 7 h. The solution was cooled to rt and triturated with Et2O (200 ml). The 
pale pink precipitate was filtered and washed with Et2O (3 x 50 ml) to af-
ford the product (5.81 g, 32%). 1H NMR (D2O) δ/ppm: 7.67 (Ph, m, 1H), 7.62 (Ph, m, 1H), 
7.52 (Ph, m, 2H), 4.37 (NCH2, t, 3JHH = 7.5 Hz, 2H), 2.70 (CH3, s, 3H), 2.27 (COCH3, t, 3JHH = 
7.2 Hz, 2H), 1.88 (NCCH2, m, 2H), 1.55 (COCCH2, m, 2H), 1.45 (C(CH3)2, s, 6H), 1.35 
N Br
O
OH
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(NCCCH2, m, 2H); 13C NMR (D2O) δ/ppm: 196.2 (CCH3), 178.6 (CO), 141.8, 140.9, 129.9, 
129.0, 123.3, 115.1 (Ph), 54.4 (C(CH3)2), 47.7 (NCH2), 33.3 (COCH2), 26.8 (NCCH2), 25.2 
(NCCCH2), 23.7 (COCCH2), 21.7 (C(CH3)2), 15.6 (CCH3); HRMS (ESI +ve) m/z: 274.1816 
[M-Br]+ calc. for [C17H24NO2]+ 274.1807; Elemental analysis: calc. (C17H24BrNO2) C 57.63%, 
H 6.83%, N 3.95%, found C 57.67%, H 6.75%, N 4.01%. 
2,3,3-Trimethyl-1-(3-sulphonatopropyl)-3H-indolium, Inner Salt (28)8-9 
2,3,3-Trimethyl-3H-indole (10 ml, 62.3 mmol, 1 eq) and 1,3-propane sultone 
(8.2 ml, 93.5 mmol, 1.5 eq) in toluene (50 ml) were heated under reflux under 
N2 for 20 h. The solution was cooled to rt and the solid was collected by filtra-
tion and washed with acetone (3 x 10 ml). Recrystallisation from MeOH/Et2O yielded pale 
pink solid (14.35 g, 82%). 1H NMR (D2O) δ/ppm: 7.73 (Ph, m, 1H), 7.64 (Ph, m, 1H), 7.55 
(Ph, m, 2H), 4.56 (NCH2, t, 3JHH = 8.0 Hz, 2H), 3.25 (CCH3, s, 3H), 3.01 (SCH2, t, 3JHH = 
7.0 Hz, 2H), 2.30 (SCCH2, p, 3JHH = 7.2 Hz, 2H), 1.48 (C(CH3)2, s, 6H); 13C NMR (D2O) 
δ/ppm: 197.1 (CCH3), 141.8, 140.8, 129.9, 129.2, 123.3, 114.9 (Ph), 54.5 (C(CH3)2), 48.8 
(NCH2), 47.4 (SCH2), 46.2 (NCCH2), 22.7 (C(CH3)2), 21.7 (CCH3); HRMS (ESI +ve) m/z: 
282.1170 [M+H]+, 304.0992 [M+Na]+ calc. for [C14H20NO3S]+ 282.1164, [C14H19NO3SNa]+ 
304.0983; Elemental analysis: calc. (C14H19NO3S) C 59.76%, H 6.81%, N 4.98%, found C 
59.53%, H 6.95%, N 4.87%. 
2,3,3-trimethyl-1-[N-(phtalimidobutyl)]-3H-indolium Bromide (29)10 
2,3,3-Trimethyl-3H-indole (2 ml, 12.5 mmol, 1.5 eq) and N-(4-
bromobutyl)phthalimide (3.51 g, 12.5 mmol, 1 eq) were added to a Schlenk 
tube under N2, the reaction was heated gently to 110 °C. The reaction was 
kept at 140 °C for 18 h with stirring. The dark red mixture was cooled to RT 
forming a solid cake. The solid was re-dissolved in DCM and solvent was 
removed in vacuo to give a fine powder. The crude product was filtered, washed with Et2O (3 
x 25 ml) and dried under N2 to afford the product as a brown red hydroscopic solid (5.19 g, 
95%). 1H NMR (CDCl3) δ/ppm: 7.83 (Ph, m, 2H), 7.75 (Ph, m, 1H), 7.56 (Ph, m, 3H), 4.90 
(CONCH2, t, 3JHH = 7.6 Hz, 2H), 3.79 (NCH2, t, 3JHH = 6.4 Hz, 1H), 1.99 (CH2CH2, m, 4H), 
1.67 (C(CH3)2, s, 6H), 1.48 (NCCH3, s, 2H); 13C NMR (CDCl3) δ/ppm: 196.7 (CCH3), 168.4 
(CO), 141.6, 141.0, 134.2, 131.8, 130.0, 129.5, 123.4, 122.3, 115.1 (Ph), 54.7 (C(CH3)2), 49.1 
(NCH2), 36.9 (CONCH2), 25.8 (NCCH2), 25.1 (CONCCH2), 23.2 (C(CH3)2), 22.8 (NCCCH2), 
16.3 (CCH2); HRMS (ESI +ve) m/z: 361.1912 [M-Br]+ calc. for [C23H25N2O2]+ 361.1916. 
General Procedure for Synthesis of Cy5 (31, 32) 
N
SO3
N
N O
O
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27 (1.43 g, 5.09 mmol, 1 eq) and malodialdehyde 
bis(phenylimine) monohydrochloride (1.58 g, 6.1 mmol, 
1.2 eq) in acetic anhydride (15 ml) was stirred under N2 at 
120 °C for 30 min. After cooling to rt, 28 or 29 (7.1 mmol, 
1.4 eq) in dry pyridine (15 ml) was added slowly under N2 and 
stirred at rt for 18 h. 
31. The crude product was purified by silica with a step gradient of 20% to 50% EtOH in 
DCM to give a golden brown solid (0.48 g, 56%). 1H NMR (MeOD) δ/ppm: 8.27 (Hb, d, t, 3JHH 
= 12.8 Hz, 2H), 7.48 (H4, 4’, m, 2H), 7.34 (H6, 6’, 7, 7’, m, 4H), 7.25 (H5, 5’, m, 2H), 6.66 (Hc, t, 3JHH 
= 12.3 Hz, 1H), 6.41 (Ha, d, 3JHH = 13.7 Hz, 1H), 6.29 (He, d, 3JHH = 13.7 Hz, 1H), 4.31 (NCH2, 
t, 3JHH = 7.5 Hz, 2H), 4.11 (NCH2, t, 3JHH = 7.1 Hz, 2H), 3.00 (SCH2, t, 3JHH = 6.7 Hz, 2H), 
2.25 (COCH2, NCCH2, m, 4H), 1.82 (SCCH2, t, 3JHH = 7.6 Hz, 2H), 1.71 (NCCH2, CH3, m, 
14H), 1.49 (COCCCH2, t, 3JHH = 6.9 Hz, 2H); 13C NMR (MeOD) δ/ppm: 174.9, 174.4 (C2, 2’), 
171.8 (CO), 155.7, 155.5 (Cb, d), 143.5 (C3a, 3a’), 142.8, 142.5 (C7a, 7a’), 129.8, 129.8 (C6, 6’), 
127.1 (Cc), 126.3, 126.1 (C5, 5’), 123.4 (C4, 4’), 112.1, 111.9 (C7, 7’), 104.6, 104.4 (Ca, e), 50.6 
(SCH2), 50.5 (C3, 3’), 44.9, 43.8 (NCH2), 36.6 (COCH2), 28.3 (SCCH2), 27.9, 27.5 (C(CH3)2), 
26.4 (NCCH2), 24.0 (NCCH2); HRMS (ESI +ve) m/z: 591.2912 [M+H]+ calc. for 
[C34H43N2O5S]+ 591.2893; UV-vis (H2O) λmax/nm = 647 (π → π*); Fluorescence (H2O) λem/nm 
= 680; Elemental analysis: calc. (C34H42N2O5S) C 69.12%, H 7.17%, N 4.74%, found C 
69.29%, H 7.15%, N 4.68%. 
32. The crude product was purified by alumina with a step gradient 10% to 50% MeOH in 
DCM to give a golden blue solid (1.55 g, 40%). 1H NMR (MeOD) δ/ppm: 8.23 (Hb, d, t, 3JHH = 
12.9 Hz, 2H), 7.86 (Phth-Ph, m, 2H), 7.80 (Phth-Ph, m, 2H), 7.38 (Ph, m, 8H), 6.63 (Hc, t, 3JHH 
= 12.4 Hz, 1H), 6.31 (Ha, e, d, 3JHH = 13.7 Hz, 2H), 4.16 (NCH2, m, 4H), 3.78 (COCH2, m, 2H), 
2.34 (NCH2, t, 3JHH = 7.2 Hz, 2H), 1.87 (CH2, m, 6H), 1.74 (CH2, CH3, m, 14H), 1.53 (CH2, t, 
3JHH = 6.7 Hz, 2H); 13C NMR (MeOD) δ/ppm: 177.3 (CO), 174.9, 174.6 (C2, 2’), 167.0 (CO), 
155.6, 155.5 (Cb, d), 143.5 (C3a, 3a’), 142.7, 142.6 (C7a, 7a’), 135.5, 124.2 (Phth-Ph), 129.8, 129.7 
(C6, 6’), 126.7 (Cc), 126.3, 126.2 (C5, 5’), 123.4, 123.4 (C4, 4’), 112.1, 112.0 (C7, 7’), 104.5, 104.4 
(Ca, e), 50.6, 50.5 (C3, 3’), 44.8, 44.3 (NCH2), 38.1 (COCH2), 34.6 (Phth-NCH2), 27.9, 27.9 
(C(CH3)2), 28.2, 27.4, 26.6, 25.7, 25.4, 24.6 (CH2); HRMS (ESI +ve) m/z: 670.3636 [M-Br]+ 
calc. for [C43H48N3O4]+ 670.3645; UV-vis (H2O) λmax/nm = 643 (π → π*); Fluorescence (H2O) 
λem/nm = 668; Elemental analysis: calc. (C43H48BrN3O4) C 68.79%, H 6.44%, N 5.60%, found 
C 68.80%, H 6.53%, N 5.59%. 
General Procedure for Amide Coupling Reaction (33-34) 
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To a solution of 31, rhodamine B or 32 (7.1 µmol, 3.4 eq) in MeCN (500 µl) was added 
HBTU (7.1 µmol, 3.4 eq) and DIEA (7.1 µmol, 3.4 eq). The reaction mixture was stirred at rt 
for 10 min before added the solution of cFLFLFK or WKYMVm (2.1 µmol) in MeCN 
(500 µl). The mixture was stirred at rt for 4 h and then added borate buffer (pH 8.5, 1 ml). The 
mixture was further stirred at rt for 18 h. The solvent was removed in vacuo. Purification was 
achieved on Sephadex G-25 column chromatography eluting with MilliQ water to give the 
product. 
33, dark blue powder (2.1 mg, 88%), MS (MALDI -ve) m/z: 1514.9 [M]+, 757.5 [M+H]2+ calc. 
for [C88H110N10O11S]- 1514.81. 
34, dark pink powder (1.2 mg, 85%), MS (MALDI -ve) m/z: 1367.5 [M]+ calc. for 
[C82H99N10O9]+ 1367.8. 
General Procedure for Amide Coupling Reaction (35-36) 
To a solution of 32 (16.5 µmol, 1.5 eq) in MeCN (500 µl) was added HBTU (16.5 µmol, 2 eq) 
and DIEA (33 µmol, 3 eq). The reaction mixture was stirred at rt for 10 min before adding the 
solution of cFLFLFK or WKYMVm (11 µmol, 1 eq) in MeCN (500 µl). The mixture was 
stirred at rt for 4 h and then borate buffer (pH 8.5, 1 ml) was added. The mixture was further 
stirred at rt for 18 h. The solvent was removed in vacuo. Purification was achieved on alumina 
column chromatography eluting with 10% MeOH in DCM to give the product. 
35, dark blue powder (14.9 mg, 96%). HRMS (ESI +ve) m/z: 1595.9019 [M]+ calc. for 
[C97H116N11O10]+ 1595.8985. 
36, dark blue powder (17.1 mg, 92%). HRMS (ESI +ve) m/z: 1507.7664 [M]+ calc. for 
[C84H107N12O10S2]+ 1507.7675. 
General Procedure for Phthalimide Deprotection (37) 
To a solution of 35 or 36 (6 µmol, 1 eq) in MeOH (1 ml) was added MeNH2 (2M in MeOH, 
56 µl, 20 eq). The mixture was heated at 65 °C for 4 h. The solvent was removed in vacuo. 
Purification was achieved on silica column chromatography eluting with 10% MeOH in DCM. 
37, dark blue powder (7.9 mg, 86%). MS (MALDI +ve) m/z: 1465.0 [M]+ calc. for 
[C89H114N11O8]+ 1464.9. 
DOTAGA-Cy5-cFLFLF (39) 
To a solution of 37 (10 mg, 6.8 µmol, 1 eq) in MeCN (500 µl) was added 25 (6.5 mg, 
14 µmol, 2 eq) and NEt3 (8 µl, 41 µmol, 6 eq). The mixture was stirred in the dark at rt for 
12 h and borate buffer (pH 8.5, 1 ml) was then added. The mixture was further stirred at rt for 
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4 h. The solvent was removed in vacuo. Purification was achieved on Sephadex G-25 column 
chromatography eluting with MilliQ water. The solution was freeze-dried to give the product 
as hydroscopic powder (12 mg, 92%). MS (MALDI +ve) m/z: 1923.2 [M]+ calc. for 
[C108H144N15O17]+ 1923.08. 
Metal Complexation (Ln.39) 
To a solution of 39 (2 mg, 0.21 mmol, 1 eq) in MilliQ water (5 ml) was added LnCl3.xH2O 
(2 mg/ml in 0.1 M in acetate buffer pH 5.5, 1.5 eq). The pH of the solution was adjusted to pH 
5.5 using 1 M NaOH solution. The reaction mixture was stirred in the dark at rt for 18 h. Ex-
cess Ln(III) ions was removed by flash column chromatography on Sephadex G-25 eluting 
with MilliQ water. The solution was freeze-dried to give the product as a hydroscopic powder. 
Tb.39, blue powder (1.3 mg, 62%). MS (MALDI +ve) m/z: 2078.2 [M+H]+ calc. for 
[C108H141GdN15O17]+ 2077.99. 
Gd.39, blue powder (1.6 mg, 76%). MS (MALDI +ve) m/z: 2079.3 [M+H]+ calc. for 
[C108H141N15O17Tb]+ 2078.99. 
9.5.6 Chapter 7 
General Procedure for Ugi-4CR 
 
To a solution of carboxylic acid (63 µmol, 1 eq) in MeOH or CF3CH2OH (5 ml) was added to 
2 M ammonia solution or 45 (1 eq). The mixture was stirred at rt and under N2 gas for 15-
30 min. 5-Methyl-thiophenecarboxaldehyde (1 eq), 2,6-dimethylphenyl isocyanide (1 eq) were 
added. The mixture was stirred and heated at 40 °C for 72 h. LC-MS samples were submitted 
in aliquot of 10 µl accordingly 
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Target 
Compound 
R1 R4 Solvent LC-MS (ESI +ve) 
41 
m/z = 394  
H MeOH 2 major peaks: m/z = 519 
at 12.74 min 
m/z = 394 at 13.70 min 
41 
 
H CF3CH2OH 1 major peak: m/z = 394 
at 13.67 min 
 
Target I: Modification at the R1 position 
Attempts towards 43 
Y.43 
m/z = 817 
 
H MeOH 2 major peaks: m/z = 858 
at 5.88 min 
m/z = 714 at 6.97 min 
Y.43 
 
 
H CF3CH2OH 1 major peak: m/z = 733 
at 15.65 min 
42 
m/z = 957 
 
H CF3CH2OH 2 major peaks: m/z = 724 
at 11.66 min 
m/z = 629 at 13.13 min 
Target II: Modification at the R4 position 
Attempts towards 46 
46 
m/z = 1120  
 
CF3CH2OH 2 major peaks: m/z = 738 
at 11.84 min 
m/z = 780 at 12.38 min 
Table 9-1 Summary table for attempted Ugi-4CR. 
DOTAGA-tBu4, NH2 (45) 
The solution of 21 (500 mg, 0.70 mmol, 1 eq) in ethylenediamine 
(1.5 ml, 21 mmol, 30 eq) was stirred at rt for 3 days. Excess eth-
ylenediamine was removed in vacuo to give an orange residue. 
Purification by alumina eluting with a gradient of 0 to 20% 
MeOH in DCM gave a pale yellow oil (390 mg, 75%). 1H NMR (CDCl3) δ/ppm: 8.15 (CONH, 
br, 1H), 3.32 (COCH2, COCH, m, 7H), 2.90 (NCH2, m, 12H), 2.53 (*CNCH2, m, 4H), 2.32 
(CH2CH2COOtBu, m, 4H), 2.14 (CH2CH2NH2, m, 4H), 2.00 (NH2, m, 2H), 1.41 (C(CH3)3 m, 
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36H); 13C NMR (CDCl3) δ/ppm: 176.7 (CH2CO), 173.1, (CO), 82.6 (C(CH3)3), 59.6 (COCH), 
52.0 (COCH2), 49.6, 47.7, 46.7, 44.6 (NCH2), 39.6 (CONHCH2), 39.3 (CH2NH2), 33.9 
(CHCH2CH2), 27.1, 27.0 (C(CH3)3), 26.9 (NCHCH2); HRMS (ESI +ve) m/z: 743.5290 [M+H]+ 
calc. for [C37H71N6O9]+ 743.5283. 
Ugi-Diamide (41)11 
Salicylic acid (1.38 g, 10 mmol, 1 eq) was added to 2 M ammonia solu-
tion in MeOH (5 ml, 10 mmol, 1 eq), the mixture was stirred at rt and 
under N2 gas for 15 min. 5-Methyl-thiophenecarboxaldehyde (1.08 ml, 
10 mmol, 1 eq), 2,6-dimethylphenyl isocyanide (1.32 g, 10 mmol, 1 eq) 
and 2,2,2-trifluoroethanol (5 ml) were added. The mixture was stirred and heated at 40 °C for 
72 h. After cooling to rt, the precipitate was filtered under suction and washed with cold 
MeOH (5 ml), petroleum ether (2 x 30 ml) to give an off white solid (1.75 g, 44%). 1H NMR 
(CDCl3) δ/ppm: 7.95 (4-Ph, dd, 3JHH = 8.2 Hz, 4JHH = 1.8 Hz, 1H), 7.40 (1-Ph, dd, 3JHH = 
8.5 Hz, 4JHH = 1.6 Hz, 1H), 7.13 (6-CH, d, 3JHH = 3.7 Hz, 1H), 7.08 (7,8-Ph, m, 4H), 6.94 (2,3-
Ph, m, 2H), 6.74 (5-CH, dd, 3JHH = 3.5 Hz, 4JHH = 1.3 Hz, 1H), 6.06 (NCH, s, 1H), 2.50 
(SCCH3, d, 4JHH = 1.0 Hz, 3H), 2.15 (Ph-CH3, s, 6H); 13C NMR (CDCl3) δ/ppm: 170.8, 168.9 
(CO), 159.6 (Ph-OH), 141.1 (Ph-N), 138.4 (Ph-CO), 137.1 (Ph-CH3), 134.9 (1-Ph), 130.8 (4-
Ph), 129.1 (7,8-Ph), 128.5 (5-C=CH), 128.0 (5-C=CH), 126.1 (SC=CH), 120.6 (SCCH3), 
118.0 (2,3-Ph), 55.0 (NCH), 18.3 (Ph-CH3), 15.3 (SCCH3); IR (KBr) νmax/cm-1: 3345, 3235 
(νN-H), 3147, 3051, 2980 (νC-H, phenyl), 1678 (νC=C), 1627 (νC=O), 1607 (δNH), 1525, 
1492, 1472, 1455 (νC=C, phenyl), 1236, 1225 (νC-N); HRMS (ESI +ve) m/z: 395.1443 
[M+H]+ calc. for C22H23N2O3S 395.1429; Elemental analysis: calc. (C22H22N2O3S) C 66.98%, 
H 5.62%, N 7.10%, found C 66.78%, H 5.43%, N 6.98%. 
9.6 Biological Assays 
In vitro assays of Cu-labelled peptides (Cu.23 and Cu.24) were performed by Dr Paul Hol-
loway, Neuroscience Centre, Imperial College London, Hammersmith Campus. 
9.6.1 Cell Culture 
HEK-293 cells stably expressing hFPR1 or hFPR2 were grown in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% fetal calf serum (FCS), gentamicin (50 µg/ml), 1% 
non-essential amino acids (NEAA) solution and 0.4% gentamicin. Briefly, cells were grown to 
80% confluence in a 75-cm2 culture flask. Cells were harvested, diluted and re-plated in 24-
well plate the day before the radioligand binding assay. The media was replaced every 3 days 
and stable transformants isolated in approximately 3 weeks. 
H
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O
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H
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8
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9.6.2 Radioligand Binding Assay 
Competitive binding assays were performed in binding assay (BA) buffer (20 mM HEPES, 
2.1 mM MgCl2, 6.63 mM CaCl2, 25 mM Tween-20, 0.5% bovine serum albumin (BSA), 
pH 7.4) in a final volume of 500 µl. Plated cells were incubated with increasing concentrations 
of ligand (0.5 nM-2 µM) followed by [125I]-fnLLFnLYK (1000 cts/s) for 2 h at rt. The cells 
were centrifuged (RCF = 21984, 4 °C, 2 min) and washed twice in BA buffer prior to γ-
counting. The radioactivity was measured. All radioligand binding data were evaluated by a 
nonlinear, least-squares curve fitting procedure using GraphPad Prism (version 5.0c, 
GraphPad Software, Inc., San Diego, USA). All data are represented as the mean ± SEM from 
three independent experiments. 
9.6.3 Human Blood Neutrophil Isolation 
Experiment using healthy volunteers was approved by the local research ethics committee 
(P/00/029 East London and The City Local Research Ethics Committee 1). Informed written 
consent was provided according to the Declaration of Helsinki. Blood was collected into 3.2% 
sodium citrate and diluted 1:1 in RPMI-1640 before separation through a double-density gra-
dient using Histopaque® 1077 and 1119 (Sigma-Aldrich, Poole, UK). 
 
Figure 9-1 Neutrophil isolation from human blood using Histopaque® double-density centrifuga-
tion. 
After centrifugation at 400 g for 30 min PMN cells were collected from the lower layers as 
shown in Figure 9-1. The PMN cells were placed in 4 ml aliquots in 15 ml centrifuge tubes 
and made up to 12 ml with RPMI-1640 supplemented with 10% FCS, L-glutamine (2 mM), 
penicillin (100 U) and streptomycin (1 mg/ml). Cells were centrifuged at 400 g for 10 min. 
The pellet was re-suspended in 9 ml of ice-cold water for 30 s and subsequently 1 ml of Hanks 
solution (10x) were added. Contaminating erythrocytes in the PMN cell suspension were re-
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moved by hypotonic lysis in ice-cold water. Cells were finally washed (400 g, 10 min) and re-
suspended in the supplemented RPMI-1640. Cell count was performed using a haemocytome-
ter on a light microscope.  
9.6.4 Chemotaxis Assay 
Chemotaxis enables phagocytes to migrate from the circulation and accumulate at sites of inju-
ry and inflammation in response to pro-inflammatory mediators or chemoattractants. This 
assay monitors in vitro neutrophil migration, from the upper chamber of a chemotaxis through 
a semi-permeable membrane to the basement chamber beneath, containing chemoattractant. 
Human neutrophils were prepared as described above and re-suspended to a concentration of 
4 x 106 cells/ml in RPMI-1640 supplemented with 0.1% BSA. The assay was performed using 
3-µm pore size ChemoTx® 96-well plates (NeuroProbe Inc., Gaithersburg, USA). 27 µl of 
chemoattractant: fMLF (10 nM), compounds synthesised (0.1-300 nM) or RPMI-1640 sup-
plemented with 0.1% BSA (vehicle) was negatively pipetted in duplicate into the basement 
wells. The polycarbonate filter was placed on top of the chemoattractant and 25 µl of cell sus-
pension was negatively pipetted on top of the filter. In some cases, the cell suspension was 
pre-incubated for 10 min with synthesised compounds. Plates were incubated for 90 min at 
37 °C with 5% CO2. After incubation, the remaining cells were aspirated with a cotton swab, 
filters was washed three times with 25 µl PBS and plates centrifuged at 312 g for 5 min. Pel-
lets were re-suspended and 20 µl was added to Turk’s solution for counting on a 
haemocytometer, viewed under a light microscope. A chemotaxis index was calculated by di-
viding the number of neutrophils migrated towards chemoattractant by control migration. 
Results were expressed as the mean chemotactic index (fold increase of cells migrating in re-
sponse to stimuli compared with assay medium alone). All experimental setups were 
performed at least three times, with duplicate parallel samples from three distinct donors. Sta-
tistical significance of the results was evaluated by ANOVA and Bonferroni post-test. 
9.6.5 TNF-α  Induced IL-1β  Production 
9.6.5.1 Neutrophil Stimulation 
Human neutrophils were prepared as described above and re-suspended to 1 x 106 cells/ml in 
RPMI-1640 supplemented with 10% FCS, L-glutamine (2 mM), penicillin (100 U) and strep-
tomycin (1 mg/ml). Cells were added to 24-well plates in 250 µl and 50 µl compounds were 
added (at 10x final concentration) for 10 min prior to addition of 50 µl TNF-α at 10x final 
concentration with a final volume of 500 µl. Plates were then incubated for 18 h at 37 °C, 5% 
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CO2. On the following day, plates were spun at 800 g for 10 min prior to collection of superna-
tant samples which were then stored at -20 °C until needed. 
Experiments were conducted with duplicate parallel samples and repeated at least three times. 
Within each set of experiments, where applicable, different blood donors were used for each 
repetition. Data are reported as mean ± SEM and statistical differences were determined by 
analysis of variance followed by ANOVA and Bonferroni post test. 
9.6.5.2 ELISA of IL-1β  
Supernatants were thawed prior to the measurement of IL-1β level using Human IL-1β ELISA 
MAX™ Deluxe Kit (BioLegend®, San Diego, USA) following manufacturer protocol. ELISA 
is an analytic biochemistry assay that uses antibodies and colour change to detect the presence 
of a substance, usually an antigen, in a liquid sample (Figure 9-2). 
 
Figure 9-2 Illustration of sandwich ELISA method. A 96-well plate is coated with suitable capture 
antibodies (Step 1). Experimental samples or standards are added to the wells and IL-1β binds to the 
antibodies (Step 2). A secondary antibody labelled with biotin is added and binds to the immobilised 
IL-1β (Step 3). Avidin-HRP is added and binds to the biotin labelled detection antibody (Step 4). Tet-
ramethylbenzidine (TMB) substrate solution is added and a blue colour is developed in proportion to the 
amount of IL-1β present in the sample. Colour development is stopped using 2 M sulphuric acid turning 
the solution to yellow and the absorbance is measured at 450 nm producing signal that is proportional to 
the amount of bound IL-1β (Step 5). 
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9.7 MRI Experiment 
Animal experiments and MRI studies were performed by Grace McGregor and Katie Murray 
in collaboration with Prof Stuart Allan, University of Manchester. Images obtained were ana-
lysed using ImageJ (version 1.46q, National Institute of Health, USA) on ROI to study the 
effect of different contrast agents. Organs harvested for biodistribution study were processed 
in Chemistry, Imperial College prior to the submission for ICP-MS analysis by Dr Stanislav 
Strekopytov at the Natural History Museum, London. 
9.7.1 Murine model of Inflammation 
7-week-old C57/BL6 male mice (Harlan Laboratory, Bicester, UK) weighing 25-30 g were 
anaesthetised with isoflurane (Baxter, Newbury, UK) delivered in 70:30 N2O/O2 at 4% for ini-
tial induction and later maintained at 1.5-2% throughout the experiment. Animal temperature 
was monitored and maintained at 37 °C using a rectal thermometer and heated mat (Havard 
Apparatus, Tonbridge, UK). The mice head was shaved and sterilised using Videne (Adams 
Healthcare, Leeds, UK). The skull was exposed via a small midline incision and a small hole 
craniotomy was performed through which mice were injected with 2 µl of LPS (4 mg/ml) via a 
glass micro-needle. Coordinates for injection from bregma: anterior-posterior 0.0 mm, lateral -
0.2 mm, deep -0.25 mm at a rate of 0.5 µl/ml. The needle was left in situ for 2 min following 
injection. The wound was closed with 2-3 interrupted sutures and EMLA was applied. Ani-
mals were recovered and were administered with 2.5 ml saline into each flank and 2 ml 
buprenorphine (MAKE) subcutaneously. Animals were returned to cages on heated blankets 
with supplemented pelleted food and water, and were closely monitored until deemed fit to 
return to normal housing. Mice were then monitored periodically until scanning. 
9.7.2 MRI 
MRI was performed on a 7 T horizontal bore magnet (Agilent, UK) interfaced to a Bruker 
Avance III console (Bruker, UK) with separate volume-transmit and surface-receive radio fre-
quency coiled. Coronal pilot images were acquired to determine the correct geometry (using a 
multi- slice gradient echo sequence). Mice were anaesthetised using 2% isoflurane delivered in 
70:30 N2O/O2 which was maintained via a face mask. A tail vein needle was inserted and se-
cured and mice were secured within the scanner where respiration rate was monitored and 
temperature maintained at 37 °C using a rectal probe. Scans were obtained using ParaVision 
software (version 5.0, Bruker, USA). A T1 weighted scan (Field of view (FOV) = 3 cm; 2 mm 
slice thickness; interslice distance = 1 mm, 15 contiguous slices, matrix size = 128 x 128, TE = 
16.5 ms). DCE-MRI (FOV = 3 cm, TE = 2.5 ms, TR = 6.3 ms; 4 averages; FA = 20°; 15 mm 
slice thickness; 0 mm interstice distance; 1 slice; matrix size 128 x 64) scans were then run for 
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20 minutes. After 5 minutes (repetition 17) into the DCE-MRI, 150 µl of contrast agent 
(Gd.DOTA, Gd.20 or Gd.23) was administered via the tail vein. After the completion of this 
scan, another T1 map was acquired with the same parameters as mentioned previously. Mice 
were then removed from the scanner and recovered. 
9.7.3 Biodistribution Study 
Mice were euthanised after each MRI experiment and main organs (liver, spleen, kidney, lung, 
brain, muscle and heart) were collected, weighed and frozen until needed. A small portion (70-
100 mg) was cut from organ and digested in concentrated nitric acid at 60-70 °C for 4 h or 
until a clear solution was obtained. Samples were diluted to 2-3% nitric acid using MilliQ wa-
ter and submitted for ICP-MS. 
9.8 Confocal Imaging 
Experiment was performed by Dr Paul Holloway, Neuroscience Centre, Imperial College 
London, Hammersmith Campus. 
9.8.1 Ligand Binding 
In order to visualise the binding of fluorescently labelled cFLFLFK (33 and 34), HEK-293 
cells stably expressing hFPR1 is seeded in µ-Slide VI 0.4 cell culture slides (IBIDI, Munich, 
Germany). Cells were first washed with PBS before fixing in acetone for 5 min and washing 
three times in PBS. Cells were then incubated with either 33 or 34 (50 nM) in PBS supple-
mented with 1 mM CaCl2, 0.5 mM MgCl2 and 0.1% BSA for 1 h. Following three washes with 
PBS the cell membrane was labelled using ConA, conjugated either to Alexa Fluor® 488 or 
TRITC (Molecular Probes®, Invitrogen, Carlsbad, USA) for 33 and 34 respectively, used at 
25 μg/ml in PBS supplemented with 1 mM CaCl2 and 0.5 mM MgCl2 and incubated for 
15 min at rt. Cells were then mounted in Vectashield with DAPI nuclear stain before imaging. 
9.8.2 FPR1 staining 
HEK-293 cells stably expressing hFPR1 or hFPR2 were seeded in µ-Slide VI 0.4 cell culture 
slides (IBIDI, Munich, Germany) at a concentration of 3 x 105 cells/ml in DMEM plus L-
glutamate supplemented with 10% FCS, 0.05 µg/ml gentamicin and 0.2 mg/ml geneticin, and 
incubated overnight at 37 °C and 5% CO2. In order to stain for the FPR1 receptor, cells were 
first washed with PBS before fixing in acetone for 5 min. Following a further three washes 
with PBS, cells were then blocked and permeabilised with PBS supplemented with 1% BSA, 
5% goat serum, 0.2% Triton-X, 0.05% Tween-20 and 100 mM glycine for 30 min. After 
washing with PBS, cells were incubated at 4 °C overnight with rabbit anti human-FPR1 anti-
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body (Abcam, Cambridge, UK) at a dilution of 1:200 in PBS supplemented with 0.1% BSA 
and 0.05% Tween 20. Following primary antibody incubation, cells were then washed with 
PBS before incubating for 1 h at rt with Alexa Fluor® 488 goat anti-rabbit IgG (Abcam, Cam-
bridge, UK). Cells were then washed and mounted in Vectashield with DAPI nuclear stain. 
9.8.3 Confocal Microscopy 
Fluorescent images of FPR1 expression and ligand binding were obtained using a Leica TCS 
SPS II confocal microscope with Leica Application Suite Advanced Fluorescence V2.0.2 ac-
quisition software. Images obtained using a 60x magnification oil immersion objective with 
pinhole set to 0.99 Airy units. Lasers (405, 488, 543 and 633 nm) were set to 20% power and 
PMT set to the required spectral band to cover the peak emission of each fluorophore. Images 
were obtained sequentially to minimise spill over between channels. 
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Appendix 
Figure I - Data and images obtained from MacGregor report. BBB breakdown was increased 
in LPS-induced neuronal inflammation. A) Ischaemic damage was significantly increased in 
LPS treated mice at 24 h but not at 6 h. B) Representative brain sections immunostained with 
IgG for neutrophil infiltration. Scale bar = 2 mm. 
 
 
 
 
